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Abstract 
 
Streptococcus pneumoniae coinfection is a major cause of influenza-associated 
mortality. In this thesis the underlying disease mechanisms and the role of the 
immune response are investigated in a mouse model. Coinfection with otherwise 
mild influenza and S. pneumoniae strains is shown to synergistically cause 
mortality and severe disease. Loss of bacterial but not viral control, and 
subsequent outgrowth, is identified as the main driver of mortality.  
 
Influenza-mediated immune impairment and lung damage have been proposed as 
mechanisms of coinfection. Here the aspects of the immune response profiled are 
not impaired; in contrast, coinfection induces a strong proinflammatory cytokine 
response and an influx of functional neutrophils. Depletion of neutrophils or TNF-
α blockade exacerbates disease and bacterial outgrowth, showing these aspects of 
the immune response are protective. In addition to profiling the downstream 
response to bacterial outgrowth, the upstream causes of bacterial colonization are 
investigated. CCR2-/- mice are shown to be more resistant to coinfection. 
Influenza-infected CCR2-/- lungs lack inflammatory monocytes and exhibit 
reduced damage prior to coinfection. How inflammatory monocyte derived 
damage is mediated is investigated. Blockade of TRAIL - a cell-death inducing 
ligand - during the viral phase prior to coinfection ameliorates disease. 
Inflammatory monocytes are shown to comprise the majority of TRAIL-
expressing cells during influenza infection, and TRAIL expression is largely 
absent in CCR2-/- mice. Therefore a mechanism is proposed for coinfection where 
influenza-induced TRAIL-expressing inflammatory monocytes cause lung 
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damage, allowing bacterial colonization, while neutrophils and TNF-α counter 
subsequent bacterial outgrowth. Other aspects of coinfection, such as bacterial 
spread to the brain and other facets of the immune response, are also investigated. 	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Chapter 1. General Introduction 
 
1.1. Project overview: Influenza A - S. pneumoniae coinfection 
 
Influenza A virus (IAV) is a negative sense RNA virus and major human 
respiratory pathogen, with recent pandemics in 1918, 1957, 1968 and 2009 
(Palese et al., 2004; Nicholls, 2013). Streptococcus pneumoniae (S. 
pneumoniae/Strep) is a gram-positive extracellular bacterium that frequently 
asymptomatically colonizes the human upper respiratory tract. It is one of the 
most common bacterial respiratory pathogens and can result in complications 
such as pneumonia and septicaemia (Kadioglu et al., 2008; Henriques-Normark et 
al., 2013).  
 
Although these pathogens individually are problematic, the serious danger of 
coinfection has long been recognised. Louis Cruveilhier commented following the 
1918 IAV pandemic: “If grippe condemns, the secondary infections execute” 
(Cruveilhier, 1919). Secondary bacterial coinfections are implicated as the cause 
of death in the majority of fatal cases in the 1918 IAV pandemic, with S. 
pneumoniae as the most commonly identified secondary infection (Morens et al., 
2008). Understanding why IAV promotes susceptibility to S. pneumoniae 
infection is therefore a crucial public health question.  
 
In this thesis the immune response to IAV-Strep coinfection is investigated in a 
mouse model. Crucial roles for neutrophils, tumour-necrosis factor-alpha (TNF-α) 
and inflammatory monocytes are described. In this general introduction the 
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biology of both IAV and Strep, and of neutrophils, TNF-α and inflammatory 
monocytes, will be outlined. The substantial medical evidence for coinfection will 
be described, and the existing literature on coinfections comprehensively 
summarized.  
 
1.2. Influenza A biology 
 
1.2.1. Viral genome, structure and classification 
 
IAV is one of three influenza types belonging to the Orthomyxoviridae family. 
These types - A, B and C – have common ancestry, but are genetically divergent 
to the extent where exchange of genetic material cannot occur. Of these types 
IAV is the most common respiratory pathogen, and is typically restricted to 
infection of respiratory epithelial cells, although influenza B also causes human 
disease (Julkunen et al., 2000). IAV virions are comprised of eight single-
stranded, negative sense RNA segments, which are coated with with 
nucleoprotein (NP) and the trimeric viral RNA polymerase (PB1, PB2 and PA 
proteins) to form ribonucleoprotein (RNP) complexes. This virion core is encased 
in matrix protein 1 (M1), which is further enveloped by a lipid layer containing 
the surface glycoproteins hemagglutinin (HA) and the neuraminidase (NA) 
(Bouvier et al., 2008). Although there are 16 known HA and 9 known NA 
subtypes, only H1-3 and N1-2 have caused human pandemics. The ion channel 
matrix protein 2 (M2) traverses the lipid envelope, with a ratio of M2 to HA 
ranging from 1:10 to 1:100 (Palese, 2004). 
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IAV nomenclature is defined by the type, location, isolate number, year of 
isolation, and subtype; for example A/Puerto Rico/8/1934 (H1N1) indicates type 
A, isolate number 8 from Puerto Rico, isolated in 1934, with hemagglutinin 
subtype 1 and neuraminidase subtype 1 (Bouvier et al., 2008).  
 
IAV RNP segments are numbered in order of decreasing length. PB2, PA, HA, 
NP and NA are encoded by segments 1, 3, 4, 5 and 6 respectively. Segment 2, 
which codes for PB1, has an alternative reading frame in some IAV strains which 
encodes PB1-F2, a small pro-apoptotic protein. Segment 7 encodes for both the 
M1 protein, and, by alternative splicing, the M2. Segment 8 encodes for the non-
structural protein 1 (NS1), an antagonist for anti-viral interferon (IFN), and, again 
due to alternative splicing, the nuclear export protein (NEP) (also referred to as 
NS2), which is required for viral RNA export from the host cell nucleus (Bouvier 
et al., 2008).  
 
As the genome is segmented, viral subtypes can “reassort” different segments. 
Reassortment of segments between different virus strains can lead to major 
changes in surface glycoproteins in a process known as  “antigenic shift”. 
Furthermore the poor fidelity of viral RNA transcription leads to the accumulation 
of mutations in a process known as “antigenic drift”. Although the selective 
pressure exerted by host anti-HA monoclonal antibodies means the main mutation 
target for antigenic drift is the stem region of HA, other viral proteins can also be 
subject to this process. These viral mutations can enable immune evasion and 
reinfection of a previously IAV-exposed population, and are a major challenge for 
IAV vaccination (Doherty et. al., 2006; Bouvier et al., 2008). 
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1.2.2. Viral life cycle 
 
Viral infection of target cells is initiated by the recognition of sialic acid moieties 
on the surface of upper respiratory tract epithelial cells by HA. Viral HA 
molecules have differing affinities for α-2,3 or α-2,6 linkages between the 
terminal sialic acid and galactose, and the distribution of these linkages affects the 
species preference of different viruses. In human respiratory epithelia α-2,6 
linkages are more common overall, although α-2,3 linkages are frequent in the 
lower respiratory tract (Julkunen et al., 2000; Bouvier et al., 2008). 
 
Viral binding leads to endocytosis by both clathrin-mediated and clathrin-
independent mechanisms, and cleavage of the HA by host proteases (Steinhauer et 
al., 1999; Lakadamyali et al., 2004). The requirement for these proteases and their 
distribution typically limits the tissue tropism of IAV to respiratory epithelial 
cells, although macrophages and leucocytes may also be infected; it is technically 
challenging to assess whether phagocytic and antigen presenting cells are 
productively infected or have simply ingested virions (Manicassamy et al., 2010). 
Following endocytosis the reduction in pH causes a conformational change in the 
HA, which mediates the fusion of the viral and endosomal membranes. 
Endosomal hydrogen ions are also pumped into the viral core by the M2 protein, 
weakening protein-protein interactions and leading to release of viral RNPs into 
the cytoplasm. Viral RNPs are then transported to the nucleus by host proteins 
due to their nuclear localisation signals. Within the nucleus the viral RNA 
polymerase, using the viral RNA (vRNA) as a template, synthesises mRNA, for 
the production of viral proteins, and complementary RNA (cRNA), which serves 
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as a template for production of more vRNA copies. RNA export from the nucleus 
is mediated by the association of M1 and NEP. Upon synthesis of viral proteins in 
the cytoplasm, viral particles are packaged; it is not clear whether this process is 
random (generating a small number of complete infectious particles) or regulated. 
NA acts as a sialidase, cleaving surface moieties on the host cell, allowing 
budding of virus particles; this protein is also subject to “antigenic drift” (; 
Julkunen et al., 2000; Bouvier et al., 2008, Doherty et. al., 2006). 
 
1.3. S. pneumoniae biology 
 
1.3.1. S. pneumoniae epidemiology 
 
S. pneumoniae (Strep) –  the “pneumococcus” - is a gram-positive extracellular 
bacterium that is the primary cause of bacterial pneumonia in developed 
countries, and can result in complications such as meningitis, otitis media and 
septicemia. It is spread by aerosol and is commonly found residing 
asymptomatically in the human nasopharynx, although spread to other, previously 
sterile sites can lead to the complications described. Asymptomatic carriage peaks 
at approximately 60% in early childhood at around 2-3 years of age, and 
diminishes to around 10% in adults. There are at least 93 different serotypes of S. 
pneumoniae, defined by their capsular structure. Rates of carriage and virulence 
vary between different serotypes. The wide variety of serotypes is a major 
difficulty for vaccination; current vaccines such as the widely used “23-valent” 
only contain polysaccharides from certain serotypes. Polysaccharide vaccines are 
poorly immunogenic, and more recently protein-polysaccharide conjugate 
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vaccines have been introduced. Typically penicillin is used to treat Strep, although 
antibiotic resistance is increasing (Kadioglu et al., 2008; Henriques-Normark et 
al., 2013). 
 
1.3.2. S. pneumoniae microbiology and colonization 
 
Strep has a 2.16 mbps genome, sequence analysis of which indicates it is a 
facultative anaerobe that depends on the fermentation of 14 different 
carbohydrates. The surface of Strep is comprised of a polysaccharide capsule, 
overlaying a peptidoglycan and lipoteichoic acid cell wall, which in turn encases 
the plasma membrane (Henriques-Normark et al., 2013). The capsule can vary 
between two states - “opaque” and “transparent” - of different thickness, 
distinguishable by their distinct colony morphologies. During the early stages of 
colonization, transparent variants are favoured. The capsule has several roles in 
promoting colonization: it hinders access of leucocytes to complement attached to 
the underlying cell wall, reduces phagocytosis, and decreases mucosal entrapment 
(Kadioglu et al., 2008).  
 
In addition to the capsule, Strep expresses a number of virulence factors that are 
involved in colonization, whether through promotion of adhesion, exposure of 
binding sites, or modulation of the immune response. ChoP promotes bacterial 
adhesion by binding to human platelet activating factor receptor (PAFR), which is 
commonly found on human epithelial tissues such as the nasopharynx (Bogaert et 
al., 2004). Some strains express a pilus like structure, which may bind to an 
unknown epithelial receptor (Henriques-Normark et al., 2013). CbpA (also known 
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as PspC) binds to human secretory component, an epithelial glycoprotein that is 
involved in the transport of immunoglobulin (Ig) across the epithelial surface. 
Furthermore it binds the complement component Factor H, reducing bacterial 
opsonisation. PavA and Eno bind to the extracellular matrix components 
plasminogen and fibronectin respectively. Neuraminidases such as NanA cleave 
terminal sialic acids found on the human epithelium and therefore may expose 
binding sites. Other proteins counter aspects of the immune response – for 
example, PspA interferes with complement deposition and phagocytosis. Secreted 
pneumolysin (Ply) forms transmembrane pores on the surface of target cells, 
reduces ciliary beating, and inhibits the phagocytic respiratory burst (Kadioglu et 
al., 2004; Kadioglu et al., 2008).  
 
1.4. Neutrophil biology  
 
Neutrophils have been shown to play a role in both influenza and Strep infections 
(Sun et al., 2007; Tate et al., 2009), and therefore are of substantial interest in 
coinfection. Neutrophils are granular, short-lived, terminally differentiated, 
polymorphonuclear phagocytic cells generated in large numbers in the bone 
marrow. Neutrophils circulate in the bloodstream and provide one of the first lines 
of defence against microbes. Production of neutrophils is regulated by 
granulocyte-colony stimulating factor (G-CSF). During development from 
hematopoietic stem cells a range of granules are formed, classified by the 
presence of certain proteins and their order of formation: primary (azurophil) 
granules containing myeloperoxidase (MPO), secondary (specific) granules 
containing lactoferrin, and tertiary granules containing gelatinase. These granules 
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also contain a wide range of other antimicrobial effectors (Borregaard et al., 
2010).  
 
Recruitment of circulating neutrophils to sites of infection is mediated by 
inflammatory stimuli such as Interleukin-1β (IL-1β) and TNF-α, which stimulate 
the upregulation of P and E-selectin on endothelial cells and lead to circulating 
neutrophils “rolling” along the vascular endothelium. Firmer attachment is 
mediated by the interaction of neutrophil integrins with ICAM. Interactions 
during the attachment process result in activation and cytoskeletal rearrangement 
within the neutrophil. A complex process mediated by junction-adhesion-
molecule A (JAM-A) and other proteins allows neutrophil transendothelial 
migration into the infected tissue (Borregaard et al., 2010). 
 
Once within the tissue, neutrophils have a wide range of antimicrobial effects. 
Neutrophils directly phagocytose microbes, creating a phagocytic compartment. 
This process is greatly augmented by opsonisation of bacteria with antibody - 
which is recognised by Fc receptors on activated neutrophils - and complement 
(Lee et al., 2003). A major mechanism of bacterial control is the “respiratory 
burst”, undertaken by Phox (phagocyte oxidase/NADPH oxidase) at the 
phagocytic membrane, which results in the release of reactive oxygen species 
(ROS) such as superoxide and hydrogen peroxide, which can directly react with 
and kill microbes (Segal, 2005). Furthermore, neutrophils release granules 
containing multiple antimicrobial effectors into the phagocytic compartment and 
the extracellular space. First discharged are the secondary and tertiary granules, 
which contain many antimicrobial peptides such as LL37, a potent pore-forming 
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protein (Duplantier et al., 2013), and tissue remodelling factors such as matrix 
metalloproteinase 9 (gelatinase), which by digesting the extracellular matrix 
disrupts the vascular basement membrane, aiding further neutrophil influx. 
Primary granule contents are then released, which contain many components 
related to digestion and microbial killing. These include myeloperoxidase, which 
catalyses the formation of potent halide species such as hypochlorous acid from 
hydrogen peroxide generated by the respiratory burst, and other antimicrobial 
agents such as pore-forming defensins and neutrophil elastase, a multifunctional 
serine protease that can degrade bacterial virulence factors (Borregaard et al., 
1997; Faurschou et al., 2003; Nathan, 2006). 
 
Another more recently described mechanism of neutrophil killing is neutrophil 
extracellular traps (NETs), where neutrophil nuclei release their chromatin into 
the extracellular space. Chromatin directly traps microbes, and is coated in 
antimicrobial proteins including histones and effectors from azurophillic granules 
such as myeloperoxidase and elastase (Urban et al., 2006). In addition to their 
described killing functions, neutrophils can produce cytokines such as TNF-α, 
and generate chemotactic factors such as chemerin; however, on a per-cell basis 
the capacity of neutrophils to produce cytokine is less than other immune cells 
such as monocytes (Nathan, 2006). 
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1.5. TNF-α  biology 
 
Tumour necrosis factor alpha (TNF-α) was originally identified as an endotoxin-
induced glycoprotein that induced necrosis of sarcomas transplanted into mice. It 
is now characterised as a canonical pro-inflammatory cytokine primarily produced 
by immune cells, including macrophages and activated T cells. It is typically only 
detected in the tissue or serum during infectious or autoimmune conditions 
(Bradley, 2008). It has a wide range of roles in many different diseases, both 
protective and pathogenic, including during influenza and Strep infection 
(Takashima et al., 1997; Hussell et al., 2001), and is therefore of significant 
interest during coinfection. 
 
TNF-α signals through two distinct receptors – tumour-necrosis factor receptor-1 
(TNFR1) and TNFR2, which are widely expressed on most tissues, although 
hematopoietic cells may preferentially express TNFR2. TNFR1 signals via TNF-
receptor associated death-domain (TRADD). This leads to the formation of the 
TRADD-RIP-1-TRAF2 complex. This complex has two possible downstream 
activities – activation of a large number of cellular signalling kinases, including 
p38 and P13K, resulting in the activation of transcription factors such as activator-
protein-1 (AP-1) and “nuclear factor kappa-light-chain-enhancer of activated B 
cells” (NF-κB); or promotion of apoptosis by the binding of “Fas-associated 
protein with death-domain” (FADD) to TRADD, leading to cleavage of pro-
caspase 8. The function of TNFR2 is less well studied; however, as this receptor 
lacks an intracellular death domain, it is believed to primarily contribute to 
proinflammatory signalling such as NF-κB activation (Bradley, 2008). 
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TNF-α signalling promotes a range of biological functions. TNF-α induces 
upregulation of adhesion molecules such as E-selectin and ICAM1 on endothelia, 
leading to recruitment of leucocytes such as neutrophils. TNF-α can promote 
classical inflammatory effects such as vasodilation through induction of 
cyclooxygenase 2 (COX2). TNF-α has been demonstrated to be a component in 
endotoxin-induced sepsis, and is essential for protection against bacterial 
infections such as S. aureus (Bradley, 2008). TNF-α promotes the respiratory 
burst in neutrophils, raises levels of intracellular calcium, and causes actin 
reorganisation (Nathan, 2006). 
 
1.6. Inflammatory monocyte biology 
 
Monocytes are a mixed population of circulating hematopoietic cells that play 
many roles in different infections, including influenza and Strep (Lin et al., 2008; 
Davis et al., 2011), that may be of interest during coinfection. Monocytes 
originate from a common myeloid progenitor, and there are various monocyte 
subsets in both humans and mice. “Inflammatory” monocytes, as opposed to 
“resident” monocytes, are typically defined in mice by the strong expression of 
lymphocyte antigen 6C (Ly6C) and are believed to be equivalent to human 
CD14high “inflammatory” monocytes (Gordon et al., 2005). Egress of Ly6C+ 
inflammatory monocytes from the bone marrow is dependent on C-C chemokine 
receptor type 2 (CCR2). CCR2 is the receptor for monocyte-chemoattractant 
protein 1 (MCP-1/CCL2) and other ligands (Serbina et al, 2006, Serbina et al., 
2008).  
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Inflammatory monocytes contribute to innate immunity through a range of 
mechanisms. Monocytes differentiate into various macrophage and dendritic cell 
(DC) populations, although the fate of each monocyte subset and their specific 
role in different tissues is complex. Stimulation of “pattern recognition receptors” 
(PRRs) - which recognise common motifs in microbial species termed “pathogen 
associated molecular patterns” (PAMPs) - on monocytes leads to production of 
cytokines such as TNF-α and IL-1β (Serbina et al., 2008). Inflammatory 
monocytes also produce reactive nitrogen intermediates through inducible nitric 
oxide synthase (iNOS). During infections, inflammatory monocytes can develop 
into a TNF-α and inducible nitric oxide synthase (iNOS)-producing DC (termed 
“tipDC”) phenotype (Aldridge et al., 2009). The crucial role of inflammatory 
monocytes in some bacterial infections has been clearly demonstrated by the 
susceptibility of CCR2-/- mice to the intracellular bacterium L. monocytogenes 
(Serbina et al, 2006; Serbina et al., 2008).  
 
1.7. The immune response to Influenza A 
 
1.7.1. Overview of the adaptive response 
 
It has long been established that the adaptive response is required for the control 
of IAV. The adaptive response is believed to be primarily stimulated by the 
migration of antigen-presenting dendritic cells from the respiratory tract to the 
lymph nodes or spleen in the first 36 hours following infection. The subsequent 
response is comprised of two crucial elements – neutralising antibody and 
cytotoxic T cells. Neutralisation of HA and to a lesser extent NA by B-cell 
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produced systemic IgG and locally produced IgA can provide sterile immunity to 
IAV virus. CD8 cytotoxic T cells play a crucial role by recognition of infected 
cells via major histocompatibility complex class I (MHCI) and subsequent 
elimination through perforin or Fas-dependent lysis. CD8 T cells tend to 
recognise more highly conserved elements of the IAV virus such as NP (Doherty 
et al., 2006). CD4 T cells may play a complementary role through promoting the 
CD8 response, and by providing cognate T-cell help to B-cells through 
TCR:MHCII interactions and costimulation via CD40L:CD40 in the spleen and 
lymph nodes, which promotes antibody production and class switching (Swain et 
al., 2012). Both CD4 and CD8 T cells, as well as neutralising antibodies and 
memory B cells, contribute to immunological memory against IAV. Different 
studies have assessed the role of these adaptive responses during IAV using mice 
deficient in or depleted of these cells. No individual aspect of the adaptive 
response is capable of controlling IAV alone; B, CD8 T and CD4 T cell responses 
are required for clearance and survival (Brown et al., 2004). IAV evades adaptive 
responses by antigenic drift, which can lead to reduced affinity antibodies and less 
sensitive CD8 responses. Also, evasion through antigenic shift can lead to a 
complete lack of pre-existing antibodies, allowing potentially severe infection and 
rapid spread throughout the population, resulting in pandemics (Schmolke et al., 
2010). 
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1.7.2. Overview of the innate response 
 
Although the adaptive response is critical for control of IAV, the innate response 
also plays a substantial role, both in priming the adaptive response and in viral 
control. During influenza, T cells reach the lung after approximately 5 days, and 
therefore, in a novel infection, early viral replication must be controlled by the 
innate response. The role of innate immunity in IAV is complex, as viral growth 
must be controlled without causing excessive immune-mediated damage to the 
respiratory epithelium (Tripathi et al., 2013). 
 
Mucins and soluble mediators 
 
Upon infection of the respiratory tract IAV encounters mucins and soluble 
mediators. Mucins, which entrap water and create a viscous layer, act as a 
physical barrier to infection and may entrap viruses, particularly - as mucins are 
predominately α-2,3 sialylated - influenza strains with affinity for α-2,3 linkages 
(Nicholls, 2013). Soluble mediators such as such as surfactant-protein A may 
reduce viral entry by acting as decoy sialic acid receptors for the HA. Other 
mediators such as surfactant protein-D and mannan-binding-lectin bind directly to 
other carbohydrate moieties on the HA (Tripathi et al., 2013).  
 
Recognition of influenza 
 
IAV induces a cellular immune response dependent on its recognition through 
either toll-like-receptors (TLRs) or cytoplasmic receptors. In IAV-infected 
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respiratory epithelial cells, cytoplasmic retinoic acid-inducible gene 1 (RIG-I) 
recognises the 5’-triphosphate of viral RNA. Recognition leads to a 
conformational change allowing interaction between the CARD domains of RIG-I 
and mitochondrial adaptor protein “mitochondrial antiviral-signaling protein” 
(MAVS). MAVS signals through the kinase TBK1/IKKε, activating the 
transcription factors interferon regulatory factor 3/7 (IRF3/7). MAVS also 
activates NF-κB via the kinase RIP1 (Kawai et al., 2006). Activation of these 
transcription factors leads to the subsequent immune response, including cell 
recruitment and production of cytokines, notably type 1 (IFNα and IFNβ) and 
type III (IFNλ) interferons (Schmolke et al., 2010; Nicholls et al., 2013).  
In addition, several TLRs have been described to be involved in recognition of 
influenza. In plasmacytoid dendritic cells, major producers of type 1 interferon, 
TLR7 recognises IAV single-stranded RNA in the endosome (Diebold et al., 
2004). Sensing of influenza by TLR3 in human respiratory epithelial cells has 
been described (Le Goffic et al., 2007). TLR4 deficient mice show reduced lung 
injury following severe influenza infection, suggesting TLR4 is in involved in 
influenza recognition (Imai et al., 2008). Furthermore, inflammasome-activating 
NOD-like-receptors (NLRs) have also been described to play a role during 
influenza (Allen et al., 2009). 
 
Activation of the cellular immune response 
 
RIG-I signalling leads to the production of type 1 interferons (IFN), which signal 
via the IFNαβ receptor. This causes formation of STAT1/2 heterodimers, which 
migrate to the nucleus and associate with IRF9. This complex binds interferon-
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stimulated regulatory elements (ISREs), leading to the transcription of many 
interferon-stimulated genes (ISGs). ISGs include antiviral proteins such as Mx 
and IFITM3, and mediators of downstream immune responses (Trincheri et al., 
2010; Iwasaki et al., 2014). To counter this, IAV NS1 protein antagonises the type 
1 - and potentially type III - interferon response at multiple levels. These include 
associating with RIG-I to prevent signalling, reducing host gene expression by 
preventing 3’ polyadenylation of pre-mRNA, and directly interfering with 
antiviral ISG function (Schmolke et al., 2010). RIG-I signalling also leads to the 
activation of NF-κB, which contributes to the induction of various 
proinflammatory cytokines. Cytokines such as TNF-α, IL-6 and IFN-γ are 
secreted in response to IAV infection (Julkunen et al., 2000; Wack et al., 2011). 
 
The cellular response to IAV is initially mediated by lung-resident alveolar 
macrophages, which upon activation become highly phagocytic and produce 
proinflammatory cytokines. Infected epithelial cells secrete chemokines such as 
MCP-1, leading to monocyte recruitment and differentiation into effector cells 
such as monocyte-derived DCs (Schmolke et al., 2010). Activation of dendritic 
cells leads to migration to the lymphoid tissues and antigen-presentation, 
prompting the adaptive immune response. IAV infection also results in the 
recruitment of natural killer (NK) cells and neutrophils, and prompts an IL-17 
response from γδ T cells (Nicholls et al., 2013; Tripathi et al., 2013).  
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1.7.3. Neutrophils in Influenza A infection 
 
The role of neutrophils in IAV infection is not yet clear, and it may be dependent 
on the severity of the influenza infection. Mouse models clearly show recruitment 
of neutrophils to the lung early during influenza infection (Tate et al., 2009). 
Several studies have used mouse models to investigate the role of neutrophils 
during influenza. 
 
The protective role of neutrophils during IAV 
 
Several studies have attempted to directly increase or decrease the neutrophil 
response to assess their role. RB6 - a monoclonal antibody against Gr-1 – is 
commonly used for depletion. Gr-1 is an epitope found on both the cell surface 
molecules Ly6G (specific for neutrophils) and Ly6C (highly expressed on 
inflammatory monocytes and at various lower levels on other cells, including 
neutrophils, dendritic cells and lymphocyte subsets) (Daley et al., 2008), and 
therefore this antibody has poor specificity. RB6 treatment exacerbates both 
severe (Tumpey et al., 2005; Fujisawa, 2008) and mild (Tate et al., 2008, Tate et 
al., 2011) IAV infection. However, due to the low specificity of neutrophil 
depletion, these results are difficult to interpret.  
 
The monoclonal antibody 1A8, which targets Ly6G, has also been used to more 
specifically deplete neutrophils. In some studies 1A8 treatment exacerbates mild 
(Tate et al., 2009; Tate et al., 2011) and severe (Dienz et al., 2012) IAV infection. 
Gain of function approaches have also been taken - mice overexpressing the 
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neutrophil promoting cytokine granulocyte-macrophage colony stimulating factor 
(GM-CSF) have increased resistance to severe influenza (Huang et al., 2011). 
However, GM-CSF has many roles, so it is not clear whether this increased 
protection is due to greater neutrophil numbers. Overall these studies suggest that 
neutrophils play a protective role in influenza, possibly limiting viral replication 
during the early phase of infection. One study shows neutrophil depletion is only 
deleterious if performed early in influenza (Tate et al., 2011), which would 
support this hypothesis.  
 
The harmful role of neutrophils during IAV 
 
However, other studies, albeit generally using more indirect readouts, suggest that 
neutrophils may be detrimental and result in tissue damage and pathology during 
influenza infection. In contrast to the previous results, one study did not observe a 
significant effect of 1A8 treatment during mild IAV infection, and furthermore 
suggested neutrophil NETs may contribute to lung damage (Narasaraju et al., 
2011). Severe pathogenesis induced by an IAV strain bearing the 1918 pandemic 
HA and NA was characterised by massive neutrophil recruitment to the lungs 
(Kobasa et al., 2004). Furthermore IFNαβR-/- mice were more susceptible to 
severe influenza infection, which is attributed to reduced inflammatory monocyte 
and increased neutrophil recruitment (Seo et al., 2011). This suggested 
neutrophils are harmful, although the lack of type I interferon signalling in this 
study may lead to deficiencies in other aspects of the immune response, so it is 
difficult to draw clear conclusions. Also notably, mice unable to produce reactive 
oxygen species were better protected during influenza, although the total number 
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of neutrophils in these mice was increased (Snelgrove et al., 2006). Mice lacking 
the receptor for IL-17 (a potent neutrophil chemoattractant) recruited less 
neutrophils and had reduced disease severity during severe IAV infection (Crowe 
et al., 2009), although there are other possible interpretations of this study, such as 
a detrimental role for Th17 cells during influenza. In summary, neutrophil may 
contribute to pathology during influenza, possibly through ROS production and 
NET formation. 
 
Other aspects of neutrophils during IAV 
 
Other studies suggest neutrophils may affect the downstream adaptive response. 
Neutrophils may contribute to antigen presentation to CD8 T cells during IAV 
infection (Hufford et al., 2012). Neutrophils are a component of the myeloid-
derived-suppressor-cell (MDSC) population, cells that can suppress T-cell 
proliferation through arginase and nitric oxide synthase 2 activity. This can cause 
harmful immunosuppression during IAV infection. This is ameliorated by 
invariant-natural killer T cells (iNKTs), which reduce MDSC proliferation and 
arginase/nitric oxide synthase 2 activity (De Santo et al., 2008). 
 
Overall the role of neutrophils in influenza is not yet clear, and in mouse models 
may be highly dependent on the experimental context, particularly the severity of 
the influenza virus infection. It is likely they help control viral replication, but in a 
setting inducing excess inflammation can contribute to pathology. 
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1.7.4. TNF-α  in Influenza A infection 
 
Mouse models show that TNF-α is produced in the lungs within 2-4 days 
following IAV infection (Vacheron et al., 1990; Hennet et al., 1992). However, 
the role of TNF-α in influenza is not clear, and appears complex - possibly 
causing excess pathology during severe infections, but protective in others.   
 
TNF-α has been shown to reduce viral replication in a porcine epithelial cell line 
(Seo et al., 2002), and increase expression of signalling proteins such as RIG-I 
crucial to viral recognition in a human epithelial cell line (Matikainen et al., 
2006). Both TNFR1 and TNFR2 signalling has been shown to regulate the 
number of effector CD8 T cells in the lung (Turner et al., 2004; DeBerge et al., 
2014). These results suggest that TNF-α is antiviral and has a role in regulating 
the adaptive response. 
 
In vivo mouse models of influenza investigating TNF-α give a range of results. 
Several severe disease models attempt to abrogate TNF-α signalling to reduce 
immunopathology. Anti-TNF-α treatment slightly reduced weight loss or 
mortality in two severe IAV models (Peper et al., 1995; Hussell et al., 2001;). 
TNFR1-/- mice exhibited slightly reduced weight loss in severe influenza models 
using H5N1 avian IAV strains or reconstructed 1918 pandemic virus (Szretter et 
al., 2007; Belisle et al., 2010). However, somewhat surprisingly, TNF-α-/- mice 
exhibit slightly increased weight loss and more severe inflammation during mild 
IAV infections (Damjanovic et al., 2011; DeBerge et al., 2014). The somewhat 
marginal weight loss differences observed in these studies suggest that TNF-α 
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deficiency alone does not greatly affect influenza infection. The contradictory 
results suggest that the beneficial or harmful role of TNF-α in influenza may 
depend on disease severity. 
 
Other studies have given further information on the role of TNF-α by attempting 
to block multiple proinflammatory cytokines induced upon influenza infection. 
Combined blockade of TNF-α, IL-6 and IL-1β reduced weight loss in a severe 
IAV model (Swiergel et al., 1999), while mice deficient in both TNFR1, 2 and IL-
1 receptor had marginally delayed mortality during lethal H5N1 infection, 
although not during another severe IAV strain (Perrone et al., 2010). Furthermore, 
another study showed that TNF-α-/-, TNFR1-/- or TNFR1-/-TNFR2-/- mice were not 
better protected against a lethal H5N1 infection (Salomon et al., 2007). Mice 
lacking the IL-17 receptor had lower levels of TNF-α, but were better protected 
from severe IAV (Crowe et al., 2009). Taken together, these studies suggest that 
TNF-α does increase pathology during severe IAV infections, but this effect is 
relatively small and somewhat variable depending on influenza severity. 
Therefore the role of TNF-α in IAV as protective or pathogenic during influenza 
is not yet clearly defined. 
 
1.7.5. Inflammatory monocytes in Influenza A infection 
 
The role of inflammatory monocytes in IAV is complex; although they appear to 
promote early immunopathology, they may be required for full adaptive 
responses, depending on the infection context. Inflammatory monocyte migration 
to the lungs during IAV infection is CCR2 dependent (Herold et al., 2006), and 
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therefore CCR2 deficient mice are frequently used to investigate the role of 
inflammatory monocytes.  
 
Inflammatory monocyte mediated lung damage during IAV 
 
Many studies suggest that inflammatory monocytes cause lung damage during 
IAV infection. CCR2-/- mice were shown to have reduced lung damage during 
severe IAV infection (Lin et al., 2008; Herold et al., 2008), while a CCR2 small 
molecule inhibitor reduced damage and mortality (Lin et al., 2011). Further 
studies have supported these findings, but also reveal a role for inflammatory 
monocytes in promoting T cell responses to IAV. CCR2-/- mice have reduced 
early pathology but somewhat reduced T cell expansion in the lymph nodes, 
leading to slightly increased viral titres (Dawson et al., 2000). A subsequent study 
shows inflammatory-monocyte derived tipDCs cause immunopathology during 
severe IAV infection, but were required for a full CD8 T cell response (Aldridge 
et al., 2009).  
 
Other studies use alternative methods to CCR2 deficiency to assess the monocyte 
response to influenza. Absence of the CCR2 ligand MCP1 has only modest effect 
- MCP1-/- mice or mice treated with anti-MCP-1 exhibit similar disease (Dessing 
et al., 2007; Narasaraju et al., 2010), although anti-MCP-1 may reduce 
inflammation in mild influenza (Damjanovic et al., 2011). Another study implies 
monocytes are protective using treatment with muramyl dipeptide. Muramyl 
dipeptide is a PAMP that stimulates NOD2, an intracellular receptor that 
recognises bacterial peptidoglycan. Muramyl dipeptide treatment increases MCP1 
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levels and monocyte recruitment during IAV, and is protective (Coulombe et al., 
2012). However stimulation of NOD2 may have other effects, making this study 
somewhat difficult to interpret. Overall inflammatory monocytes appear to cause 
early damage during IAV, but can also play a role in downstream T cell 
responses, and therefore whether in a given context they are protective or harmful 
is not yet clear.  
 
TRAIL as a mechanism of inflammatory-monocyte mediated damage 
 
Other studies have focused on the molecular mechanisms of inflammatory 
monocyte mediated damage. One molecule that has been heavily implicated in 
inflammatory-monocyte mediated damage during influenza infection is TNF-
related apoptosis-inducing ligand (TRAIL) (Herold et al., 2008). TRAIL was 
originally identified genetically due to its homology to TNF superfamily ligands, 
and was initially mainly studied in the context of tumour cell apoptosis. More 
recently, roles for TRAIL in the immune system and during infection have been 
explored. TRAIL is a membrane bound or soluble ligand that induces apoptosis 
on target cells through two death receptors in humans and one in mice – death 
receptor 5 (DR5). Mice also encode decoy receptors that can increase resistance to 
TRAIL-mediated apoptosis by reducing ligand availability or activating cell 
survival pathways (Benedict et al., 2012).  
 
In vitro studies show IAV induces TRAIL expression on immune cells, and 
demonstrate TRAIL-mediated lysis of various cell lines. IAV increases TRAIL 
expression on human peripheral blood mononuclear cells (PBMC), which leads to 
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killing of a melanoma-derived cell line. Furthermore IAV infection of a human 
lung epithelial cell line increases susceptibility to lysis mediated by recombinant 
TRAIL (Brincks et al., 2008). Human-monocyte-derived macrophages treated 
with influenza upregulate TRAIL, and can kill a human T cell line in a partially-
TRAIL dependent manner (Zhou et al., 2006). In a human lung epithelial cell line 
TRAIL is directly induced by IAV and promotes increased viral replication 
(Wurzer et al., 2004). 
 
In vivo studies have confirmed that TRAIL-mediated killing is a mechanism for 
inflammatory-monocyte mediated epithelial damage during severe IAV infection. 
TRAIL expressed by inflammatory monocytes (in one study cited here termed 
“exudate macrophages”) leads to the apoptosis of DR5 expressing alveolar 
epithelial cells and pathology; and therefore anti-TRAIL treatment improves 
survival (Herold et al., 2008; Davidson et al., 2014). Inflammatory monocyte 
upregulation of TRAIL may be dependent on IFN-β derived from alveolar 
macrophages (Hogner et al., 2013). However, the role of TRAIL is still somewhat 
unclear, as TRAIL-/- mice are more susceptible to severe IAV, as TRAIL may be 
involved in the CD8 T cell clearance of infected cells, and regulation of the 
overall CD8 T cell response (Brincks et al., 2008; Brincks et al., 2011). In 
summary TRAIL expressed by inflammatory monocytes causes damage during 
IAV infection; however, different studies have given contradictory results on 
whether the overall presence of TRAIL during influenza is beneficial. 
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1.8. The immune response to S. pneumoniae  
 
1.8.1. Overview of the adaptive response 
 
The adaptive response plays a crucial role in countering Strep infection. 
Antibody-mediated complement-dependent opsonophagocytosis is believed to be 
the primary mechanism of Strep control, and the presence of serotype-specific 
IgG against the bacterial polysaccharide capsule correlates with protection. 
Traditional “23-valent” polysaccharide vaccines attempt to elicit this antibody 
response. However, polysaccharide antigens are poorly immunogenic, and 
therefore more recently polysaccharide-protein conjugate vaccines, which elicit T 
cell help and lead to stronger antibody responses, have been developed (Casal et 
al., 2003).  
 
Preformed “natural antibodies” - antibodies formed without prior Strep infection, 
produced in response to normal gut flora - against phosphocholine moieties in the 
bacterial cell wall have also been described to be protective (Mold et al., 2002). In 
addition to promoting humoral immunity, CD4 T cells may also play a further 
protective role. CD4 T cells infiltrate rapidly to Strep infected tissues in a 
pneumolysin-dependent manner, and may be required for bacterial clearance 
through induction of a Th1 response (Kadioglu et al., 2008).  
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1.8.2. Overview of the innate response 
 
Innate immunity to Strep infection is essential for bacterial recognition and 
mediating - in conjunction with the adaptive response - opsonophagocytosis. 
Furthermore the innate response plays a role in activating adaptive immunity 
(Casal et al., 2003). 
 
Recognition of S. pneumoniae 
 
Strep infection is detected through multiple pathways. TLR2 recognises 
streptococcal cell wall lipoteichoic acid and other lipopeptides. TLR4 - which 
senses lipopolysaccharide (LPS) from gram-negative bacteria - is also involved in 
the response to Strep, possibly through recognition of pneumolysin. Streptococcal 
DNA is sensed by TLR9, while both pneumolysin and streptococcal DNA can 
induce inflammasome activation. Streptococcal DNA may also induce type 1 IFN 
signalling via stimulator of interferon genes (STING) (Koppe et al., 2012). In 
addition, the cytoplasmic receptor NOD2 senses cell wall peptidoglycan digested 
by lysozyme in phagocytes. (Davis et al., 2011). In response to streptococcal 
recognition, many pro-inflammatory cytokines are induced and contribute to 
defence, including IL-6, IL-12, IL-17, IL-18 and TNF-α (Casal et al., 2003; 
Bordon et al., 2012). 
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Opsonophagocytosis of S. pneumoniae 
 
Neutrophils and complement play, in conjunction with antibody, a crucial role in 
opsonophagocytosis of Strep. Neutrophil chemotaxis to Strep infected sites is 
promoted by both cytokines and bacterial components such as pneumolysin. 
Deposition of complement C3 on the surface of the bacteria is essential for 
protection against Strep. The relative contributions of the classical complement 
pathway, which is activated through antibodies bound to the surface of the 
bacterium and is considered an aspect of the adaptive response, or the alternative 
and lectin pathways, which are activated by direct binding of bacterial cell surface 
components and therefore are considered aspects of innate immunity, is still 
unclear. In addition to complement, soluble mediators such as the mucosal 
antimicrobial peptide surfactant protein D can promote opsonophagocytosis by 
binding streptococcal carbohydrates, causing bacterial aggregation and increasing 
neutrophil uptake (Casal et al., 2003; Kadioglu et al., 2004). 
 
Other aspects of the innate immune response to S. pneumoniae 
 
Complement may also be involved in activating adaptive immunity, as splenic 
marginal zone B-cells and follicular dendritic cells both express high levels of 
complement receptors, and these receptors appear to be required for the full 
induction of humoral immunity to Strep (Casal et al., 2003; Kadioglu et al., 
2004). Macrophages also contribute to streptococcal control by cytokine 
production and phagocytosis (Weiser, 2010).  
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1.8.3. Neutrophils in S. pneumoniae infection 
 
The antibacterial role of neutrophils during Strep infection has been extensively 
studied. Neutrophils migrate into Strep infected mouse lungs (Mizgerd et al., 
1996), and as previously outlined their role in opsonophagocytosis has been long 
established, as human neutrophils can kill Strep in vitro in an antibody and 
complement dependent manner (Janoff et al., 1999).  
 
Some in vivo mouse pneumonia models indirectly suggest that neutrophils are 
protective during Strep infection. Mouse strains that recruit more neutrophils 
during Strep infection are more resistant (Gingles et al., 2001). Overexpression of 
the neutrophil-promoting cytokine GM-CSF two weeks prior to streptococcal 
infection is protective (Steinwede et al., 2011), and neutrophils can also produce 
IFN-γ, which is shown to be protective, in response to Strep (Yamada et al., 
2011).  
 
Studies more directly addressing the role of neutrophils give more mixed results. 
Poorly specific neutrophil depletion by RB6 treatment exacerbates moderate Strep 
pneumonia (Sun et al., 2007; Zhang et al., 2009) and meningitis (Mildner et al., 
2008), although another pneumonia study finds RB6 reduces bacterial loads 
during severe pneumonia (Marks et al., 2007). Another study finds no effect of 
RB6-treatment during mild pneumonia (Stegemann et al., 2009). These 
discrepancies may be due to the use of different streptococcal isolates in each 
study, as well as different mouse strains and pathogen doses, giving different 
disease severities. It may be that, as is the case during IAV infection, neutrophils 
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are protective or pathogenic depending on disease context. Furthermore, despite 
the clear relevance of neutrophils to Strep control shown in some mouse models 
and in vitro studies, a strong association has not yet been found between human 
phagocyte deficiencies and opportunistic Strep infection (Rosenweig et al., 2009). 
 
Another notable study, although in a somewhat unusual context, shows specific 
neutrophil depletion using anti-Ly6G treatment increases bacterial loads in an 
infant mouse Strep carriage model (Short et al., 2012). This suggests that 
neutrophils help control bacterial load during Strep carriage. Notably, the higher 
bacterial loads result in greater transmission of Strep to cohoused “contact” mice 
infected with influenza, which is also relevant to coinfection.  
 
Strep uses different mechanisms to evade and counter the neutrophil response. An 
in vitro study shows Strep promotes neutrophil cell death (Zysk et al., 2000). 
Strep expresses endonucleases that enable evasion of NET-mediated killing 
(Beiter et al., 2006). Furthermore the bacterial capsule helps evade the 
opsonophagocytic neutrophil response by reducing complement deposition, 
interfering with both the classical and alternative complement pathways (Hyams 
et al., 2010).  
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1.8.4. TNF-α  in S. pneumoniae infection 
 
TNF-α is one of many proinflammatory cytokines induced during Strep, and is 
believed to have a protective role. Strep cell wall components stimulate TNF-α 
production by human monocytes (Heumann et al., 1994).  Mouse models have 
shown that TNF-α is upregulated during Strep pneumonia, and anti-TNF-α 
treatment increases bacterial loads and decreases survival (Van der Poll et al., 
1997), as well as decreasing immune cell numbers (Takashima et al., 1997). 
Another study corroborated these findings, and identified Gr-1+ cells as the major 
source of TNF-α (Hatta et al., 2010). Furthermore, TNFR1-/- mice have higher 
bacterial loads when challenged with Strep (Kerr et al., 2002).  
 
In contrast, another study found that TNF-α was not required for protection or 
pulmonary inflammation during a mild Strep infection, but helped prevent 
systemic disease in a lethal setting (Kirby et al., 2005). This may suggest TNF-α 
may only be crucial in more severe Strep infections. There may be some 
redundancy between TNF-α and IL-1β, as IL-1R1-/- mice show increased 
susceptibility to Strep only when also treated with anti-TNF-α (Rijneveld et al., 
2001). This is supported by the increased bacterial loads and reduced neutrophil 
infiltrate observed in TNFR1-/-TNFR2-/-IL-1R1-/- “triple mutant” mice (Jones et 
al., 2005); “single mutant” TNFR1-/-, TNFR2-/- or IL-1R1-/- mice did not show an 
impairment in neutrophil recruitment. In summary the majority of studies suggest 
TNF-α plays a protective role promoting pulmonary inflammation during Strep 
infection, but this may be dependent on the severity of the bacterial strain used, 
and there may be some redundancy with other proinflammatory cytokines. 
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1.8.5. Inflammatory monocytes in S. pneumoniae infection 
 
The role of CCR2-dependent inflammatory monocytes in Strep infection has not 
been extensively studied. In one study a protective monocyte/macrophage (in this 
case defined as F4/80+CD11b-, which may not be the cell population defined here 
as inflammatory monocytes) influx is reported to aid bacterial control. CCR2-/- 
mice have reduced monocyte/macrophage recruitment and moderately higher 
bacterial loads following Strep infection. The protective monocyte/macrophage 
influx is dependent on NOD2-sensing of bacterial peptidoglycan digested by 
lysozyme in phagocytes. NOD2 sensing also promotes downstream antibacterial 
antibody responses (Davis et al., 2011). Consistent with this, overexpression of 
MCP-1 in the lung increased mononuclear phagocyte recruitment (here defined as 
F4/80+CD11b+CD11clow) and reduced bacterial load during Strep pneumonia, 
although the danger of excessive immune responses was highlighted as MCP1 
overexpressing mice developed bronchiolitis obliterans (an inflammatory or 
fibrotic narrowing of the bronchioles) (Winter et al., 2007). In a different setting, 
CCR2 deficiency did not affect a mouse model of streptococcal meningitis 
(Mildner et al., 2008). Overall CCR2 dependent monocyte recruitment appears to 
be moderately beneficial during Strep infection, although this is dependent on the 
experimental context, and excessive monocyte recruitment may lead to lung 
damage. 
 
The role of TRAIL - a key inflammatory monocyte effector - in Strep infection 
has been investigated by two studies. Human monocytes stimulated with Strep or 
type 1 IFN in vitro upregulate TRAIL (Halaas et al., 2004). TRAIL-/- mice are 
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more susceptible to a moderate severity strain of Strep (Steinwede et al., 2012). It 
is proposed that TRAIL-expressing cells promote apoptosis rather than necrosis of 
DR5 expressing macrophages, which promotes bacterial killing. The protective or 
pathogenic role of TRAIL has not been investigated in more mild or severe Strep 
disease contexts, and therefore remains to be determined. 
 
1.9. Medical evidence for coinfection 
 
Coinfections in the 1918 pandemic 
 
There is a large body of medical evidence showing that IAV predisposes to 
secondary bacterial infections, particularly Strep. An analysis of bacterial culture 
records from autopsies in the 1918 “Spanish Flu” pandemic revealed that over 
95% of fatal cases had bacterial colonization in the lung (Morens et al., 2008). 
Strep was the most common bacterium identified, present in approximately 24% 
of cases. This suggests that many or even the majority of those killed in this 
pandemic may have died of coinfection.  
 
Coinfections in the 2009 pandemic 
 
More recent evidence from the 2009 “swine flu” IAV pandemic, where 
coinfection rates are likely to be reduced due to widespread antibiotic use, has 
supported this view. However there is substantial variation in the reported 
proportion of coinfections, possibly reflecting the different treatment and 
screening protocols in different regions. Many studies were carried out in the 
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United States. A report on postmortem samples from eight different US states 
showed 29% had evidence of coinfection, with Strep again the most common 
(Centre for Disease Control, 2009). Another US study of 100 fatal cases found 
25% showed evidence of coinfection, with Strep and S. aureus as the most 
common (Shieh et al., 2010). An analysis of medical records in New York found 
histological or microbiological evidence for coinfection in 55% of fatal cases (Gill 
et al., 2009). A screening of nasopharyngeal swab samples from pandemic 
patients most commonly detected S. aureus, S. pneumoniae, and H. influenzae, at 
approximately 15, 10 and 5% of patients respectively (Koon et al., 2010). 
Somewhat contradictorily, a study assessing the risk factors associated with death 
or hospitalisation in patients in California found bacterial coinfections in only 4% 
of patients (Louie et al, 2009).  
 
Studies in other countries also show variable rates of coinfection. An observation 
of 337 patients on mechanical ventilation in Argentina showed 8.3% had Strep 
coinfection (Estenssoro et al., 2010), while another study on hospitalised patients 
in Spain found 62% had Strep coinfection (Cilloniz et al., 2012). An Australian 
analysis found a 25% coinfection rate in 2009 pandemic cases, with S. aureus as 
the most common (Blyth et al., 2013). A South African study of Strep 
bacteraemia from 2009-11 found prior influenza in 8% of patients, and a 
correlation with increased pneumococcal load (Wolter et al., 2013). 
 
Whether coinfection is more common during pandemic or seasonal influenza, and 
whether this affects the severity of pandemics, is not yet clear. A study assessing 
seasonal versus pandemic IAV from 2005-2009 in Sweden found lower levels of 
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coinfection during the pandemic, although again identified Strep as the most 
common coinfection (Liderot et al., 2013). In contrast to this, a study on 
American children found more cases of coinfection in pandemic than non-
pandemic influenza, identifying Strep and S. aureus the most common (Dawood 
et al., 2013). Furthermore incidence of invasive pneumoccal pneumonia was 
higher during 2009 than 2008 in Barcelona, correlating with the influenza 
pandemic (Pedro-Botet et al., 2014). Overall, a wide range of evidence suggests 
Strep and to a lesser extent S. aureus coinfection was a widespread complicating 
factor during the 2009 IAV pandemic.  
 
Coinfections from seasonal influenza 
 
In addition to reports from IAV pandemics, another study has reported a 
correlation between seasonal IAV and the incidence of invasive pneumococcal 
pneumonia (Fleming-Dutra et al., 2013). Mathematical models have reinforced 
this conclusion (Grabowska et al., 2006), and proposed there is a short term 
“susceptibility window” following IAV infection (Shrestha et al., 2013). Another 
model proposes an association between Strep meningitis and prior viral infection 
(Opatowski et al., 2013). In summary, there is substantial evidence for both IAV-
Strep coinfection and other secondary bacterial coinfections, both in pandemic 
and seasonal settings, and therefore investigating this phenomenon is highly 
relevant to public health. 
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1.10. In vitro models of coinfection 
 
1.10.1. Influenza A-S. pneumoniae models 
 
Studies of IAV-Strep coinfection generally attribute mortality to a failure to 
control the bacterial infection, and propose mechanisms that fit into two broad 
categories. Firstly, those suggesting prior influenza leads to immune impairment 
in the antibacterial response to Strep. Secondly, those proposing lung dysfunction 
- such as epithelial damage or increased bacterial adhesion - allows Strep 
colonization. Many studies have investigated these causes of coinfection in vitro. 
 
Immune impairment 
 
Several studies have investigated different aspects of immune impairment during 
coinfection. The combination of IAV and bacteria may lead to immune 
impairment through neutrophil dysfunction. IAV accelerates E. coli induced 
human neutrophil apoptosis (Colamussi et al., 1999), and a subsequent study 
reproduced this result with Strep (Engelich et al., 2001). However, IAV also 
caused increased neutrophil function such as ROS production and phagocytosis, 
contrary to the concept of “impairment”. Combining these two concepts, excess 
apoptosis was later attributed to cooperative IAV-E. coli stimulation of the 
respiratory burst (Engelich et al., 2002). Therefore it appears that IAV can lead to 
hyperactivation and excess neutrophil death, although whether this would 
represent “impairment” in vivo is not clear.  
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Contrasting with the concept of immune impairment, two studies have observed 
greater release of proinflammatory cytokines from human monocyte-derived 
dendritic cells when stimulated with IAV and Strep than with each stimuli alone 
(Wu et al., 2011; Kuri et al., 2013). In summary although in vitro studies suggest 
IAV can lead to neutrophil dysfunction, it is not clear whether strong immune in 
vivo impairment occurs. 
 
Epithelial adhesion 
 
Other in vitro studies have suggested IAV allows greater epithelial adhesion by 
Strep. IAV and other viral infections increase the adherence of Strep and H. 
influenzae to primary and immortalised cell lines (Avadhanula et al., 2006). IAV 
also increases Strep adherence to a human alveolar cell line (McCullers, 2004). 
This effect is ameliorated by inhibition of the viral neuraminidase, which may 
expose bacterial binding sites on epithelial cells through sialic acid cleavage. 
However, in this instance it is not clear whether the protective effect of 
neuraminidase inhibition is due to prevention of pneumococcal binding site 
exposure or treatment of the underlying viral infection. 
 
Secondary Strep infection may also have an affect on primary IAV infection. 
Blockade of influenza replication in a Madin-Darby canine kidney (MDCK) cell 
line by a viral neuraminidase inhibitor is rescued by addition of a streptococcal 
neuraminidase, suggesting some cooperation between pathogens in viral release 
(Nishikawa et al., 2012). In summary in vitro models suggest that IAV can 
increase Strep adhesion to epithelial cells, and may have effects on viral release. 
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1.10.2. Other in vitro coinfection models 
 
Although Strep appears to be the most common secondary coinfection following 
IAV many other coinfections have been detected. This may indicate that IAV 
promotes susceptibility to secondary infections through a broad, non-specific 
mechanism, or through multiple different mechanisms. Other coinfections 
following IAV have also been investigated in vitro, and may also provide useful 
insights into IAV-Strep coinfection. As with IAV-Strep coinfection models, they 
generally suggest immune impairment or increased epithelial adhesion as 
mechanisms of coinfection. 
 
Immune impairment 
 
One possible mechanism of immune impairment is the antagonism of Type I IFNs 
with IL-1β production in human bone-marrow-derived macrophages (Guarda et 
al., 2011), which is of interest as type I IFNs are induced in influenza infection. 
Type I IFN-IL-1β antagonism may be mediated through the induction of nitric 
oxide, which inhibits the NLRP3 inflammasome (Hernandez-Cuellar et al., 2012). 
Components of the type I IFN signalling pathway may also inhibit other 
proinflammatory cytokine production. RIG-I stimulation in mouse peritoneal 
macrophages leads to activation of IRF3, which can bind to the IL-12 promoter 
and directly suppress IL-12p40 protein production, causing susceptibility to L. 
monocytogenes (Negishi et al., 2012). However, in contrast to effect of interferon 
alone in these studies, human peripheral blood leucocytes produce more TNF-α 
and IL-1β upon endotoxin treatment with prior IAV stimulation (Ludemose et al., 
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1993). Overall, it is possible to speculate that IAV derived type 1 IFN may hinder 
aspects of the immune response, such as the inflammasome; however, a combined 
IAV-bacterial stimulus may also lead to more proinflammatory cytokine 
production. 
 
Epithelial adhesion 
 
Other in vitro coinfection models also show that influenza can promote bacterial 
epithelial adhesion. IAV increases adhesion of S. aureus to alveolar cell lines 
(Passariello et al., 2011), and promotes invasion by methicillin-resistant S. aureus 
into the MDCK cell line (Takayama et al., 2014). Furthermore, swine H1N1 IAV 
increases adhesion of S. suis (a streptococcus swine pathogen) to a swine tracheal 
epithelial cell line (Wang et al., 2013). Therefore IAV appears to increase 
bacterial adhesion to epithelial cells in multiple species. 
 
1.11. Mouse models of coinfection 
 
1.11.1. Characteristics of Influenza A-S. pneumoniae mouse models 
 
There are many in vivo mouse models suggesting a range of mechanisms for 
coinfection. Similar to results from in vitro models, either IAV-mediated immune 
impairment or lung damage/dysfunction are generally proposed as mechanisms. 
The majority of models focus on acute coinfection in the first two weeks 
following influenza infection, and share several common characteristics. 
Typically a window of susceptibility to secondary infection from 3 to 14 days post 
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influenza is observed, with greatest susceptibility at approximately 7 days 
(McCullers et al., 2002). Also observed is loss of bacterial control in the lung and 
subsequent dissemination to other organs (Goulding et al., 2011). In some models 
using severe influenza infections, coinfection delays viral clearance (Smith et al., 
2013). Increases in many proinflammatory cytokines are also frequent (Smith et 
al., 2007). 
 
1.11.2. Immune impairment in coinfection 
 
Several different aspects of the immune response have been reported to be 
impaired during IAV-Strep coinfection. While most models focus on acute 
coinfection, influenza can lead to long-term desensitisation to TLR ligands, 
causing increased susceptibility to Strep up to 6 weeks following primary IAV 
infection (Didierlaurent et al., 2008). 
 
Alveolar macrophage impairment 
 
In acute coinfection models alveolar macrophages have been reported to be 
impaired - decreased alveolar macrophage phagocytosis, changes in functional 
state and a reduction in total numbers have been observed.  IFN-γ produced 
during the T-cell response to IAV impairs bacterial phagocytosis by reducing the 
expression of the scavenger receptor MARCO on alveolar macrophages (Sun et 
al., 2008). The negative role of IAV-induced IFN-γ is supported by another study 
showing treatment with linezolid - which moderately reduces the IFN-γ response 
to influenza - improves survival during coinfection (Breslow-Deckmann et al., 
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2013). CD200 is a cell-surface ligand expressed on apoptotic cells during 
influenza that negatively regulates alveolar macrophages via CD200R. CD200R-/- 
mice have increased resistance to coinfection, suggesting that CD200 expression 
reduces the alveolar macrophage antibacterial response (Goulding et al., 2011). It 
is also possible that macrophages are in the “wrong” functional state - the 
expression of genes associated with alternatively activated macrophage activation 
such as FIZZ-1 are elevated during influenza. As these macrophages may be less 
antibacterial than classically activated macrophages, this may contribute to 
coinfection (Chen et al., 2012). Reduction in the total number of alveolar 
macrophages by influenza prior to coinfection has also been described (Ghoneim 
et al., 2013). To summarize, alveolar macrophages may be depleted and impaired 
during influenza, causing susceptibility to secondary Strep infection. 
 
Neutrophil impairment 
 
Influenza may also impair neutrophil function although, unlike alveolar 
macrophages, total neutrophil numbers are increased during coinfection (LeVine 
et al., 2001; Li et al., 2013). One study reports greater neutrophil numbers and 
increased myeloperoxidase activity in the lung, but does show the phagocytic 
capacity of neutrophils from coinfected mice is marginally decreased in vitro 
(Damjanovic et al., 2013).  Another study reports reduced myeloperoxidase per 
neutrophil in the lung (LeVine et al., 2001). The level of alpha-1-anti-trypsin, 
which may impair the activity of neutrophil proteolytic enzymes, is also increased 
in coinfection (Kosai et al., 2008). Although influenza can induce neutrophil 
NETs, these do not appear to participate in subsequent Strep killing (Moorthy et 
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al., 2013). Overall whether neutrophils are impaired in coinfection remains 
unclear; total neutrophil numbers and some aspects of their function are increased, 
but others appear to be moderately impaired. 
 
Two studies have attempted to deplete neutrophils in coinfection to further 
elucidate whether they are impaired, and to determine whether they are on balance 
protective or pathogenic. However, various issues with these studies means it is 
difficult to clearly assess the role of neutrophils. One study reports specific 
neutrophil depletion using 1A8 does not exacerbate bacterial load or pathology 
during coinfection (Damjanovic et al., 2013). However, in this coinfection model 
all mice reach endpoint, and therefore only a very strong positive effect of 
depletion would be detectable; a negative effect would not be detected. Another 
study depletes neutrophils with low specificity using RB6 during Strep and 
coinfection. This depletion exacerbates Strep infection, and Strep coinfection 
performed 3 days after IAV; however, it had no effect when coinfection was 
performed 6 days after IAV (McNamee et al., 2006). This study suggests this is 
due to progressively increasing neutrophil impairment during IAV infection, 
rendering them non-protective (and therefore depletion has no effect) at 6 days 
post infection (dpi). Somewhat confusingly given this premise, this study showed 
that ROS production and neutrophil-bacterial association in vitro is reduced in 
neutrophils extracted from influenza-infected mouse lungs at both 3 and 6dpi. 
Furthermore, to increase the number of neutrophils elicited for functional assays, 
this study simultaneously treated influenza-infected mice with LPS aerosolization. 
Therefore the poor specificity of in vivo depletion and potentially confounding 
factor of LPS aerosolization make these results hard to interpret. An alternative 
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interpretation of these results is that lower bacterial loads observed following 
Strep infection alone and during coinfection performed at 3dpi can be exacerbated 
by neutrophil depletion, while there is no capacity to exacerbate the already very 
high loads observed during coinfected performed at 6dpi. Therefore whether 
neutrophils are protective or pathogenic during coinfection remains unclear.   
 
Impairment mediated by influenza induced cytokines 
 
Cytokines produced during influenza may contribute to coinfection susceptibility 
through immune impairment. The anti-inflammatory cytokine IL-10 may promote 
coinfection by inhibiting the immune response, as anti IL-10 treatment 
ameliorates disease (Van der Sluijs et al., 2004), although this was not reproduced 
with IL-10-/- mice (Sun et al., 2008).  
 
Several studies have implicated influenza-induced type I IFNs as detrimental to 
the antibacterial response – IFNαβR-/- mice are more resistant to coinfection, 
produce more of the neutrophil chemoattractants KC and MIP2, and recruit 
greater neutrophil numbers (Shahangian et al., 2009). Also of note is that this 
result also implies, but does not confirm, that neutrophils are protective during 
coinfection; this is reinforced as administration of recombinant KC and MIP2 
increases protection in wild-type mice. Another study with a similar implication 
shows Type I IFN transiently reduces IL-17 production by γδ T cells, leading to 
moderately reduced neutrophil recruitment (Li et al., 2012); this effect may be 
mediated by IFN-induced IL-27 (Cao et al., 2014). Polyinosinic:polycytidylic 
acid (Poly I:C) – a TLR3 agonist that induces a type I IFN response – promotes 
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susceptibility to subsequent Strep infection (Tian et al., 2012). Type I IFN can 
also exacerbate pre-existing pneumococcal carriage through the inhibition of 
CCL2 production and macrophage recruitment (Nakamura et al., 2011). However, 
in contrast to these studies showing a detrimental role for type I IFN, expression 
of IFNα through treatment with an adenoviral vector increases survival and the 
neutrophil response in an otherwise lethal Strep infection (Damjanovic et al., 
2014). Therefore whether type I IFN derived from influenza promotes 
susceptibility to Strep infection is not clear, although the majority of studies 
suggest it plays a harmful role. 
 
Not all influenza-induced cytokines necessarily have a detrimental role during 
coinfection; influenza induces IL-22, and IL-22-/- mice are more susceptible to 
coinfection, suggesting this induction is protective (Ivanov et al., 2013).  
 
Strong proinflammatory responses during coinfection 
 
In contrast to the studies above, other investigations suggest that coinfection 
induces a strong inflammatory response.  Multiple studies have observed 
increased levels of proinflammatory cytokines induced in coinfection relative to 
IAV or Strep alone, such as IL-1β and TNF-α (LeVine et al., 2001), and IL-12 
and IFN-γ (Seki et al., 2004; Smith et al., 2007; Kukavica-Ibrulj et al., 2009). As 
previously stated, neutrophil numbers are also increased in coinfection (LeVine et 
al., 2001; Li et al., 2013). Given that many aspects of the immune response are 
increased in coinfection, one possible critique of studies suggesting immune 
impairment as a mechanism is that they focus strongly on one aspect of the 
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immune response that is decreased, while overlooking an otherwise greatly 
heightened proinflammatory response. 
 
Interventions affecting the immune response and their implications 
 
Interventions that promote aspects of the immune response are sometimes 
protective in coinfection. This implies that these components of the immune 
response in coinfection are often insufficient; however it does not confirm that 
these are impaired relative to the response to single Strep infection. Combination 
therapy following bacterial infection with intravenous immunoglobulin and P4 
peptide - an immunomodulator that increases the activity of phagocytic cells - 
improves coinfection survival (Weeks et al., 2011). TLR4 agonistic antibody 
treatment during IAV and Strep infection improves coinfection survival and 
reduces bacterial loads (Tanaka et al., 2013). However, reduced levels of the 
proinflammatory cytokines TNF-α, IL-6, KC and MIP2 are observed following 
this treatment, which may be a consequence of reduced bacterial loads. Therefore 
whether this study “increases” the immune response is not clear.  
 
In contrast some interventions dampening components of the immune response 
during coinfection are protective. This contrasts with the concept that these 
factors of the immune response are impaired, instead suggesting they may be 
excessively induced and contribute to immunopathology. Treatment with 
dexamethasone – an anti-inflammatory steroid – improves survival of severely ill 
coinfected mice (Ghoneim et al., 2013).  Inhibition of indoleamine-2,3-
dioxygenase (a tryptophan-catabolising enzyme, which, although canonically 
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associated with anti-inflammatory responses, can increase cytokine production in 
epithelial cells) marginally reduces bacterial outgrowth and the levels of TNF-α 
and IL-10 during coinfection (van der Sluijs et al., 2006). Although this implies 
these cytokines are harmful, it is possible that the effect of indoleamine-2,3-
dioxygenase inhibition is through another mechanism, and, similar to previous 
suggestions, reduction of cytokine levels is a consequence rather than a cause of 
reduced bacterial loads. 
 
A study assessing the efficacy of different antibiotics during coinfection 
suggested that TLR2 recognition of Strep and the resultant excessive 
inflammation may be harmful. TLR2-/- mice are marginally more protected from 
coinfection, and ampicillin was shown to be a poor antibiotic, as it led to excess 
Strep lysis and TLR2 stimulation (Karlstrom et al., 2009; Karlstrom et al., 2011). 
However these results are somewhat in contrast to other studies where TLR2-/- 
mice did not exhibit any changes relative to wild type mice in susceptibility to 
coinfection (Dessing et al., 2007), and where ST2 (a negative regulator of TLR2) 
deficiency has no effect (Blok et al., 2013). Overall, it remains unclear whether 
the aspects of the immune response to coinfection are impaired, and whether 
decreasing or promoting these responses is protective.  
 
1.11.3. Lung dysfunction or damage in coinfection 
 
In addition to immune impairment, the other major proposed cause of 
susceptibility to IAV-Strep coinfection is lung damage or dysfunction caused by 
influenza infection. This can take a range of forms, such as exposure of bacterial 
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binding sites and increased adhesion, a gross reduction in integrity due to viral 
damage, or decreased mechanical bacterial clearance.  
 
Increased epithelial adhesion 
 
Several studies have suggested IAV increases streptococcal binding to the lung 
epithelium. IAV increases streptococcal adherence to mouse tracheal epithelial 
cells (Plotkowski et al., 1986). One proposed mechanism is for this exposure of 
bacterial binding sites due to sialic acid cleavage by viral neuraminidase. 
Supporting this, treatment with the neuraminidase inhibitor oseltamivir 
ameliorates coinfection (McCullers et al., 2003), although this may simply reflect 
treatment of the primary initial viral infection.  
 
One bacterial binding site that may be exposed by influenza during coinfection is 
the epithelial receptor PAFR, which is bound by the streptococcal virulence factor 
ChoP. PAFR mRNA expression is highly upregulated in influenza infected and 
coinfected mouse lungs, and PAFR-/- mice are slightly more resistant to 
coinfection, with moderately reduced bacterial loads (van der Sluijs et al., 2006; 
Seki et al., 2009). Furthermore, in a model of single Strep infection, reduction of 
PAFR levels upon treatment with type I IFN reduced streptococcal binding and 
epithelial transmigration (LeMessurier et al., 2013). These studies suggest 
upregulation and exposure of PAFR during coinfection contributes to bacterial 
colonization. However another coinfection study shows that treatment with a 
competitive PAFR antagonist increases bacterial load (McCullers et al., 2002). 
Therefore whether PAFR binding is a significant contributor to coinfection 
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susceptibility remains unclear. In summary IAV increases streptococcal epithelial 
binding, and different binding sites have been implicated; however, it has not 
been shown conclusively that this is a mechanism of coinfection. 
 
Lung damage and other lung dysfunctions 
 
Influenza-induced lung damage may also promote coinfection, as demonstrated 
by several studies assessing the effect of the proapoptotic viral peptide PB1-F2. 
IAV strains expressing PB1-F2 and the resulting lung damage and inflammation 
cause more severe coinfections (McAuley et al., 2008). This may be dependent on 
a specific PB1-F2 sequence (Alymova et al., 2013), and different PB1-F2 variants 
have been correlated with coinfections of different severity (Weeks-Gorosope et 
al., 2012).  
 
Influenza may also reduce mechanical clearance of streptococci. Influenza 
infection suppressed ciliary beating in an ex vivo trachea model, leading to 
reduced bacterial clearance (Pittet et al., 2010), and this may contribute to 
streptococcal colonization of the lung in vivo.  
 
Most coinfection studies imply mortality is a consequence of bacterial outgrowth, 
and propose mechanisms that facilitate streptococcal outgrowth. However, 
another lung dysfunction that may contribute to mortality is a lack of lung repair. 
Transcriptional profiling in a model of 2009 pandemic IAV-Strep coinfection 
showed a lack of lung repair responses (Kash et al., 2011). However, these mice 
also exhibited bacterial outgrowth and bacteraemia, which may cause mortality. 
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Furthermore, lack of lung repair may be due to a loss of pathogen control, where 
inflammation rather than resolution and repair may be a more appropriate 
response.  
 
1.11.4. Other aspects of coinfection mouse models 
 
Many other models of IAV-Strep coinfection that do not focus on immune 
impairment or lung dysfunction also provide further insights into the synergy 
between infections. One study shows influenza may have a direct effect on Strep 
biology – damage signals induced by influenza may cause the transition of Strep 
from a biofilm-like to a potentially more infectious dispersed state (Marks et al., 
2013). Another study focuses on aspects of Strep that promote colonization during 
coinfection. PspA - a virulence factor that interferes with complement deposition  
- deficient streptococci cause less severe coinfections (King et al., 2009). This 
indicates that intact streptococci expressing bacterial virulence factors are 
required for coinfection. 
 
In addition to promoting coinfection within individuals, IAV also promotes 
transmission of Strep. IAV increases Strep transmission between infant mice 
(Diavatopoulous et al., 2010) and in ferrets (McCullers et al., 2010). Whether this 
is due to a defined mechanism or simply a consequence of increased bacterial 
loads in coinfected donor animals raising the probably of transmission is not clear. 
 
There are various proposed interventions for coinfection, which may give further 
mechanistic information. Several quinolone antibiotics have been shown to be 
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protective (Hayashi et al., 2006), as is garenoxacin (Fukada et al., 2013), 
suggesting bacterial outgrowth is the primary driver of mortality in coinfection. 
Reducing the severity of prior influenza infection through vaccination with 
FluMist is protective (Sun et al., 2011). Live attenuated influenza vaccine is also 
protective, but not pneumococcal conjugate vaccine (Mina et al., 2013). These 
results hint that the key determinant of coinfection is the severity of primary viral 
infection rather than anti-streptococcal immunity, and therefore ameliorating 
influenza represents the best therapeutic strategy. However, somewhat countering 
this concept, immunization with pneumococcal PspA, whether alone (Seo et al., 
2012) or with Poly I:C treatment (Ezoe et al., 2011) also ameliorates coinfection.  
 
1.11.5. Mouse models of other influenza A coinfections 
 
Mouse models of other IAV coinfections can also provide useful insights into 
possible IAV-Strep coinfection mechanisms, particularly where similar 
mechanisms are observed. The diversity of coinfections observed may indicate 
that IAV promotes susceptibility to secondary infections through a broad, non-
specific mechanism, or through multiple different mechanisms.  
 
Immune impairment during S. aureus coinfection  
 
S. aureus is a common coinfection, and has been extensively investigated in 
mouse models. The majority of studies focusing on IAV-S. aureus coinfection 
show immune impairment, particularly of proinflammatory cytokines and 
phagocytes. Whether these mechanisms are directly applicable to IAV-Strep 
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coinfection is not clear, although some similarities are evident. Similarly to results 
from an IAV-Strep coinfection study (Li et al., 2012), IAV reduced the IL-17 
response to S. aureus (Kudva et al., 2010; Robinson et al., 2013). Inhibition of the 
IL-17 response can lead to reduced IL-1β production (Robinson et al., 2013). 
Influenza induced IFN-γ can also reduce phagocytosis of S. aureus by alveolar 
macrophages (Hang et al., 2011). This is similar to IFN-γ mediated suppression of 
the phagocytic receptor MARCO on alveolar macrophages during IAV-Strep 
coinfection (Sun et al., 2008). Influenza also impairs the NK cell response to S. 
aureus in the lung (Small et al., 2010). 
 
Similarly to prior reports in IAV-Strep coinfection (McNamee et al., 2006), 
influenza may also inhibit the neutrophil response to S. aureus coinfection. 
Influenza inhibits the NADPH oxidase involved in the neutrophil respiratory burst 
during IAV-S. aureus coinfection (Sun et al., 2014), and promotes neutrophil 
death mediated by the S. aureus cytotoxic factor Panton-Valentine leukocidin 
(Niemann et al., 2012). Mice overexpressing GM-CSF were protected against S. 
aureus coinfection due to greater numbers of alveolar macrophages and 
neutrophils (Subramaniam et al., 2013). Depletion of alveolar macrophages, 
neutrophils or reactive oxygen species removes the protective effect of GM-CSF 
overexpression. These studies strongly suggest neutrophil death or reduced 
function contributes to bacterial coinfection. However, in another IAV-S. aureus 
coinfection model, depletion of neutrophils or alveolar macrophages had no effect 
(Iverson et al., 2011). In summary, although not all results are completely 
consistent with this view, susceptibility to S. aureus coinfection is likely due to 
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suppression of proinflammatory cytokines and phagocytes by influenza, and this 
immune impairment may be relevant to IAV-Strep coinfection. 
 
Immune impairment in other coinfections 
 
Other coinfections have also been investigated, and may also provide mechanistic 
information that relates to IAV-Strep coinfection. Immune impairment mediated 
by influenza-derived cytokines has been investigated. Peak susceptibility to N. 
meningitis correlates with influenza-induced IFN-γ (Alonso et al., 2003). 
Although this specific study does not investigate immune impairment, it is notable 
that influenza-induced IFN-γ appears to increase susceptibility to several different 
bacteria, and IFN-γ mediated immune impairment may represent a general 
mechanism of coinfection.  
 
Type I IFNs also appear to promote susceptibility to a range of bacterial infections 
through immune impairment. As type I IFNs are induced during influenza, this 
may be highly relevant to IAV-Strep coinfection, although most studies described 
here induce type I IFNs through other means than IAV infection. Type I IFNs can 
induce susceptibility to L. monocytogenes (O'Connell et al., 2004; Auerbuch et 
al., 2004; Carrero et al., 2004), possibly through suppression of protective IFNγ 
signalling in macrophages (Rayamajhi et al., 2010), or overactivation and death of 
bone marrow granulocytes (Navarini et al., 2006). This observation may be 
relevant to IAV-Strep models where IFNαβR-/- mice are more granulophillic and 
coinfection resistant (Shahangian et al., 2009). In addition, induction of type I 
IFNs by Poly I:C treatment appears to exacerbate M. tuberculosis infection 
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(Antonelli et al., 2010), and type I IFNs suppress protective IL-1 production 
(Mayer-Barber et al., 2011). More directly linking type I IFNs to coinfection, one 
study shows prior influenza can exacerbate M. tuberculosis infection in a type 1 
IFN dependent manner (Redford et al., 2014).  
 
Another aspect of influenza-mediated immune impairment is the production of 
glucocorticoids, which can lead to systemic suppression of the immune response 
and susceptibility to L. monocytogenes (Jamieson et al., 2010). However, it is 
notable that removal of the glucocorticoid response by adrenalectomy led to an 
excessive immune response and mortality, and therefore this highlights the 
delicate balance between bacterial control and immunopathology required to 
control coinfection.  
 
Immunopathology and tissue damage in other coinfections 
 
Some studies suggest immunopathology is the primary driver of mortality during 
coinfection, and attempt to ameliorate this. One study attempted to reduced IAV- 
immunopathology during IAV-H. influenzae coinfection, but disease severity was 
not ameliorated by CCR2 or TNFR1 deficiency (Lee et al., 2010). An IAV-B. 
pertussis model - although observing increased bacterial loads - attributed 
mortality to immunopathology, especially excessive neutrophil recruitment 
(Zavitz et al, 2010). However, this model gave somewhat contradictory results, as 
while blockade of the neutrophil chemoattractant MIP2 was protective, blockade 
of its receptor CXCL2 (which is also a receptor for the neutrophil chemokine KC) 
was harmful. This highlights the difficulty, in the context of bacterial outgrowth 
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during coinfection, in dissecting protective and pathogenic aspects of the immune 
response. 
 
One study attempts to address this practical difficulty using a highly unusual IAV-
L. pneumophila coinfection model. This study shows mortality even in the 
absence of bacterial outgrowth, which is attributed to an inability to tolerate tissue 
damage. This coinfection can be ameliorated by treatment with amphregulin - an 
epithelial growth factor - in TLR2 and 4 deficient mice (Jamieson et al., 2013). 
Complicating these findings, tissue damage does not appear to be dependent on 
the immune response. Although a context where bacterial outgrowth does not 
occur is useful, it is arguable it renders this model somewhat unphysiological and 
difficult to compare to other mouse models. 
 
Bacterial infections prior to influenza 
 
Although almost all studies focus on bacterial coinfections following influenza, a 
small proportion test the effect of pre-existing bacterial colonization. As pre-
existing carriage of Strep is common (Kadioglu et al., 2008), these models may 
have some relevance to IAV-Strep coinfection.  
 
Interestingly, application of bacteria prior to influenza (“coinfection in reverse”) 
can ameliorate the subsequent influenza infection. Exposure to a H. influenzae 
lysate (Tuvim et al., 2009) or L. rhamnosus (Harata et al., 2010; Youn et al., 
2012) increases the immune response against influenza. Priming with low-
pathogenicity S. aureus can lead to alternative macrophage activation during 
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influenza, reducing lung injury (Wang et al., 2013). These protective effects, 
albeit with inactivated or non-pathogenic bacteria, may imply the timing of 
coinfection is crucial. 
 
1.12. Project outline: Investigating the immune response to Influenza A-S. 
pneumoniae coinfection  
 
Although there has been extensive research on the immune response to IAV-Strep 
coinfection, several aspects remain unclear, and there are limitations to many 
existing studies. Downstream consequences of bacterial outgrowth are frequently 
not separated from assessment of the underlying influenza-induced factors that 
allow initial bacterial colonization. Very severe coinfection regimes are used, 
which only give scope to perform strongly protective interventions, limiting what 
can be investigated. Furthermore, not all single infection controls are performed, 
leaving interpretation of interventions difficult. In this thesis I use a mouse model 
of IAV-Strep to investigate the underlying mechanisms involved in bacterial 
colonization, and investigate the subsequent immune response, while attempting 
to address these issues.  
 
Several aspects of the immune response during coinfection merit further 
investigation. The protective role of neutrophils has been implied by previous 
studies (Shahangian et al., 2009) but has not been assessed with a specific 
depletion except in the context of a severe coinfection (Damjanovic et al., 2012). 
Furthermore neutrophil function has not been assessed using lung neutrophils 
without confounding factors such as LPS aerosolization (McNamee et al., 2006). 
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Although an increase in TNF-α during coinfection (LeVine et al., 2001) has been 
observed previously, its role as beneficial or as a promoter of immunopathology is 
not clear. The role of CCR2 dependent inflammatory monocytes has only been 
studied in a pneumococcal carriage-IAV model (Nakamura et al., 2011), not in 
acute coinfection.  
 
Therefore in this thesis I investigate a mouse model of IAV-Strep coinfection. I 
use low virulence single infections to assess synergy rather than effects of the 
single infections themselves. I initially perform broad profiling of the immune 
response, and observe substantial upregulation of neutrophils and 
proinflammatory cytokines, including TNF-α. The coinfection model is then 
calibrated to approximately 50% mortality, allowing both positive and negative 
interventions to be detected. Using a range of interventions to investigate 
mechanisms, I propose a model where influenza induced TRAIL-expressing 
inflammatory monocytes mediate lung damage, allowing bacterial colonization 
and outgrowth. Outgrowth is subsequently countered by a protective TNF-α and 
neutrophil response, which does not appear to be functionally impaired, but can 
often be insufficient to prevent mortality. In addition to the main focus of my 
thesis, I also more briefly investigate other aspects of coinfection that have not 
been previously comprehensively studied, such as bacterial spread to the brain. 
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Chapter 2. Materials and Methods 
 
Mice: All experiments unless otherwise specified used 6-10 week old C57BL/6 
mice bred at the MRC-National Institute for Medical Research (NIMR) under 
specific pathogen–free conditions. Rag1-/- (C57BL/6 Jackson Rag1-/- - MOM) mice 
were bred at the NIMR under specific pathogen–free conditions. CCR2-/- 
(C57BL/6) mice were kindly provided by Dr. A. O’Garra (NIMR) and Dr. J. 
Langhorne (NIMR). IFNαβR-/- (C57BL/6) mice were kindly provided by Dr. A. 
O’Garra (NIMR). TNFR1-/- (p55) (C57BL/6 N6) and TLR2-/- (C57BL/6 N7) mice 
were kindly provided by Dr. J. Langhorne (NIMR). All protocols for breeding and 
experiments with animals were approved by the Home Office, UK, under the 
Animals (Scientific Procedures) Act 1986 and project licence 70/7643. 
 
Clinical scoring and endpoints: Mice were deemed to have reached endpoint at 
75% of starting weight or at a moderate severity clinical score of 5 or greater. 
Clinical scores were determined by (1 point each) piloerection, hunched posture, 
laboured breathing, decreased movement, movement only on provocation, 
absence of movement on provocation, hypothermia, partially closed eyes or 
evidence of middle ear infection (disrupted balance). 
 
Preparation of pathogens and mouse infections: Influenza A virus strain X31 
(H3N2) (a reassortment virus with the A/PR/8/34 (H1N1) backbone) was grown 
in day 10 embryonated chicken eggs (kindly performed by the Division of 
Virology, NIMR), stored at -80° and titrated on confluent monolayers of MDCK 
cells, with cellular lysis observed after 3 days. TCID50 was calculated according 
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to the Spearman-Karber method. S. pneumoniae D39 (a kind gift from Dr. M. 
Coles, University of York) was stored at -80° on cryopreservative beads 
(Technical Services Consultants). Identity of Strep bead stocks was verified by 
observation of α-hemolysis and optochin-sensitivity upon plating on brain heart 
infusion agar plates supplemented with defibrinated horse blood, and using API 
Strep 20 kits (Biomerieux) as per the manufacturer’s instructions. Strep for mouse 
infection was grown from bead stocks in brain-heart infusion broth under 
microaerophillic conditions at 37° for 16 hours to autolytic phase, then 
subcultured and grown to an optical density of 0.4, then centrifuged at 3000rpm 
for 5 minutes and room temperature, before resuspension in PBS immediately 
prior to infection. When described as “heat killed” the bacterial preparation was 
incubated 80° for 10 minutes, and killing of bacteria confirmed by plating. Mice 
were typically infected under light transient isoflurane-induced anaesthesia with a 
30µl volume via the intranasal route (i.n.). Where specified, mice were infected 
under ketamine-induced anaesthesia with a 20µl volume via the intratracheal 
route (i.t.). Mice were awakened from ketamine anaesthesia using atipamezole. 
 
Mouse Treatments: 15µg/30µl Pam3CSK4 (Enzo Life Sciences) was given i.n. 
under light transient isoflurane-induced anaesthesia at 5dpi. 50µg/30µl Poly I:C 
(Enzo Life Sciences) was given under light transient isoflurane-induced 
anaesthesia at 3 and 4 dpi. All antibody treatments were given via the 
intraperitoneal route (i.p.) in a 200µl volume. 150µg anti-Ly6G (clone 1A8) or 
isotype control (2A3) (BioXCell) were given every 24 hours from 4 to 12dpi. 
500µg anti-Gr-1 (RB6-8C5) (BioXCell) or vehicle control (PBS) were given 
every 48 hours from 4 to 8dpi. 500µg anti-TNF-α (XT3.11) or isotype control 
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(HRPN) (BioXCell) were given on 5 and 7dpi. 150µg anti-TRAIL (Cambridge 
Bioscience) or vehicle (PBS) were given as either continuous treatment every 48 
hours from 1 to 9dpi, early treatment at 1 and 3dpi, or late treatment at 6 and 8dpi.  
 
Histology: Whole lungs were perfused with 10% neutral buffered formalin (NBF) 
in situ. Tissue was then fixed for 24 hours in 10% NBF, embedded in paraffin and 
sectioned. Each lung specimen was stained with hematoxylin and eosin (H&E) 
(performed with the assistance of Histology section, NIMR). Imaging of slides 
was performed on a VS120 slide scanner (Olympus) with a VC50 camera, a 
UPLSAPO lens, at magnification of 20x and a numerical apeture of 0.75. Images 
were analysed using OlyVia Image Viewer 2.6 (Olympus). 
 
Quantification of live bacterial loads: Streptococcal loads were determined in 
mouse lung, spleen, brain, bronchoalveolar lavage fluid (BAL) and blood. Lung, 
spleen or brain tissue were homogenized in PBS through a 70µm filter prior to 
storage at -80°. BAL was centrifuged at 1400rpm for 5 minutes at 4° and 
supernatant stored at -80°. Blood was taken by cardiac puncture and clotting 
prevented by keeping samples on ice with heparin (20U/ml) (Sigma), before 
centrifugation at 1400rpm for 5 minutes at 4° and storage of supernatant -80°. 
Serial dilutions of single cell suspensions, BAL or blood supernatant were 
performed on brain heart infusion agar plates supplemented with defibrinated 
horse blood and the number of colony-forming units (CFUs) counted.   
 
Quantification of live viral loads: Live viral loads were quantified in the lung and 
spleen. Lungs were excised from mice, digested with 20µg/ml Liberase TL 
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(Roche) and 50µg/ml DNAse 1 (Sigma), and homogenised using gentleMACS 
(Miltenyi), as per the manufacturer’s instructions. Spleens were homogenized 
through a 70µm filter. All samples were stored at -80°. Samples were titrated on 
confluent monolayers of MDCK cells and cellular lysis observed after 3 days. 
TCID50 was calculated according to the Spearman-Karber method. 
 
Viral and bacterial RNA quantification: Viral and bacterial RNA levels were 
quantified in the lung and spleen. Lung or spleen were homogenised in PBS, 
passed through a 70µm filter and centrifuged at 1400rpm for 5 minutes at room 
temperature. RNA was extracted from lung or spleen homogenate pellet using 
TRI reagent (Ambion) as per the manufacturer’s instructions. 400ng total RNA 
was reverse transcribed using the ThermoScript RT-PCR System kit (Invitrogen) 
as per the manufacturer’s instructions. The cDNA served as template for 
quantitative PCR using TaqMan Gene Expression Assays (Applied Biosystems), 
universal PCR Master Mix (Applied Biosystems) and the ABI-PRISM 7900 
sequence detection system (Applied Biosystems). IAV Matrix and Strep 16s 
rRNA were quantified relative to the housekeeping gene (Hprt1) as previously 
described (Ward et al., 2004; Kash et al., 2011). Primers for influenza matrix M1 
gene were as follows: forward: 5’-AAGACCAATCCTGTC ACCTCTGA-3’; 
reverse: 5’-CAAAGCGTCTACGCTGCAGTCC-3’; and probe: 5’-
TTTGTGTTCACGCTCACCGT-3’. Primers for Strep 16s rRNA were as follows: 
forward: 5’-GGTGACGGC AAGCTAATCTCTT-3’; reverse, 5’-
AGGCGAGTTGCAGCCTACAA-3’; and probe, 5’-
AAGCCAGTCTCAGTTCG-3’. 
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Preparation of single cell suspensions from the lung for flow cytometry: Lungs 
were excised from mice, digested with 20µg/ml Liberase TL (Roche) and 
50µg/ml DNAse 1 (Sigma) for 30 minutes at 37° and 5% CO2, and homogenised 
using gentleMACS (Miltenyi), as per the manufacturer’s instructions. For analysis 
of epithelial cells, the gentleMACS homogenisation step was not performed. Lung 
suspension was then passed through a 70µm cell strainer and washed with PBS. 
Red blood cells were lysed using ammonium chloride and cells were seeded into a 
96-well U-bottom plates.  
 
Preparation of single cell suspensions from the brain for flow cytometry: Brains 
were excised from mice, homogenised through repeated passage into a 1ml 
syringe into a digest solution of Collagenase D (Roche) (0.5mg/ml), Dispase II 
(Roche) (2mg/ml) and DNAse 1 (Sigma) (3.5µg/ml). Following 30 minutes 
digestion at 37° and 5% CO2, brain suspension was then passed through a 70µm 
filter and washed with PBS. The suspension was resuspended in 70% Percoll (GE 
Healthcare) and overlaid with 30% Percoll before centrifugation, retaining the 
fraction at the interface. 
 
Flow cytometry: Lung or brain single cell suspensions or BAL fluid were 
preincubated with anti-FcγRIII/II (Fc block, to reduce non-specific Fc receptor 
binding of antibody constant regions) in PBS prior to 30 min incubation with one 
or more of the following fluorochrome labelled antibodies (Biolegend unless 
otherwise specified): FITC-conjugated anti-Ly6G; APCCy7 conjugated Ly6G; 
PerCpCy5.5-conjugated anti-Ly6C; FITC-conjugated anti-Ly6C; PECy7-
conjugated anti-CD11b; APC-conjugated anti-CD11b; APCCy7-conjugated anti-
 74	  
CD3; PE-conjugated anti-F4/80; PE-conjugated anti-TRAIL; PE-conjugated anti-
DR5; APC-conjugated CD45; APCCy7-conjugated anti-EpCam; V450-
conjugated anti-CD4; PE-Texas Red conjugated anti-CD8; PerCpCy5.5-
conjugated anti-NKp46; FITC-conjugated anti-E-cadherin and V450-conjugated 
anti-CD11c (BD Biosciences). Cells were then washed with PBS and stained with 
LIVE/DEAD Fixable Dead Cell Stain (Life Technologies) prior to fixation in 4% 
formaldehyde, and were then assessed using a LSR II Fortessa or an LSR II 
(Becton Dickinson). Data analysis performed on FlowJo (Treestar). Cell counts 
were performed on a Brightline hemacytometer (Hausser Scientific) with Trypan 
blue exclusion. 
 
Cytokine quantification: Cytokine levels were quantified in BAL fluid and from in 
vitro neutrophil culture supernatants. BAL fluid was recovered and centrifuged at 
1400rpm for 5min at 4ºC and supernatant collected. In vitro neutrophil culture 
supernatants were taken after 5 hours following cell adhesion to the culture plate. 
Concentrations of cytokines were assessed by Milliplex Map Kit (Millipore) as 
per manufacturer’s instructions and read on a Luminex 100 (BioRad). 
Concentrations of TNF-α and IL-22 (e-Bioscience), KC and MPO (R and D 
systems), and IFN-α and IFN-β (PBL Assay Science) were quantified by ELISA 
according to the manufacturer’s protocol. ELISA plates were read on a Safire II 
plate reader (Tecan). 
 
Neutrophil purification: Neutrophils were purified for in vitro assays from whole 
mouse lung by manual maceration followed by 20 minutes digestion at 37° and 
5% CO2, with Collagenase D (Roche) (0.5mg/ml), Dispase II (Roche) (2mg/ml) 
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and DNAse 1 (Sigma) (3.5µg/ml), with EDTA (Sigma) (10µM) added for the 
final 5 minutes (to chelate calcium, thus reducing integrin association and aiding 
digestion). Digested lung was mashed through a 70µm filter, and neutrophils 
separated from the single cell suspension by positive selection on two sequential 
MACS columns using anti-Ly6G-biotin and anti-biotin microbeads (Miltenyi 
Biotec), as per the manufacturers instructions. In some cases remaining dead cells 
were removed by overlaying cell suspension on a 40%/85% Percoll gradient, 
centrifuging for 20 minutes at 800xg and room temperature, and retaining the 
fraction at the 40/85% interface.  
 
Other neutrophil purifications tested during optimization process: During 
optimization of the protocol above, other purification procedures were attempted. 
In place of manual maceration homogenization using gentleMACS (Miltenyi), as 
per the manufacturer’s instructions, was attempted. In place of Collagenase D and 
Dispase II other digest mixes – containing Liberase (20µg/ml) (Sigma) or 
Collagenase IV (400µg/ml) (Sigma) (all digest mixes contained 3.5µg/ml DNAse 
1 (Sigma)) were tested.  
 
Reactive oxygen species: 5x104 lung neutrophils were seeded on a white 96-well 
flat-bottomed plate in calcium and magnesium positive media and rested at 37° 
for 1 hour. Luminol (Sigma) (50µM) and Horseradish Peroxidase (Sigma) 
(1.2U/ml) were added followed by stimulation with PDBu (Sigma) (50nM) or 
media. Luminescence was immediately read on a Safire II plate reader (Tecan).  
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NET formation: 5x104 lung neutrophils were seeded onto a 24-well flat bottomed 
transparent plate in calcium and magnesium positive media supplemented with 
3% mouse plasma and rested at 37° for 1 hour, followed by stimulation for 2 
hours with 5x105 CFU C. albicans (clinical isolate SC 5314; a kind gift from Dr. 
J. Duarte) or media. After 2 hours incubation at 37° NET formation was 
visualized by addition of the DNA stain Sytox (Life Technologies) (8.3µM). 
Images were taken and analyzed on a DM IRB (Leica) microscope with an Orca-
ER Digital Camera C4742 80 (Hamamatsu) camera, and an N PLAN PH1 lens 
(Leica), at magnification of 10x and a numerical aperture of 0.25. Image 
acquisition software was Micromanager 1.4 and processing was performed using 
ImageJ 1.64. NETs were defined as Sytox+ areas >2000µm2 (in collaboration with 
Ms. N. Branzk, NIMR). 
 
Neutrophil culture: 1x105 (unless otherwise specified) lung neutrophils were 
seeded onto a 96-well flat bottomed plate in complete media (RPM1 1640 
supplemented with 10% fetal calf serum, penicillin, streptomycin, glutamate, and 
β-mercaptoethanol) and rested for 1 hour, followed by stimulation with 
Pam3CSK4 (Enzo Life Sciences) (1µg/ml), LPS (Enzo Life Sciences) (1µg/ml), 
PDBu (Sigma) (50nM) or media. Culture supernatants were removed after 5 hours 
and protein concentrations assessed by ELISA as described above. Where 
specified prior to stimulation neutrophils were pretreated with recombinant mouse 
IFNα (PBL Assay Science) (10 or 100 U/ml) for 1 hour. 
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Quantification of lung damage: Lung damage was assessed in BAL fluid. Lactate 
dehydrogenase (LDH) activity was assessed using the enzymatic detection step of 
the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) according to the 
manufacturer’s instructions. Protein levels were quantified by Pierce BCA protein 
assay (Thermo Scientific) as per the manufacturer’s instructions. Assay plates 
were read on a Safire II plate reader (Tecan).  	  
Statistics: All statistical comparisons were performed using Prism 6 (GraphPad). 
Specific statistical tests used for each experiment are specified in accompanying 
figure legends. A p value of <0.05 was considered significant. n.s. = not 
significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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Chapter 3. Causes of mortality in a mouse model of 
Influenza A-S. pneumoniae coinfection 
 
3.1. Background 
 
Before investigating mechanisms of coinfection, it was necessary to establish a 
model, and determine what drives mortality. There are several possible drivers of 
mortality during IAV-Strep coinfection – a loss of viral control, a loss of bacterial 
control, or immunopathology due a strong immune response.  
 
Many IAV-Strep mouse models do not quantify viral load in a coinfection setting. 
Where quantified, viral clearance does not appear to be impaired (McNamee et 
al., 2006), or is marginally delayed (Li et al., 2012; Smith et al., 2013). In 
contrast, almost all models report increased streptococcal loads and bacterial 
spread to other organs during coinfection (for example, LeVine et al., 2001). 
Many studies report a very strong inflammatory response, with many 
proinflammatory cytokines induced (Smith et al., 2007), which may lead to 
immunopathology. It therefore is possible that each of these factors contributes to 
mortality, although it is likely one is the primary driver. 
 
Recent studies testing different antibiotics in coinfection have given indirect 
information on the causes of mortality. These studies support the hypothesis that 
bacterial outgrowth is the primary driver of mortality. A recent study showed 
treatment with the immunosuppressive corticosteroid dexamethasone did not 
ameliorate coinfection, but treatment with the antibiotic azithromycin did 
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(Damjanovic et al., 2013). This suggests bacterial outgrowth is more responsible 
for driving mortality than immunopathology. Combination therapy with 
dexamethasone and antibiotic was marginally more effective than antibiotic alone, 
suggesting once bacterial outgrowth is controlled, a modest improvement can be 
achieved by ameliorating any remaining immunopathology.  
 
Another study demonstrates that, while all antibiotic treatments tested are 
somewhat protective, those that did not exacerbate immunopathology were 
superior; for example, azithromycin increased survival more than ampicillin. This 
study proposes that ampicillin promotes immunopathology due to excessive 
inflammation in response to bacterial lysis (Karlstrom et al., 2009). This 
reinforces the concept of bacterial outgrowth as the primary driver of mortality, 
and immunopathology as a consequence of this. 
 
Overall, these antibiotic studies suggest bacterial outgrowth is the primary driver 
of mortality. Immunopathology appears to be a secondary issue that does not 
appear to drive mortality alone; it may be a consequence of a strong immune 
response to bacterial outgrowth. A further complication in investigating this is 
that immunosuppressive therapy to reduce immunopathology may exacerbate 
bacterial outgrowth. Overall, further clarity on the drivers of mortality in 
coinfection are needed. 
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3.2. Hypotheses and Aims 
 
I therefore aimed to establish a mouse model of IAV-Strep coinfection, with two 
key questions as a starting point. Firstly, is viral or bacterial outgrowth, or 
immunopathology, the primary driver of mortality during coinfection? Secondly, 
what are the mechanisms by which influenza promotes this mortality? I proposed 
to use influenza and Strep single infections of low or moderate severity, to allow 
focus on synergy between infections rather than their individual effects. In this 
chapter I will focus on the establishment of the model and the causes of mortality.  
 
I hypothesised that: 
• Influenza would lead to increased susceptibility to streptococcal infection. 
• Viral clearance would either be unchanged or only marginally impaired by 
coinfection.   
• Bacterial outgrowth would be observed during coinfection, and required 
for mortality. 
 
3.3. Results 
 
Selection of infectious agents and disease readouts 
 
To establish a murine model of IAV-Strep coinfection, appropriate mild to 
moderate single infections and a suitable mouse strain were required. The 
majority of influenza research undertaken in mice uses inbred C57BL/6 or 
BALB/c mice infected intranasally with A/Puerto Rico/8/1934 (H1N1) (PR8), 
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although use of other strains such as A/WSN/1933 (H1N1) (WSN) is also 
common (Bouvier et al., 2010). For consistency and to allow comparison with 
other studies, as well as the availability of many genetically modified mice, 
C57BL/6 mice were used.  
 
PR8 is potentially useful as a model as, unlike most recent human isolates of 
influenza, it induces severe disease and substantial mortality in inbred mice. 
However, for the study of coinfection, a severe initial influenza infection may 
make it difficult to assess synergy with Strep, and therefore the milder X31 strain 
was used. X31 is a reassortant virus bearing the HA and NA of A/Hong 
Kong/1/1968 (H3N2), with all other viral genes from PR8. This strain is 
particularly useful as it induces moderate disease without - except at very high 
doses - causing excessive mortality (Bouvier et al., 2010).  
 
D39 is a common laboratory strain of Strep frequently used in mouse models 
(Chiavolini et al., 2008), including coinfection (Goulding et al., 2011). It was 
originally isolated in 1916 and was used in Avery’s experiments demonstrating 
DNA is the genetic material (Avery et al., 1944; Lanie et al., 2007). While 
commonly referred to as virulent, its pathogenicity in mice shows substantial 
variation depending on mouse strain, dose, route of administration, and volume 
administered. Furthermore due to the age of the strain, different divergent stocks 
of D39 now show substantial variation in virulence. D39 was selected as a 
potentially mild strain of Strep that would allow comparisons with other studies. 
Although some coinfection studies administer bacteria via the intratracheal route 
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(for example, Shahangian et al., 2009), here more physiological intranasal 
administration was used.  
 
To assess coinfection, appropriate disease readouts were required. Weight loss is a 
common feature of mouse models of many viral infections, including influenza 
and coinfection, and relates closely to disease outcome; is has been shown during 
influenza to not be caused by dehydration or malnutrition (Sanders et al., 2012). It 
is therefore a good readout for disease severity. In contrast, studies on Strep 
infections rarely assess weight loss to determine disease severity, and therefore 
clinical scores are useful as a supplementary readout. Mice were therefore defined 
to have reached endpoint when they reached 75% of starting weight, or a high 
clinical score (defined as 5 or greater, assessed as described in materials and 
methods). Weight loss, clinical score and survival therefore are reliable 
measurements for disease severity during coinfection.  
 
Coinfection causes synergistic disease in a murine model 
 
I established an infection regime for IAV-Strep coinfection five days apart (shown 
in Fig. 1A, all days post infection hereafter specified refer to the primary 
influenza infection). A previous study had reported a peak in susceptibility at 7dpi 
(McCullers et al., 2002), leading to mortality under 24 hours, which is somewhat 
impractical for further investigations. Therefore 5dpi  - where mice were reported 
to survive at least 3 days – was selected as a more appropriate timepoint for 
secondary infection.  
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In this model weight loss (Fig. 1B; for clarity, in all weight figures, mice 
euthanized after reaching endpoint are included at their final weight in the 
calculation of subsequent means), mouse mortality (Fig. 1C) and disease severity 
as assessed by clinical signs (Fig. 1D; again, for clarity, mice euthanized after 
reaching endpoint are included at their final clinical score in calculation of the 
mean) were observed. Intranasal administration of 8x103 TCID50 X31 (hereafter 
referred to simply as IAV unless otherwise specified) induced moderate weight 
loss of approximately 15% of body weight in C57BL/6 mice (Fig. 1B), and very 
mild clinical symptoms - typically piloerection and decreased movement - in a 
small proportion of mice (Fig. 1D), with only a small number of mice reaching 
endpoint (Fig. 1C). Intranasal administration of 2x107 CFU D39 (hereafter 
referred to simply as Strep unless otherwise specified) induced no signs of disease 
in the majority of mice, although a small proportion developed high clinical 
scores (Fig. 1D) and reached endpoint (Fig. 1C). In contrast, IAV and Strep 
coinfection hugely increased weight loss (Fig. 1A) and gave high clinical scores 
(Fig. 1D), with almost all mice reaching endpoint (Fig. 1C). As these pathogen 
doses caused almost complete mortality during coinfection, they are hereafter 
referred to as “high dose”. 
 
Assessment of lung infiltrate by histology showed little cell recruitment during 
Strep infection, and a moderate infiltrate during IAV, but large regions of 
overwhelming infiltrate and few unobstructed airspaces during coinfection (Fig 
1E) (experimental assistance provided by Histology Section, NIMR). The strong 
synergy observed during coinfection and the relatively mild to moderate effects of 
single infections made this model highly suitable for the study of synergy.   
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Figure 1: Influenza A predisposes mice to S. pneumoniae coinfection. 
(A) Infection scheme. (B) Weight loss and (C) mortality following infection of C57BL/6 mice 
with 8x103 TCID50 IAV X31, 2x10
7 CFU S. pneumoniae D39 or mock (PBS) (data shown is 
pooled from 4 independent experiments, n=6-9. On weight loss plot mice reaching endpoint 
retained thereafter at final weight. Dosing hereafter referred to as “high dose”). (D) Clinical 
scores (n=9, representative of 2 independent experiments, mice reaching endpoint retained 
thereafter at final clinical score). (E) H+E staining of lung tissue sections (n=3) at 7dpi. Data 
displayed as arithmetic means ±SEM (weights and clinical scores) or percent survival 
(mortality). Significance assessed by 2-way ANOVA (weights and clinical scores) or Log-
rank (Mantel-Cox) test (mortality). ****p<0.0001. 
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Coinfection leads to bacterial but not viral outgrowth 
 
I then profiled pathogen loads during coinfection to elucidate the causes of 
mortality. Consistent with its low virulence, Strep was not detected at any point in 
the first three days following secondary infection. However, coinfection led to 
high bacterial loads in the lung (Fig. 2A), and systemic spread by 7 to 8dpi to the 
spleen (Fig. 2B) and brain (Fig. 2C). Viral clearance was not affected by 
coinfection, with viral load as assessed by RNA in the lung falling from 6dpi to 
8dpi (Fig. 2D) and live virus being below the limit of detection by 8dpi - the point 
where typically coinfection induced mortality begins to occur (Fig. 2E). IAV does 
not typically colonize other tissues; however, this may have been altered by 
coinfection. To assess this, spleen viral RNA was quantified relative to control 
infected and uninfected lungs. Viral RNA was not detected (i.e. the level observed 
was equivalent to an uninfected lung) in the spleen during IAV or coinfection 
(Fig. 2F). Therefore bacterial, but not viral, outgrowth occurs during coinfection 
and is likely to be a driver of mortality. 
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Figure 2: Coinfection causes bacterial but not viral outgrowth. 
(A) Streptococcal load in the lung, (B) spleen and (C) brain during high dose coinfection 
(n=4-5, representative of 2 independent experiments, dashed line indicates detection limit). 
(D) Quantitative PCR for influenza matrix RNA in the lung (n=5). (E) Live virus assayed by 
tissue culture in the lung (n=2-5) (data shown is pooled from 2 independent experiments, 
dashed line indicates detection limit). (F) Quantitative PCR for influenza matrix in the spleen 
at 8dpi. Lungs used as positive (6dpi IAV) and negative (naive) controls (n=5). Data 
displayed as geometric means. Significance assessed by Mann-Whitney test. n.s. = not 
significant, **p<0.01
E
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Bacterial outgrowth occurs following an initial decrease from inoculum 
 
High streptococcal loads in the lung indicate two possibilities: that the inoculum 
of bacteria largely survives and persists, or largely dies, but a small proportion 
colonizes and subsequently outgrows. Profiling of airway bacterial loads at 5dpi + 
4hrs to 5dpi + 16hrs (i.e. 4 to 16 hours after secondary infection) showed that 
most inoculum (amount given shown as a datapoint on the figure) dies in the first 
4 hours following infection, although slightly more survives in coinfected mice. In 
coinfected mice, the remaining small proportion of inoculum rapidly grows, 
leading to high bacterial loads by 5dpi + 16hrs (Fig. 3A).  
 
To ensure that low levels of bacteria at 5dpi + 4hrs relative to the inoculum is due 
to bacterial death rather than a technical issue - i.e. to ensure that the bacterial 
inoculum reaches the lung - I assessed bacterial 16s rRNA levels in the lung at 
5dpi + 4 and 5dpi + 48 hours during coinfection. Bacterial 16s rRNA can be used 
to detect both live bacteria and total streptococcal material, and therefore by 
assessing this at 4 hours after inoculation, both live and recently deceased 
bacterial inoculum will be detected. 16s rRNA profiling showed high levels of 
streptococcal material (relative to uninfected baseline background signal) at 4 
hours in both Strep infected and coinfected mice, indicating successful 
inoculation; however, high levels of streptococcal material only persist to 48 
hours in coinfected mice where bacterial replication occurs (Fig. 3B). Therefore 
the initial bacterial inoculum reaches the lung, but largely does not survive. In 
coinfection a small surviving proportion is able to colonize and outgrow. 
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Figure 3. Rapid death of the majority of bacterial inoculum is followed by outgrowth 
during coinfection. 
(A) Streptococcal load in the airways early during high dose coinfection (n=3-6). Bacterial 
inoculum given per mouse shown on the left. (B) Quantitative PCR for streptococcal 16s 
rRNA early and late during high dose coinfection (n=10). Data shown as geometric means. 
Significance assessed by Mann-Whitney test. n.s. = not significant. ****p<0.0001.
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Live bacteria are required for mortality 
 
Having observed bacterial outgrowth, I then attempted to determine whether 
bacterial outgrowth was required for mortality. Mice were coinfected either with 
live bacteria, heat-killed bacteria, or Pam3CSK4, a TLR2 agonist that mimics 
lipopeptides found in gram-positive bacterial cell walls (Manukyan et al., 2005). 
Only live bacteria caused synergy in weight loss (Fig. 4A) and mortality (Fig. 4B) 
with influenza. This shows live bacteria are required for synergistic mortality, and 
a non-replicating bacterial stimulus alone is not sufficient to induce 
immunopathology. This further supports the hypothesis that bacterial outgrowth is 
the primary driver of mortality. Immunopathology, which may still contribute to 
mortality, may be a downstream consequence of bacterial outgrowth. 
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Figure 4. Live bacteria are required for mortality during coinfection.
(A) Weight loss and (B) mortality following high dose coinfection with live bacteria, heat-
killed bacteria, or 15µg Pam3CSK4 (n=9, representative of 2 independent experiments, on 
weight loss plot mice reaching endpoint retained thereafter at final weight, in some groups 
to aid visualisation final data point extended). Data displayed as arithmetic means (SEM 
(weights) or percent survival (mortality). Significance assessed by 2-way-ANOVA (weights) 
or Log-rank (Mantel-Cox) test (mortality). *p<0.05, ****p<0.0001. 
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3.4. Conclusions and Discussion 
 
I established a mouse model of IAV-Strep coinfection with mild to moderate 
single infections, which, as will be shown in later chapters, allowed study of 
synergy rather than strong effects of the single infections. Consistent with other 
studies (Goulding et al., 2011), coinfection is characterised by bacterial but not 
viral outgrowth.  
 
These results expanded upon previous studies by confirming that bacterial 
inoculum, although reaching the lung, largely does not survive; however, a small 
proportion colonizes and leads to bacterial outgrowth. This is in contrast to a 
study showing stable levels of Strep in the lung from 0-6hrs following 
inoculation, followed by outgrowth in coinfected mice (Li et al., 2012). However, 
in this study Strep infection alone is more virulent, and is detected in the lung as 
late as 60 hours following secondary infection. This may account for this 
discrepancy.  
 
Live bacterial replication is required for mortality, suggesting bacterial outgrowth 
is the primary driver of mortality. Observation of bacterial outgrowth and its role 
as the primary driver is consistent with the implications of previous antibiotic and 
immunosuppression intervention studies outlined previously (Damjanovic et al., 
2013). Although neither the implications of antibiotic versus immunosuppressive 
treatment or the approach used here of infecting with non-replicating bacterial-
like stimuli directly confirm that bacterial outgrowth rather than 
immunopathology is the primary driver of mortality, the combination of 
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observations is highly suggestive that this is the case. It is still possible that a 
strong immune response to high bacterial loads and resulting immunopathology is 
the ultimate cause of death; however, bacterial outgrowth is required for this to 
occur. 
 
A critique of the experiment showing that non-replicating bacterial stimuli such as 
heat-killed bacteria and TLR2 agonist cannot induce synergistic mortality through 
immunopathology is that these may represent an insufficient stimulus relative to 
live bacteria, as live, replicating bacteria may provide more constant immune 
stimulation. Furthermore, heat treatment may destroy some of the immune 
stimulating properties of bacteria, and TLR2 agonist represents only one signal, 
while live Strep is detected by multiple mechanisms (Koppe et al., 2012). 
However, if these critiques were correct some trend towards increased mortality 
would be expected even with an insufficient heat-killed bacterial or TLR2 agonist 
stimulus. As no trend is detected at all, it suggests lack of synergy is due to the 
fundamental requirement for live bacteria to drive mortality.  One possible 
strategy to address these critiques is to treat mice with multiple bacteria like-
stimuli, such as combined TLR2 and TLR4 stimulation, or repeated TLR2 
stimulation. 
 
It is somewhat unclear whether persistent high bacterial loads in the lung itself or 
dissemination to other organs, or a combination of both factors, is the driver of 
mortality. This is difficult to experimentally test; hypothetically coinfection with a 
mutant strain of Strep that can colonize the lung but is deficient in epithelial 
translocation, and therefore does not disseminate, could be a method to test this.  
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Chapter 4. The immune response in coinfection 
 
4.1. Background 
 
Having established a model and determined that bacterial outgrowth is the 
primary driver of mortality during coinfection, I then proceeded to profile the 
immune response. Results are somewhat contradictory on the immune response to 
coinfection.   
 
Many studies observe a strong cytokine response in coinfection, with increases in 
neutrophil numbers and proinflammatory cytokines such as TNF-α, IL-6, MIP-2 
and RANTES (LeVine et al., 2001, Seki et al., 2004, Shahangian et al., 2009). 
However, as previously described, other studies suggest the immune response to 
coinfection is impaired. Reduced IL-17 production relative to single Strep 
infection has been reported (Li et al., 2013); although it must be noted that this 
study also shows increases in several other proinflammatory cytokines such as 
TNF-α and G-CSF. One possibility is that immune profiling at different 
timepoints may give different results, and it has been hypothesised that although 
bacterial outgrowth during coinfection elicits a strong immune response, the early 
response when bacterial colonization occurs is defective. One study supports this 
by showing early TNF-α and IL-1β production during coinfection is reduced (Sun 
et al., 2008).  
 
Several prior studies do not include all single infection controls, making it 
difficult to assess which aspects of the immune response are induced by which 
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infection. For example, one study shows greater neutrophil recruitment to the lung 
in IFNαβR-/- mice compared to wild-type mice during coinfection, but does not 
compare this to the number of neutrophils induced by Strep alone (Shahangian et 
al., 2009). It is therefore hard to determine whether neutrophil recruitment in 
wild-type coinfected mice could be considered “impaired”.  
 
4.2. Hypotheses and Aims 
 
I therefore decided to profile the immune response during coinfection, and look 
for evidence of immune impairment. I decided to use broad profiling using flow 
cytometry and multiplex to test the numbers of many immune cells and multiple 
cytokine levels during coinfection. I proposed to investigate the immune response 
both early and late during coinfection to determine whether at any time point 
immune impairment was evident. I also ensured that all appropriate single 
infection controls were included. 
 
Based on the previous literature, I hypothesised that: 
• Coinfection would induce a strong, overall proinflammatory immune 
response. 
• Some aspects of the immune response would be impaired in coinfection 
relative to Strep single infection. 
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4.3. Results 
 
Coinfection induces a strong neutrophil response 
 
Flow cytometry was performed on lung at 7dpi to assess the cellular response to 
bacterial outgrowth. A small number of neutrophils were recruited by both Strep 
and IAV infection. However, coinfection led to a very large neutrophil response 
(Fig. 5A). Inflammatory monocytes are induced by IAV, and to a slightly greater 
extent during coinfection, but synergy is not a striking as for the neutrophil 
response (Fig. 5B). A trend was observed for reduced alveolar macrophages 
during influenza infection and coinfection although this change was not 
significant (Fig. 5C). Typical FACS gating strategies are shown in Appendix 1 A 
(myeloid) and B (lymphoid). 
 
Influenza-induced recruitment of CD4 (Fig. 5D), CD8 (Fig. 5E) and NK (Fig. 5F) 
cells was unchanged by coinfection. These cells were not recruited during Strep 
infection. No significant change in B cell numbers was observed during any 
infection profiled (Fig. 5G). Therefore coinfection induces a strong neutrophil 
response and gave no clear sign of immune impairment in terms of cell 
recruitment relative to the modest response induced by mild Strep infection alone.  
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Figure 5. Coinfection induces a strong neutrophil response.
Flow cytometry quantification of (A) Neutrophils (Ly6G+CD11b+) (B) Inflammatory mono-
cytes (Ly6C+CD11b+F4/80+) (C) Alveolar macrophages (CD11c+F4/80+) (A-C data pooled 
from 2 independent experiments, n=2-3), (D) CD4 T cells (CD3+CD4+) (E) CD8 T cells 
(CD3+CD8+) (F) Natural killer cells (CD3-CD4-CD8-NKp46+) and (G) B cells (CD3-CD19+) 
(D-G n=2-5) in the lung during high dose coinfection. Data displayed as arithmetic means ± 
SEM. Significance assessed by Mann-Whitney test. n.s. = not significant. *p<0.05. **p<0.01.
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Coinfection induces a strong proinflammatory cytokine response 
 
Having profiled the cellular response, cytokine concentrations at 7dpi in the 
airways (BAL fluid) were then assessed. Broad profiling of a range of cytokines 
was performed by multiplex (select cytokines shown in Fig. 6A, table of all 
shown in top section of table in Fig. 6B). The concentration of IL-22 and type I 
IFNs was also assessed by ELISA (bottom section of Fig. 6B). Strep modestly 
induced a small number of cytokines relative to uninfected mice, including G-
CSF and IL-6. IAV induced a broader range of cytokines at higher levels, 
including IFN-γ and IL-10. However, coinfection hugely increased the majority of 
cytokines tested relative to both single infections. Of particular note, TNF-α, of 
which only very low levels were induced by both Strep and IAV, was greatly 
upregulated by coinfection. Chemokines associated with neutrophil recruitment 
such as KC and MIP-2, and with inflammatory monocyte recruitment such as 
MCP-1, were also greatly increased. Crucially, almost every cytokine tested was 
increased in coinfection relative to either single infection, and therefore there is no 
clear immune impairment in the cytokine response (note – some cytokines 
assessed by multiplex, such as LIX, show somewhat high background levels in 
uninfected mice; this is likely an artefact of the assay, as the detection limits for 
different cytokines vary). The only cytokine where a very slight decrease was 
observed was IL-22, which was reduced during both influenza and coinfection 
from already low levels in Strep and uninfected mice. Therefore coinfection 
induces a strong and seemingly unimpaired cytokine response.
 98	  
 
Na
ive
St
rep IA
V
IA
V +
 St
rep
Na
ive
St
rep IA
V
IA
V +
 St
rep
Na
ive
St
rep IA
V
IA
V +
 St
rep
Na
ive
St
rep IA
V
IA
V +
 St
rep
0
200
400
2000
6000
10000
20000
30000
pg
/m
l
**
TNF KC MIP2
**
**
**
**
**
7 dpi7 7
MCP1
**
**
7
Figure 6
A
B
  
 Cytokine at 7dpi (pg/ml)   
Naïve Strep IAV IAV + Strep 
TNF_ 8 11 45 5682 256 
MIP1_ 61 321 1338 87599 134 
RANTES 12 10 16 1517 119 
GCSF 31 1002 4864 183797 83 
IL10 2 4 137 1858 80 
IL6 5 101 9325 69182 71 
MIP1  ` 101 228 1139 30002 59 
IP10 10 2006 10511 253229 55 
MIP2 128 143 190 8962 54 
IFNa 26 26 3591 14232 47 
KC 10 65 281 4778 36 
MIG 26 671 10622 75288 28 
MCP1 63 506 1828 21613 22 
LIF 2 3 311 431 13 * 
MCSF 11 15 48 349 13 *,† 
Eotaxin 14 18 565 830 8 * 
VEGF 15 65 86 426 6 *,†
IL1_ 137 130 36 366 5 *,† 
IL15 16 14 7 48 5 *,† 
IL1` 84 96 90 441 5 *,† 
IL17 2 3 16 34 5 * 
LIX 222 176 174 717 4 
IL5 4 9 429 225 4 * 
GMCSF 32 41 37 75 2 
IL12 (p40) 21 50 22 57 2 † 
IFN_ 1 7 12 115 13 * 
IFN` 0 1 6 29 11 
IL22 24 52 18 26 0.8 * 
 
 
*,†
IL2, IL3, IL4, IL7, IL12p70, IL13 all excluded as means all <20pg/ml
vs. single 
infections 
Fold change
Figure 6. Coinfection induces a strong proinflammatory cytokine response.
Multiplex and ELISA quantification of airway cytokines during high dose coinfection - select 
cytokines shown in (A) and table of all shown in (B). Multiplex is top section of table, lower 
section is ELISAs (Multiplex: n=2-3, samples pooled from 3 independent experiments; IL-22 
ELISA: n=3-8, samples pooled from 3 independent experiments; type I IFN ELISA: n=3-8; 
samples pooled from 2 independent experiments). Data shown as arithmetic means (SEM 
(graph) or arithmetic means only (table). Cytokines in table ranked by fold change relative to 
single infections, shown in the right hand column. This is calculated by taking the geometric 
mean of fold change IAV + Strep vs. IAV and fold change of IAV + Strep vs. Strep. Signifi-
cance assessed by Mann-Whitney test. **p<0.01 (graph). *p<0.05 IAV+Strep vs. Strep; 
†p<0.05 IAV + Strep vs IAV (table).
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IAV does not impair the early cellular response to Strep 
 
There is a strong immune response and no clear impairment in cell recruitment or 
cytokine production at 7dpi, showing bacterial outgrowth induces a robust 
response. However, it is possible that the immune response is impaired at an 
earlier phase in secondary infection, allowing bacterial colonization. Therefore the 
cellular response in the airways from 5dpi + 4hrs to 5dpi + 16hrs hours during 
coinfection (i.e. 4 to 16 hours following secondary infection) was profiled by flow 
cytometry.  
 
Strep induced a small neutrophil response from 5dpi + 12 hours onwards (Fig. 
7A), consistent with the small neutrophil infiltrate observed in the lung at 7dpi; no 
neutrophils were detected earlier at 5dpi + 4hrs. IAV maintains a consistent level 
of neutrophils, higher than induced by Strep, throughout the period observed. The 
number of neutrophils during coinfection is equivalent to IAV at 5dpi + 4hrs and 
begins to rise substantially at 5dpi + 12hrs, with high levels at 5dpi + 16hrs - 
consistent with the high levels in the lung at 7dpi. Therefore the number of 
neutrophils present during coinfection is higher than Strep at early time points 
during secondary infection, and therefore neutrophil recruitment cannot be 
considered to be impaired. 
 
As at 7dpi in the lung, inflammatory monocytes are not induced by Strep but are 
recruited by both IAV and coinfection (Fig. 7B). Alveolar macrophage numbers 
are somewhat variable in all infection settings, and no clear trend is discernible; 
however, at no point are the number present in coinfected mice significantly 
reduced relative to Strep infection (Fig. 7C). As observed at 7dpi, the developing 
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CD8 T cell response to IAV is unaffected by coinfection (Fig. 7D). Therefore 
overall coinfection induces a strong neutrophil response, which develops as 
bacterial loads increase, and at no time point was a reduction in cell numbers 
during coinfection detected. 
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Figure 7. Cell recruitment to the airways is not impaired early during coinfection.
Flow cytometry quantification of (A) Neutrophils (Ly6G+CD11b+) (B) Inflammatory Monocytes 
(Ly6C+CD11b+F4/80+) (C) Alveolar Macrophages (CD11c+F4/80+) (D) CD8 T Cells (CD3+CD8+) in 
the airways early during high dose coinfection (n=3-6). Data displayed as arithmetic means 
(SEM. Significance assessed by Mann-Whitney test. n.s. = not significant. *p<0.05.**p<0.01.
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IAV does not impair the early cytokine response to Strep 
 
Although a strong cytokine response was observed at 7dpi, it is possible this could 
be impaired early following secondary infection. Cytokine levels were therefore 
profiled in the airways at 5dpi + 4hrs. Broad profiling of a range of cytokines was 
performed by multiplex (select cytokines shown in Fig. 8A, table of all shown in 
top section of table in Fig. 8B). Concentrations of IL-22 and type I IFNs were also 
assessed by ELISA (bottom section of Fig. 8B).  
 
The cytokine response to Strep was greater than observed later at 7dpi, with 
increases in proinflammatory cytokines and neutrophil-recruiting chemokines 
such as TNF-α, MIP-2 and KC, possibly reflecting the recent bacterial stimulus. 
During IAV, a similar cytokine profile to 7dpi was evident. TNF-α, MIP-2 and 
KC are less induced by IAV than Strep infection at this point. The strong synergy 
in cytokine production during coinfection observed at 7dpi was much less evident 
at this time point. Relative to Strep infection, several cytokines such as TNF-α 
and MIP-1α were moderately increased in coinfection, although much less so than 
at 7dpi, while others, such as KC, GM-CSF and MIP2 showed a very modest, 
non-significant decrease. Somewhat refuting the concept of immune impairment, 
no cytokine observed was significantly reduced relative to either single infection 
during coinfection. The only exceptions to this were an extremely slight decrease 
during coinfection in IL-22 relative to Strep infection and uninfected mice, and a 
small decrease in IL-5 relative to IAV infection; however, IL-5 is not induced by 
Strep and therefore is unlikely to be a crucial factor in the antibacterial immune 
response. 
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Broad cytokine profiling by multiplex and ELISA was also performed on two 
further time points – 5dpi + 12hrs and 5dpi + 16hrs (see Appendix 2A and B for 
tables) with no reduction in any cytokine during coinfection relative to single 
infections evident. Therefore cytokine production does not appear to be impaired 
early during secondary infection. 
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Figure 8. Cytokine production is not impaired early during coinfection.
Multiplex and ELISA quantification of airway cytokines during high dose coinfection select 
cytokines shown in (A) and table of all shown in (B). Multiplex is top section of table, lower 
section is ELISAs (Multiplex: n=3-6, ELISAs: n=3-6). Data shown as arithmetic means 
(SEM (graph) or arithmetic means only (table). Cytokines in table ranked by fold change 
relative to single infections, shown in the right hand column. This is calculated by taking the 
geometric mean of fold change IAV+Strep vs. IAV and fold change of IAV+Strep vs. Strep. 
Significance assessed by Mann-Whitney test. **p<0.01 (graph). *p<0.05 IAV+Strep vs. 
Strep; †p<0.05 IAV + Strep vs IAV (table)
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4.4. Conclusions and Discussion 
 
In summary, coinfection induced a large neutrophil and proinflammatory cytokine 
response. This response increased in similar time frame to previously shown 
bacterial outgrowth and was strongly developed by 7dpi. In contrast, Strep alone 
induced a much more modest, transient proinflammatory response at 5dpi + 4hrs, 
with recruitment of small number of neutrophils by 5dpi + 12hrs. As low 
virulence Strep is largely cleared from the lung by 5dpi + 4hrs, it is likely the 
small cytokine and downstream neutrophil response is a by-product of bacterial 
stimulus, and is not required for clearance. This suggests, although does not 
confirm, that the immune response is only required for bacterial clearance in the 
context of coinfection; this is further investigated in later chapters.  
 
No aspect of the immune response during coinfection was reduced relative to 
Strep infection including, in contrast to prior studies (Sun et al., 2008; Li et al, 
2012), IL-17 and TNF-α. However there was a very slight decrease in IL-22 from 
very low baseline levels. This is of some interest and will be discussed in chapter 
9. Overall no clear impairment in either cell recruitment or cytokine production 
was observed.  
 
As a relatively comprehensive timepoint range was profiled it is unlikely that this 
accounts for the lack of immune impairment detected as compared to previous 
studies. Most likely differences are due to the virulence of the Strep strain used. It 
could be argued that use of non-colonizing, low virulence Strep is not that suitable 
for investigating immune impairment in coinfection, as it induces a very modest 
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immune response, leaving little scope for reduction. However, as low virulence 
Strep is capable of outgrowth and causing mortality following influenza, it is still 
highly relevant for studying mechanisms of coinfection susceptibility. The 
virulence of Strep used may accentuate or reduce the relative importance of 
influenza-mediated immune impairment as a mechanism of coinfection. A 
possible experiment to assess whether influenza impairs cellular and cytokine 
responses independent of the virulence of the Strep strain used is influenza 
followed by TLR2 stimulation. 
 
As expected, IFN-α is present during influenza infected and coinfected mice at 
5dpi + 4hrs. However, it only persists and is somewhat increased in coinfected 
mice at 7dpi. It is probable the increase in IFN-α in coinfected mice at 7dpi is a 
side effect of general strong inflammation; it is more likely that interferon induced 
during the viral infection (i.e. that detected at 5dpi + 4hrs) influences the 
downstream immune response. The presence of type I IFNs is of interest due to 
the reported inhibition of MIP2 and KC production by type I IFNs, and the 
resulting resistance of IFNαβR-/- mice to coinfection (Shahangian et al., 2009). 
However, in this setting KC and MIP2 production are greatly increased in 
coinfection relative to Strep alone at 7dpi, and showed only marginal, non-
significant reductions at 5dpi + 4hrs. Furthermore, despite the reported 
antagonism between type I IFN and IL-1β in other experimental systems (Guarda 
et al., 2011), prior influenza infection and the presence of IFN-α does not appear 
to inhibit IL-1β production during coinfection. Furthermore, IL-1β is not 
significantly induced by low virulence Strep alone, suggesting it is not required 
for bacterial control in this context. Therefore, although IFN-α is present during 
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both viral infection and coinfection, it does not appear to inhibit the downstream 
immune response in this model. 
 
Although quite broad profiling has been performed, it is difficult to conclusively 
rule out immune impairment as a factor during coinfection, as other aspects of the 
immune response not assessed here may be impaired. One aspect that did show a 
moderate reduction - consistent with other studies (Ghoneim et al., 2013) – was 
the number of alveolar macrophages during coinfection at 7dpi. However trends 
at earlier timepoints were somewhat unclear, and the reduction relative to Strep 
infection was at no timepoint significant, suggesting that insufficient alveolar 
macrophage numbers is not the primary cause of coinfection.  
 
It is possible that reduced alveolar macrophage function may be a factor in 
coinfection susceptibility (Goulding et al., 2011), as here only alveolar 
macrophage numbers are assessed (neutrophil function will be assessed in a later 
chapter). Furthermore there are other cells implicated in coinfection susceptibility 
that have not been profiled such as γδ T cells (Li et al., 2012; Cao et al., 2014), 
which are outside the scope of this study. However, despite these caveats, there is 
a strong immune response induced by coinfection, with no clear impairment in 
any factor assessed here.  
 
There is no change in the antiviral aspects of the immune response such as CD8 T 
cells numbers during coinfection, consistent with intact viral control previously 
observed, although it must be noted total CD8 T cell numbers does not indicate 
that these cells have equivalent influenza-infected cell specificity or cytotoxic 
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activity. The presence of cytokines induced in the antiviral response to IAV could 
also be a factor in coinfection susceptibility – for example, the reported 
detrimental role of IFN-γ (Sun et al., 2008), particularly as this is increased during 
coinfection. 
 
IL-10, a cytokine with many anti-inflammatory roles that has been reported to 
contribute to coinfection susceptibility (van der Sluijs et al., 2004), is also 
modestly induced by IAV and greatly increased during coinfection. However, 
despite its presence and well-characterised anti-inflammatory role, many 
proinflammatory cytokines and a strong neutrophil response are induced, 
suggesting IL-10 is not blocking the immune response. Furthermore, the role of 
IL-10 as a factor contributing to coinfection susceptibility has been disputed, as 
the original result showing anti-IL-10 ameliorates coinfection (van der Sluijs et 
al., 2004) could not be reproduced in a subsequent study with IL-10-/- mice (Sun 
et al., 2008). 
 
Although the immune response to coinfection appears to be strong and 
unimpaired, it is possible that this response is excessive and harmful, promoting 
immunopathology. Previously bacterial outgrowth was identified as required to 
drive mortality, but whether the ultimate cause of death is high bacterial loads or 
an excessive immunopathological response to outgrowth is not clear. To address 
this, in later chapters, some aspects of the immune response such as neutrophils 
and TNF-α are depleted, and found to be protective, suggesting this response is 
not excessive. However, the possibility remains that other factors of the strong 
immune response to coinfection induced contribute to eventual mortality.  
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Chapter 5. Neutrophils in coinfection 
 
5.1. Background 
 
Having observed a strong proinflammatory immune response to coinfection and 
somewhat countered the concept of immune impairment, I decided to investigate 
whether this response was protective or pathogenic. I initially focused on 
neutrophils due to their striking recruitment in large numbers to the lung. 
Although previous studies have attempted to assess the role of neutrophils in 
coinfection, no study has specifically depleted them in a context where both a 
positive and negative effect of intervention could be detected. In addition, 
previous results are somewhat variable, which may reflect different disease 
settings in various models.  
 
Some studies deplete neutrophils in coinfection with anti-Gr-1, which is poorly 
specific (Daley et al., 2008), making these results difficult to interpret. One study 
reported that anti-Gr-1 treatment increased bacterial loads 24 hours following 
secondary infection in a moderate to severe coinfection (Sun et al., 2008). 
Another severe coinfection study also used anti-Gr-1, which exacerbates of 
bacterial loads if secondary infection is performed at 3dpi, but not 6dpi 
(McNamee et al., 2006). This study highlights the difficulties in using more 
virulent Strep strains to investigate coinfection, as in this study anti-Gr-1 also 
exacerbates bacterial loads in single infection. The authors attribute lack of effect 
of anti-Gr-1 treatment during coinfection at 6dpi to neutrophil impairment, 
arguing that depletion of already impaired neutrophils has no effect. An 
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alternative interpretation is that anti-Gr-1 exacerbates disease in both Strep and 
coinfection, and as bacterial loads are already very high following coinfection at 
6dpi, there is little capacity for further exacerbation. Overall, anti-Gr-1 treatment 
appears to increase bacterial loads when they are not already extremely high due 
to severe coinfection, although these results are hard to interpret due to poor 
specificity.  
 
Use of a severe coinfection setting, and thus an inability to exacerbate already 
high bacterial loads, may also apply in another study using more specific anti-
Ly6G to deplete neutrophils. In this severe coinfection study it was hypothesised 
that neutrophils were harmful, causing immunopathology. Depletion of 
neutrophils failed to ameliorate severe pathology and did not affect very high 
bacterial loads (Damjanovic et al., 2013). Although this suggests neutrophils have 
no role, there is no capacity to detect a harmful effect of neutrophil depletion in 
this setting.  
 
In contrast to studies showing no effect of neutrophil depletion, another study 
suggests neutrophils are protective: IFNαβR-/- mice are better protected from a 
moderate to severe coinfection, which is attributed to production of more of the 
neutrophil chemoattractants KC and MIP2, and greater neutrophil recruitment 
(Shahangian et al., 2009). Addition of KC and MIP2 to wild-type mice confers 
resistance, while blockade of CXCR2, the common receptor for KC and MIP2, 
renders IFNαβR-/- mice susceptible. This indirectly implies, although does not 
directly confirm, that neutrophils are protective in coinfection.  
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Other studies have reported neutrophils are functionally impaired during 
coinfection, although this is somewhat unclear. It has been reported that 
neutrophils from IAV infected mice have reduced ROS production and 
phagocytic capacity. (McNamee et al., 2006). Another study reported reduced 
levels of total myeloperoxidase and myeloperoxidase per neutrophil during 
coinfection, but no impairment in ROS production (LeVine et al., 2001). In 
contrast, another study reports an increase in total myeloperoxidase levels, but 
also reports a very large increase in the number of neutrophils, so it is also 
possible myeloperoxidase per neutrophil is decreased (this is not assessed). This 
study also reports a marginal reduction in neutrophil phagocytic capacity 
(Damjanovic et al., 2013). Overall these results suggest neutrophils show some 
functional impairment during coinfection, although these effects are somewhat 
marginal and variable in different contexts.  
 
There are various factors that may account for the discrepancy between these 
studies. The first study outlined (McNamee et al., 2006) uses LPS aerozolisation 
to increase the number of neutrophils available for assays, which may be a 
confounding factor. This may explain why impaired ROS production was not 
detected in the second study described (LeVine et al., 2001). Severity of 
coinfection may account for differences in reported myeloperoxidase production; 
the study reporting increased total myeloperoxidase (Damjanovic et al., 2013) 
shows more severe outgrowth than that reporting reduced total myeloperoxidase 
(LeVine et al., 2001), which may different amounts of neutrophil degranulation in 
response to more or less bacterial stimulus. 
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5.2. Hypotheses and Aims 
 
Therefore I decided to attempt to clarify the role of neutrophils in coinfection. I 
aimed to: 
• Test whether neutrophils are functionally impaired during coinfection.  
• Optimise the coinfection model to give a context where both a positive 
and detrimental effect of depleting neutrophils could be observed. This is 
to avoid the disadvantages of only using a severe context, where only a 
very strong positive effect of neutrophil depletion could be observed.  
• Specifically deplete neutrophils in this context and assess whether they are 
on balance protective or harmful. 
• If possible to optimise a setting where neutrophil depletion does not affect 
single infections, to allow study of their role in coinfection alone. 
 
As prior studies have suggested inconclusively that neutrophils are somewhat 
impaired during coinfection, and others imply but do not confirm they are 
protective, I hypothesised: 
• Neutrophils may exhibit functional impairment during coinfection. 
• Neutrophil depletion would have no effect during low virulence single 
Strep or IAV infection. 
• Depletion of neutrophils would be detrimental during coinfection. 
• Depletion of neutrophils in coinfection would exacerbate bacterial 
outgrowth. 
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5.3. Results 
 
Collagenase D digestion gives highly pure mouse lung neutrophils 
 
To test neutrophil function during coinfection, mouse neutrophils were purified 
from coinfected mice at 6dpi. To achieve this a positive separation of Ly6G+ cells 
on a Magnetic Activated Cell Sorting (MACS) column was utilised. Several steps 
had to be optimised before high purity neutrophils were derived (I am grateful for 
the help of Dr. C. De Santo (WIMM, University of Oxford) and Dr. V. 
Papayannopoulos, (Division of Molecular Immunology, NIMR) with neutrophil 
purification). Initially, different enzyme mixes for digestion of the lung tissue 
prior to separation were tested. Collagenase D digest of manually macerated 
tissue resulted in the highest purity neutrophils after one round of MACS 
separation - approximately 30% of total material was comprised of neutrophils 
(Fig. 9A, neutrophils defined as proportion of ungated material Ly6G+CD11b+), 
while over 80% of live cells were neutrophils (Fig 9B, neutrophils defined as 
proportion of Death Stain-FSC>very lowSSC>very low material Ly6G+CD11b+). This 
suggested good purification; however, the discrepancy between the proportion of 
neutrophils in the total material and the live cell gate suggested the main 
contaminant was a large population of dead cells. 
 
To remove dead cells, a second run through a MACS column and, where very 
high purity was required, a separation over a Percoll gradient, was performed. 
This removed much of the dead cell contamination, increasing the proportion of 
neutrophils in the total preparation (Fig. 9C), and ensuring neutrophils made up 
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the huge majority of live cells (Fig. 9D). To improve the speed of processing 
replacing manual maceration of the lung tissue with a gentleMACS homogeniser 
was tested; however, this reduced the proportion of neutrophils in both total 
material (Fig. 9E) and the live cell gate (Fig. 9F) and therefore was not used in 
subsequent purifications.  
 
Therefore the final optimised purification protocol (shown in Fig. 9G) was a 
manual homogenisation of tissue, followed by digestion of the lung with 
collagenase D digest mix, then sequential positive selection for Ly6G+ cells on 
two MACS columns. Where further removal of dead cells was desirable, 
neutrophils were also further purified over a Percoll gradient (whether this step 
was performed is specified in subsequent figure legends).  
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Figure 9. Optimisation of neutrophil purification.
% Neutrophils (Ly6G+CD11b+) derived from 6dpi IAV infected mouse lungs after different purifica-
tion regimes: Neutrophils obtained through one round of MACS separation following lung diges-
tion with different enzyme mixes containing Liberase, Collagenase IV or Collagenase D - total 
material shown in (A) and live cells only in (B). Neutrophils obtained following Collagenase D 
digestion with one or two rounds of MACS separation, followed by a 40/85% Percoll gradient, 
taking cells at the interface - total material shown in (C) and live cells only in (D). Neutrophils 
obtained with Collagenase D digestion and two rounds of MACS separation following homogeni-
sation by maceration or using a gentleMACS tissue disassociator - total material shown in (E) and 
live cells only in (F). Each experiment represents neutrophils pooled from the lungs of 2-6 mice. 
Data is shown as % Neutrophils of either total material (ungated) or live cells (Death stain-FSC>very 
lowSSC>very low). (G) Scheme of optimised purification protocol.
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Neutrophils are not functionally impaired during coinfection 
 
Using the established purification protocol, neutrophils were purified from mouse 
lungs at 6dpi during coinfection or Strep infection and their capacity to respond to 
restimulation was assessed. Neutrophil ROS production has been extensively 
studied using phorbol myristate acetate (PMA) stimulation (Nauseef et al., 1991). 
Coinfected neutrophils had equivalent ROS production to those from Strep 
infected mice upon restimulation with the PMA analogue phorbol 12,13-
dibutyrate (PDBu) (Fig. 10A). C. albicans has been shown to induce neutrophil 
NET formation (Urban et al., 2006). Similar levels of NET formation upon 
restimulation with C. albicans were observed (Fig. 10B) (experiment performed 
in collaboration with Ms. Nora Branzk, Division of Molecular Immunology, 
NIMR; C. albicans kindly provided by Dr. J. Duarte, Division of Molecular 
Immunology, NIMR). 
 
I then assessed capacity of purified neutrophils to produce cytokines. Production 
of TNF-α and KC by purified mouse bone marrow neutrophils has previously 
been described (Zhang et al., 2009). TNF-α and KC production by mouse lung 
neutrophils was similar or greater in those from coinfected mice (Fig. 10C) upon 
stimulation with the TLR2 agonist Pam3CSK4, the TLR4 agonist LPS, or PDBu. 
The ability to produce similar levels of reactive oxygen species and cytokines, and 
an equivalent capacity to form NETs, suggests that neutrophil function on a per-
cell basis is not impaired during coinfection. 
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In addition to profiling the response of restimulated neutrophils in vitro, in vivo 
function was tested by assessing myeloperoxidase levels in the BAL fluid of 
coinfected and Strep infected mice at 6dpi. Myeloperoxidase levels were 
moderately higher in the BAL fluid of coinfected mice (Fig. 10D). This suggests 
neutrophil degranulation is not impaired in the lung during coinfection in vivo. 
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Figure 10. Lung neutrophils are not functionally impaired during coinfection. 
(A) ROS production by luminol assay of PDBu (50nM) stimulated MACS purified lung neu-
trophils from high dose Strep or coinfected mice at 6dpi (neutrophils from 9 mice pooled into 
3 separate replicates/group, with technical triplicates performed in the assay/condition; 
representative of 2 independent experiments). (B) Percentage of NET forming cells 
assessed by microscopy of C. albicans stimulated MACS/Percoll purified neutrophils 
QHXWURSKLOVIURPPLFHSRROHGJURXS&(/,6$TXDQWLILFDWLRQRI71)ĮDQG.&SURGXFHG
E\3DP&6.JPO/36JPORU3'%XQ0VWLPXODWHG0$&6SXULILHGQHXWUR-
phils (neutrophils from 3 mice pooled/group, with technical triplicates performed in the 
assay/condition). (D) ELISA quantification of myeloperoxidase in the airways at 6dpi 
(n=3-5). Data displayed as percentage of neutrophils (NET formation) or arithmetic means 
±SEM (ROS, cytokine production, airway MPO).
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Low dose coinfection gives moderate mortality 
 
Having confirmed there is a strong neutrophil response during coinfection and 
that on a per-cell basis they do not appear functionally impaired, I then attempted 
to directly assess in vivo the role of neutrophils in coinfection. However, to 
achieve this, the current “high dose” coinfection setting, where almost all mice 
reach endpoint - although highly suitable for profiling synergistic effects in 
coinfection - was not appropriate for interventions, as only a strong positive effect 
of neutrophil depletion would be detected. Therefore both IAV and Strep doses 
were titrated down to give a “low dose” setting where approximately 50% of mice 
reached endpoint during coinfection (Fig. 11A, titration of single infections also 
shown in Fig. 11B). 
 
Low dose coinfection indicates bacterial outgrowth correlates with mortality 
 
Although optimised for the purpose of assessing interventions, low dose 
coinfection setting was also useful to further confirm bacterial outgrowth as the 
driver of mortality during coinfection. As not all mice reach endpoint at a low 
dose, mice can be classified by disease status as “endpoint” or “recovering”, and 
therefore it was possible to determine whether bacterial outgrowth correlates with 
mortality.  
 
Therefore in a low dose coinfection, mice reaching endpoint (this occurred from 
8-10 dpi) were harvested. Mice showing weight gain - classified as “recovering” 
were concurrently harvested, as weight gain is typically an indicator of recovery. 
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For comparison, a high dose coinfection, where all mice reach endpoint, was also 
performed. There was a very strong correlation between reaching endpoint and 
high streptococcal loads in the lung (Fig. 11C, left panel shows all high dose mice 
versus all low dose mice, right panel shows low dose mice separated by disease 
status), spleen (Fig. 11D) and brain (Fig. 11E). Recovering mice had little, if any, 
bacteria present. All high dose coinfected mice reached endpoint and exhibited 
high bacterial loads. Therefore low dose coinfection, as well as enabling a greater 
range of inventions to be investigated, demonstrates clearly that bacterial 
outgrowth correlates very closely with mortality.  
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Figure 11. Bacterial outgrowth correlates with mortality in a low dose coinfection. 
(A) Mortality following coinfection with high (8x103 TCID50 IAV, 2x10
7 CFU Strep) or low (400 
TCID50 IAV, 2x10
5 CFU Strep) doses (n=9, representative of 3 independent experiments). 
All infections are shown in table (B). (C) Comparison of streptococcal load in the lung, (D) 
spleen and (E) brain in mice harvested upon reaching endpoint or concurrently harvested 
recovering (gaining weight) mice, during low and high dose coinfection from 8-10 dpi. All 
mice at high dose reached endpoint; all low dose mice are grouped (left panels) and then 
separated into recovering and endpoint groups (right panels) (n=13-21). Data displayed as 
percent survival (mortality) or geometric means (bacterial loads). Significance assessed by 
Mann-Whitney test (bacterial loads) or Log-rank (Mantel-Cox) test (mortality). n.s. = not 
significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ND=not done. 
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Neutrophils are protective in coinfection 
 
Having established a suitable low dose coinfection setting for interventions, 
neutrophils were depleted by treating with anti-Ly6G prior to secondary infection 
(every 24 hours from 4-12dpi). Antibody treatment was performed one day prior 
to secondary infection to ensure neutrophils were depleted upon bacterial 
inoculation. However, in order to focus on their effect in coinfection, neutrophils 
were not depleted during the early influenza phase of infection (i.e. from 0-3dpi). 
The efficacy of anti-Ly6G treatment was verified through neutrophil 
quantification by flow cytometry in coinfected lungs at 6 and 7dpi (Fig. 12A). In 
this quantification it was not possible to identify neutrophils as previously done 
(for example, in Fig. 5A) based on their expression of Ly6G, as the same antibody 
clone is used for depletion and staining. Therefore neutrophils were identified on 
the basis of other marker characteristics as granular (SSC>low) cells expressing 
CD11b and with intermediate (i.e. lower than inflammatory monocytes) or low 
expression of Ly6C. They were negative for the markers of other cell types MHC 
Class II, F4/80 and CD11c (for flow cytometry gating strategy, see Appendix 3). 
 
Specific neutrophil depletion increased weight loss (Fig. 12B) and mortality (Fig. 
12C) during low dose coinfection, with no effect during single IAV or Strep 
infections. Neutrophil depletion also led to increased streptococcal loads in the 
lung (Fig. 13A), spleen (Fig. 13B) and brain (Fig. 13C) at 8dpi. No effect on viral 
titres was observed (Fig. 13D). I also corroborated these findings by depleting 
with less specific anti-Gr-1 from one day prior to secondary infection (every 48 
hours from 4-8dpi), which exacerbated weight loss (Fig. 14A) and mortality (Fig. 
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14B), with no substantial effects during single IAV or Strep infections. A small 
increase in weight loss in Strep infected mice did not translate into a significant 
difference in mortality. In summary neutrophil depletion during secondary 
infection is detrimental, confirming that the neutrophil response during 
coinfection is protective.  
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Figure 12. Neutrophil depletion exacerbates low dose coinfection.
(A) Flow cytometry quantification of lung neutrophils following vehicle (veh) or anti-Ly6G 
treatment during low dose coinfection. Neutrophils identified as CD11b+ SSC>low F4/80- 
CD11c- MHCII- Ly6Cint (n=3-5, representative of 2 independent experiments). (B) Weight 
loss and (C) mortality during low dose coinfection with isotype (iso) or anti-Ly6G treatment 
(n=9, data pooled from 2 independent experiments, arrows indiciate timing of antibody treat-
ments, on weight loss plot mice reaching endpoint retained thereafter at final weight, in 
some groups to aid visualisation final datapoint extended). Data is shown as arithmetic 
means (SEM (depletion and weights) or % survival (mortality). Significance assessed by 
Mann-Whitney test (depletion), 2-way ANOVA (weights) or Log-Rank (Mantel-Cox) test 
(mortality). *p<0.05, **p<0.01, ****p<0.0001.
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Figure 13. Neutrophil depletion exacerbates bacterial outgrowth during low dose coinfec-
tion. 
(A) Streptococcal load during low dose coinfection in the lung, (B) spleen and (C) brain following 
treatment with anti-Ly6G or isotype control (data shown is pooled from 2 independent experi-
ments, n=5-10). For clarity bacterial loads are also represented in a table immediately below. (D) 
Quantitative PCR for influenza viral matrix in the lung during low dose coinfection with anti-Ly6G 
or isotype control treatment (n=4-10). Data displayed as geometric means (graphs) or number of 
mice (tables). Significance assessed by Mann-Whitney test. n.s. = not significant, *p<0.05, 
**p<0.01
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Figure 14. Anti-Gr-1 treatment exacerbates low dose coinfection.
(A) Weight loss and (B) mortality during low dose coinfection with vehicle or anti-Gr-1 treat-
ment (data pooled from 2 independent experiments, n=5-12, arrows indiciate timing of anti-
body treatments, on weight loss plot mice reaching endpoint retained thereafter at final 
weight, in some groups to aid visualisation final datapoint extended). Data shown as arith-
metic means (SEM (weights) or % survival (mortality). Significance assessed by Mann-
Whitney test (weights) or Log-Rank (Mantel-Cox) test (mortality). *p<0.05, ****p<0.0001.
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5.4. Conclusions and Discussion 
 
It can therefore be concluded that the coinfection induces a strong, functional 
neutrophil response that is on balance protective, contributing to control of 
bacterial outgrowth. The protective role of neutrophils is consistent with the 
increased protection observed in granulophilic IFNαβR-/- mice (Shahangian et al., 
2009) and with previous studies showing exacerbated coinfection after poorly 
specific anti-Gr-1 treatment (McNamee et al., 2006; Sun et al., 2008). The use of 
low dose coinfection allows the detrimental effect of neutrophil depletion to be 
observed, which was not detected in a more severe context (Damjanovic et al., 
2013). Therefore the combination of specific depletion and low-dose coinfection 
allows the role of neutrophils to be clearly demonstrated for the first time. 
 
The complex role of neutrophils in both Strep and IAV single infections has 
previously been outlined. Here neutrophil depletion has no effect during IAV 
when given at 4 - 12dpi. This is consistent with a previous study showing no 
effect of neutrophil depletion commencing several days into IAV infection (Tate 
et al., 2011). It is likely, although the antibacterial role of neutrophils is well 
characterised, that neutrophil depletion does not exacerbate Strep single infection 
due to the low virulence, non-colonizing nature of Strep in this model (as shown 
in Fig. 3A), which is largely cleared prior to the induction of any neutrophil 
response (Fig. 7A).  
 
By the readouts assessed, neutrophil function does not appear to be impaired by 
prior coinfection. This contradicts aspects of previous studies. One study 
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reporting deficiencies in ROS production and phagocytosis (McNamee et al., 
2006), as already outlined, is somewhat confounded by the use of LPS 
aerozolisation to induce greater neutrophil recruitment, and therefore is difficult to 
interpret. Another study reports no differences in ROS generation, consistent with 
the results shown here (LeVine et al., 2001). However it also suggests 
myeloperoxidase per neutrophil in the lung is reduced. This is somewhat 
contradictory with another study that total myeloperoxidase in the lung is 
increased (Damjanovic et al., 2013). It is possible the results shown here are 
consistent with both studies. I observed an increase in total myeloperoxidase in 
the airway (Fig. 10D) in coinfected mice relative to single Strep infection; 
however, it is notable that this increase is proportionally smaller than the rise in 
neutrophil numbers in the lung (Fig. 5A). Therefore it is possible that on a per-
neutrophil basis myeloperoxidase release is reduced in coinfection, and this could 
be assessed by performing flow cytometry to enumerate neutrophils and 
quantifying myeloperoxidase by ELISA on the same airway samples. 
Nevertheless, as total myeloperoxidase is increased, it is unlikely that lack of 
myeloperoxidase production is a cause of coinfection susceptibility. Phagocytosis 
is not assessed here, although the reductions reported by a previous study are 
somewhat marginal (Damjanovic et al., 2013). 
 
Another criticism that could be raised of in vitro profiling of neutrophil function is 
that purification from the lung prior to restimulation is a biased selection of the 
neutrophil population. As neutrophils are terminally differentiated, short-lived 
effector cells (Nathan et al., 2006), it is possible that the purification process 
selects against those that have already begun to perform their effector functions, 
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as they may be more susceptible to cell death during processing. Purification may 
select for recently recruited neutrophils, which may be less likely to be “impaired” 
due to less exposure to influenza and subsequent effectors in the lung (unless the 
effects of influenza on neutrophils are systemic). Therefore to complement the 
observation that neutrophils are not impaired upon purification and restimulation, 
readouts not requiring purification may be useful. Profiling of myeloperoxidase 
levels in the airway somewhat achieves this, although levels of other effectors 
such as elastase could also be assessed. Furthermore in vivo neutrophil cytokine 
production could be assessed by performing intracellular staining on whole lung 
cell populations. 
 
In summary, low dose coinfection showed a strong correlation between bacterial 
outgrowth, spread to other organs, and poor disease outcome. Absence of 
bacterial outgrowth correlated with signs of recovery. This supports the earlier 
conclusions that bacterial outgrowth is the primary driver of mortality during 
coinfection. Neutrophils appear to be functional and on balance protective during 
coinfection, helping to counter bacterial outgrowth and dissemination. 
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Chapter 6. TNF-α in coinfection 
 
6.1. Background 
 
Another aspect of the strong proinflammatory response that was strikingly 
increased during coinfection is TNF-α. Interestingly, this was not present in either 
single infection. I therefore wanted to test whether this part of the response was 
protective or pathogenic. Furthermore, although it cannot be assumed to be a 
surrogate for all proinflammatory cytokines, investigating TNF-α does give 
information on whether the broader proinflammatory cytokine response observed 
in coinfection is protective. TNF-α is also highly relevant to the neutrophil 
response, promoting neutrophil recruitment to infected tissues (Borregaard, 2010), 
release of reactive oxygen species, and degranulation (Nathan et al., 2006).  
 
Although in this model TNF-α was not observed in single infections, it has a well-
characterised role in bacterial infections, and is protective during a virulent Strep 
infection (Hatta et al., 2010). It has also been identified as a possible source of 
immunopathology during severe IAV infection (Hussell et al., 2001), although 
reducing TNF signalling does not always show a beneficial effect (Salomon et al., 
2007).  
 
The role of TNF-α in IAV-Strep coinfection has not been studied; although 
several studies have observed a rise in TNF-α levels either 24 or 48 hours 
following coinfection (LeVine et al., 2001; Seki et al., 2004; Smith et al., 2007). 
Another study reported a decrease in TNF-α in coinfection relative to Strep 
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infection 4 hours following secondary infection (Sun et al., 2008). This 
discrepancy may be due to the different time points observed, although another 
study reported increases in TNF-α at both 4 and 24 hours following coinfection 
(Li et al., 2012). Furthermore, consistent with this, I observed increases in TNF-α 
at 4 and 24 hours following coinfection (Fig. 6A, Fig. 8A). Why one study 
observes a decrease in TNF-α in contrast to the majority of others is not clear, as 
studies reporting a rise in TNF-α during coinfection reflect inoculation with 
different amounts and strains of Strep, with a range of virulences.  
 
A severe IAV-H. influenzae model (with 100% mortality) is the only coinfection 
study performing a direct intervention to assess the role of TNF-α (Lee et al., 
2010). In this model both bacterial outgrowth and mortality are observed, but the 
drivers of mortality are not determined. The authors hypothesised TNF-α may be 
harmful, and TNFR1-/- mice would have reduced immunopathology and less 
severe disease. However, in the context of complete mortality, a protective effect 
was not observed. 
 
6.2. Hypotheses and Aims 
 
Having observed that neutrophils are protective during coinfection, but are not 
required during single Strep infection, I decided to test if the TNF-α cytokine 
response was also protective. TNF-α was a good target for investigation as it was 
highly upregulated versus both single infections, and its antibacterial role and 
ability to activate neutrophils are well defined.  
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Two loss of function approaches to test the role of TNF-α in coinfection were 
considered – use of TNFR1-/- mice, which are deficient in what are believed to be 
the primary aspects of TNF-α signalling (Bradley et al., 2008), and treatment with 
anti-TNF-α antibody, which has been shown to be effective in vivo previously 
(Hussell et al., 2001). I proposed to use a low dose coinfection setting so both 
positive and negative effects of interventions could be detected. 
 
As I had already confirmed that the neutrophil response to coinfection was 
protective, and TNF-α promotes this response, I hypothesised that:  
• TNF-α is protective during coinfection. 
• TNFR1 deficiency would exacerbate disease during coinfection.  
• TNFR1 deficiency would increase bacterial loads during coinfection. 
• Blockade of TNF-α would exacerbate disease during coinfection. 
• Blockade of TNF-α would increase bacterial loads during coinfection. 
• Blockade of TNF-α or TNFR1 deficiency would have no effect on low 
virulence Strep or IAV infections. 
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6.3. Results 
 
TNFR1-/- mice are more susceptible to IAV and coinfection 
 
TNFR1-/- mice were infected with a low dose coinfection, and demonstrated 
increased weight loss (Fig. 15A) and mortality (Fig. 15B) relative to wild-type 
mice, suggesting TNF-α is protective during coinfection. However, TNFR1 
deficiency also increased susceptibility to IAV and led to slight increase in weight 
loss during Strep infection. In this context it is difficult to assess the causes of 
increased susceptibility to coinfection, as it may be due to a worse response to the 
primary viral infection; therefore use of these mice was discontinued.  
  
 134	  
 
  
Figure 15
A
B
Weights: TNFR1-/-
0 5 10 15
70
80
90
100
110
Days post infection
%
 o
f s
ta
rti
ng
 w
ei
gh
t 
Strep
Strep - TNFR1-/-
IAV
IAV - TNFR1-/-
IAV + Strep
IAV + Strep - TNFR1-/-
****
****
****
Survival: TNFR1-/-
0 5 10 15
0
50
100
Days post infection
%
 s
ur
vi
va
l Strep
Strep - TNFR1-/-
IAV
IAV - TNFR1-/-
IAV + Strep
IAV + Strep - TNFR1-/-
*
n.s.
*
Figure 15. TNFR1 deficiency exacerbates influenza and coinfection.
(A) Weights and (B) mortality of wild-type (C57BL/6) or TNFR1-/- (B6) mice during low dose 
coinfection (n=9, representative of 2 independent experiments, on weight loss plot mice 
reaching endpoint retained thereafter at final weight, in some groups to aid visualisation final 
data point extended). Data displayed as arithmetic means ±SEM (weights) or percent 
survival (mortality). Significance assessed by 2-way ANOVA (weights) or Log-rank (Mantel-
Cox) test (mortality). n.s. = not significant. *p<0.05. **p<0.01. ****p<0.0001.   
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TNF-α is protective in coinfection 
 
Anti-TNF-α was used to blockade TNF-α signalling during a low dose 
coinfection. To assess the role of TNF-α during coinfection, without affecting the 
prior viral phase, treatment was given immediately prior to and during secondary 
infection at 5 and 7dpi. Anti-TNF-α treatment led to increased weight loss (Fig. 
16A) and mortality (Fig. 16B) during coinfection. No effect on IAV or Strep 
infections was observed, suggesting that TNF-α is only required in the lung 
during coinfection, consistent with its absence in single infections. The more 
severe disease observed during single infections with TNFR1-/- mice is likely due 
to other confounding factors, rather than the absence of TNF-α in the lung. 
 
Anti-TNF-α treatment also exacerbated bacterial loads in the lung (Fig. 17A), 
spleen (Fig. 17B) and brain (Fig. 17C). Consistent with the lack of effect on 
weights or survival during IAV infection, no effect on viral titres was observed 
(Fig. 17D). Therefore the high level of TNF-α produced during coinfection is on 
balance protective. 
  
 136	  
  
Survival: TNF-  depletion
0 5 10 15
0
50
100
Days post infection
%
 s
ur
vi
va
l
Strep + iso
Strep + anti-TNF-
IAV + iso
IAV + anti-TNF-
IAV + Strep + iso
***IAV + Strep + anti-TNF-
n.s.
anti-TNF-
Figure 16
A
B
   
Weights: TNF-  depletion
0 5 10 15
70
80
90
100
110
Days post infection
%
 o
f s
ta
rti
ng
 w
ei
gh
t 
Strep + iso
Strep + anti-TNF-
IAV + iso
IAV + anti-TNF-
IAV + Strep + iso
IAV + Strep + anti-TNF- ****anti-TNF-
Figure 16. TNF-_ depletion exacerbates low dose coinfection.
(A) Weights and (B) mortality during low dose coinfection following treatment with 
anti-TNF-Į or isotype control (n=9, representative of 2 independent experiments. On weight 
loss plot mice reaching endpoint retained thereafter at final weight, arrows indicate timing of 
antibody treatments, in some groups to aid visualisation final data point extended). Data 
displayed as arithmetic means ±SEM (weights) or percent survival (mortality). Significance 
assessed by 2-way ANOVA (weights) or Log-rank (Mantel-Cox) test (mortality). n.s. = not 
significant. ***p<0.001. ****p<0.0001.
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Figure 17. TNF-_ blockade exacerbates bacterial outgrowth during low dose coinfection.
(A) Streptococcal load during low dose coinfection in the lung, (B) spleen and (C) brain following 
treatment with anti-TNF-Į or isotype control (data shown is pooled from 2 independent experi-
ments, n=3-9). For clarity bacterial loads are also represented in a table immediately below. (D) 
Quantitative PCR for influenza viral matrix in the lung during low dose coinfection with anti-TNF-Į 
or isotype control treatment (n=5-6). Data displayed as geometric means (graphs) or number of 
mice (tables). Significance assessed by Mann-Whitney test. n.s. = not significant, **p<0.01, 
***p<0.001.
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6.4. Conclusions and Discussion 
 
The harmful effect of anti-TNF-α treatment during low dose coinfection confirms 
the strong TNF-α response observed is on balance protective during coinfection. 
This is somewhat at odds with a previous study, which reports that treatment with 
linezolid - which substantially reduces IFN-γ and marginally reduces TNF-α - 
ameliorates coinfection (Breslow-Deckmann et al., 2013). However the authors 
primarily attribute the protective effect to reducing IFN-γ, which has already been 
reported to play a detrimental role during coinfection (Sun et al., 2008). Therefore 
it is difficult to draw clear conclusions of the role of TNF-α from linezolid 
treatment. 
 
The increased susceptibility of TNFR1-/- mice to IAV is of interest. Although 
TNFR1 signalling appears to be slightly detrimental due to TNF-α driven 
immunopathology in severe IAV (Salomon et al., 2007; Szretter et al., 2007; 
Belisle et al., 2010), its absence has not previously been shown to exacerbate 
disease in a mild to moderate IAV setting. As TNFR1-/- mice have been reported 
to have a defect in antibody production (Le Hir et al., 1995), TNFR1 deficiency 
may lead to an impaired antibody response against influenza. This may not have 
been previously observed in severe influenza infections where immunopathology 
leads to rapid mortality, before a defect of antibody mediated viral control may be 
detectable.  
 
However, it is notable that the absence of TNFR1-/- does not reduce CD8 T cell 
numbers during severe or mild influenza (Szretter et al., 2007; Deberge et al., 
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2014). Therefore viral control may still be partially intact in TNFR1 deficient 
mice, as there is some redundancy between CD8 and antibody responses (Brown 
et al, 2004). Whether the antibody response is defective in TNFR1 deficient mice, 
and the relative contribution of antibodies and CD8 T cells to viral control, may 
be worthy of further investigation, although it is not directly relevant to 
coinfection. 
 
Although anti-TNF-α slightly prolongs survival in severe IAV models (Hussell et 
al., 2001; Peper et al., 2005), and may be modestly detrimental during infection 
with some Strep strains (Kirby et al., 2005; Hatta et al., 2010), in the mild to 
moderate single infections used here no effect was observed. This is particularly 
useful as it allowed investigation of the role of TNF-α in coinfection without 
confounding changes in susceptibility to single infections. It is likely that specific 
blockade of TNF-α in the lung during acute disease has substantially different 
effects to constitutive deficiency in TNF signalling throughout life, therefore it is 
unlikely that anti-TNF-α treatment, unlike TNFR1 deficiency, leads to 
impairment in antiviral antibody production. It should be noted that anti-TNF-α is 
not given during the early stage of influenza, when TNF-α may play a role; this 
may be an alternative explanation for the discrepancy with the susceptibility of 
TNFR1-/- mice to influenza. To address this, anti-TNF-α treatment could be 
performed throughout influenza infection.  
 
To summarize, upon bacterial colonization and outgrowth in the lung during 
coinfection, a strong immune response is mounted. The neutrophil and TNF-α 
components of this response are protective. The TNF-α and neutrophil response in 
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coinfection is of greater magnitude than the mild, transient and seemingly non-
essential response to low virulence Strep infection, and therefore cannot be 
considered “impaired”. This suggests that the fundamental issue during 
coinfection is the underlying factors that promote initial bacterial colonization in 
the lung, rather than subsequent immune impairment. In a coinfection setting 
where colonization occurs, a strong TNF-α and neutrophil response contributes to 
controlling bacterial outgrowth, but is frequently insufficient. Therefore in later 
chapters the underlying causes of initial bacterial colonization will be 
investigated. 
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Chapter 7. Inflammatory-monocyte mediated damage as 
a mechanism of coinfection 
 
7.1. Background 
 
As clear immune impairment was not detected during coinfection, it is possible 
early bacterial colonization may instead be due to lung damage. In addition to 
damage mediated directly by viral cytolysis, the immune response to influenza 
could be a source of damage. One of the effects of influenza is to induce 
inflammatory monocyte recruitment, which has been previously shown to induce 
damage in severe influenza (Lin et al., 2008). The role of influenza-induced 
inflammatory monocytes during coinfection has not yet been investigated.  
 
Whether inflammatory monocytes are on balance beneficial or harmful during 
influenza is somewhat unclear, although their role in causing damage is well 
established. Inflammatory monocytes are difficult to deplete with a high 
specificity, and therefore the majority of studies assessing their role use CCR2-/- 
mice. CCR2-/- mice lack the crucial chemokine receptor required for inflammatory 
monocyte release from the bone marrow into the bloodstream, and therefore are 
deficient in peripheral inflammatory monocytes (Serbina et al., 2006). Most 
studies of CCR2-/- mice during influenza are in a context of severe infection with 
high mortality. An early study established that CCR2-/- mice have reduced early 
pathology but less subsequent T-cell recruitment (Dawson et al., 2000).  Another 
study corroborated this, showing that inflammatory monocytes (in this case 
termed tipDCs) caused pathology but were required for full CD8 T-cell responses 
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(Aldridge et al., 2009). CCR2-/- mice and those treated with a CCR2 small 
molecule inhibitor had reduced lung damage (Lin et al., 2008; Lin et al., 2010). 
Overall, inflammatory monocytes promote damage during (severe) influenza, but 
may be required for full adaptive responses. The role of inflammatory monocytes 
in Strep infections has not been extensively studied, although CCR2-/- mice show 
slightly higher bacterial loads during a virulent Strep infection (Davis et al., 
2011).  
 
TRAIL, a pro-apoptotic ligand, has been identified as a source of inflammatory 
monocyte mediated damage during influenza. The results of different studies are 
somewhat contradictory and share similarities to results obtained with CCR2-/- 
mice; again, the main focus is severe influenza. TRAIL has been shown to signal 
to DR5 on epithelial cells during severe influenza and promote pathology; and 
anti-TRAIL treatment ameliorates this (Herold et al., 2008; Davidson et al., 
2014). In contrast another study has shown that TRAIL-/- mice are more 
susceptible to severe influenza, which may be due to a defective CD8 response 
(Brincks et al., 2008; Brincks et al., 2011). The role of TRAIL in Strep infection 
has not been extensively studied, although TRAIL-/- mice are more susceptible to 
a virulent Strep infection (Steinwede et al., 2012).  
 
The role of inflammatory monocytes during coinfection has been briefly alluded 
to in a previous study, which was largely focused on IAV alone. This study, to 
demonstrate the safety of using a CCR2 small-molecule inhibitor to ameliorate 
influenza, also performs a secondary streptococcal coinfection (Lin et al., 2011). 
In this very severe coinfection context there is an extremely marginal reduction in 
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very high bacterial loads. These results are difficult to interpret due to the severe 
coinfection context, the only partial block in inflammatory monocyte recruitment 
by the inhibitor, and effects of the inhibitor on other populations such as dendritic 
cells. 
 
7.2. Hypotheses and Aims 
 
Previous results in this thesis suggested that influenza allows bacterial 
colonization during coinfection, inducing a strong, unimpaired and on balance 
protective - but frequently insufficient - neutrophil and TNF-α response. This 
immune response was only required for protection in the context of coinfection. 
Single Strep infection induces only a modest immune response and depletion of 
neutrophils or TNF-α blockade during Strep infection has no effect. This implies 
immune impairment is not responsible for allowing bacterial colonization. An 
alternative cause of colonization may be reduced lung integrity. 
 
As inflammatory monocytes have been shown to cause lung damage in severe 
influenza, I speculated that this may be a mechanism during moderate influenza to 
allow bacterial colonization. I also proposed that TRAIL may be a molecular 
mechanism for this. To investigate this I decided to assess the susceptibility of 
CCR2-/- and anti-TRAIL treated mice to low dose coinfection.  
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I hypothesised that: 
• Influenza-induced inflammatory monocyte-mediated lung damage 
promotes early bacterial colonization during coinfection. 
• CCR2-/- mice would therefore be less susceptible to coinfection. 
• TRAIL is a molecular mechanism of inflammatory monocyte-mediated 
damage. 
• Anti-TRAIL treated mice would therefore be less susceptible to 
coinfection. 
• Damage at the point of bacterial inoculation would be the determinant of 
susceptibility. Therefore only anti-TRAIL treatment during the influenza 
phase of coinfection, prior to bacterial colonization, would be protective. 
Treatment during bacterial phase, following bacterial colonization, would 
be ineffective. 
• Neither CCR2 deficiency or anti-TRAIL treatment would substantially 
affect my mild to moderate single IAV and Strep infections. 
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7.3. Results 
 
CCR2-/- mice have reduced mortality and bacterial outgrowth during low dose 
coinfection 
 
Low dose coinfection was performed on CCR2-/- and wild-type mice and weights 
(Fig. 18A) and mortality (Fig. 18B) observed. No major changes during single 
Strep and IAV infections were observed, although there was a slight protective 
effect on weights during Strep infection; however, this was not significant in 
terms of mortality. In contrast, during coinfection CCR2-/- mice showed 
significantly less weight loss and mortality. Consistent with reduced mortality, 
CCR2-/- mice had dramatically reduced streptococcal loads during low dose 
coinfection in the lung (Fig. 19A), spleen (Fig. 19B) and brain (Fig. 19C). No 
effect on viral titres was observed (Fig. 19D).  
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Figure 18. CCR2 deficiency ameliorates low dose coinfection.
(A) Weights and (B) mortality of wild type (C57BL/6) or CCR2-/- (B6) mice during low dose 
coinfection (n=6-9, data shown pooled from 2 independent experiments, on weight loss plot 
mice reaching endpoint retained thereafter at final weight, in some groups to aid visualisa-
tion final data point extended). Data displayed as arithmetic means ±SEM (weights) or 
percent survival (mortality). Significance assessed by 2-way ANOVA (weights) or Log-rank 
(Mantel-Cox) test (mortality). n.s. = not significant. *p<0.05. ****p<0.0001.
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Figure 19. CCR2 deficiency ameliorates bacterial outgrowth during low dose coinfection.
(A) Streptococcal load in the lung, spleen (B) and brain (C) of wild type (C57BL/6) or CCR2-/- (B6) 
mice during low dose coinfection (data shown is pooled from 2 independent experiments, n=4-9). 
For clarity bacterial loads are also represented in a table immediately below. (D) Quantitative PCR 
for influenza viral matrix in the lung during low dose coinfection (n=5-9) Data displayed as geo-
metric means. Significance assessed by Mann-Whitney test. n.s. = not significant, **p<0.01, 
***p<0.001.
Number of mice 
CFU/
lung 
Strep  
Strep  
-CCR2 
-/- 
IAV + 
Strep  
IAV + 
Strep  
-CCR2 
-/- 
>104 0 1 10 2 
50-104 0 2 3 5 
<50 9 7 5 9 
Number of mice 
CFU/
spleen 
Strep  
Strep  
-CCR2 
-/-
IAV + 
Strep  
IAV + 
Strep  
-CCR2 
-/- 
>104 0 0 4 0 
50-104 0 1 4 3 
<50 9 9 10 13 
Number of mice 
CFU/
brain 
Strep  
Strep  
-CCR2 
-/- 
IAV + 
Strep  
IAV + 
Strep  
-CCR2 
-/- 
>104 0 0 2 0 
50-104 0 1 9 3 
<50 9 9 7 13 
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CCR2-/- mice are deficient in inflammatory monocytes during influenza 
 
Having confirmed CCR2-/- mice are less susceptible to coinfection, cell 
recruitment to the lung was then tested at the point of (5dpi) and during (7dpi) 
high dose coinfection. There were no significant changes in CCR2-/- mice in 
neutrophil (Fig. 20A), alveolar macrophage (Fig. 20C), CD3+ (Fig. 20D) or B cell 
levels (Fig. 20E) at 5 or 7dpi, although, consistent with greatly reduced bacterial 
colonization and outgrowth, there was a strong trend for reduced neutrophil 
recruitment at 7dpi. As expected, no inflammatory monocytes were present in 
CCR2-/- mice in any context at 5 or 7dpi (Fig. 20B).  
 
Some modest differences in influenza-induced cytokine production in CCR2-/- 
mice were observed at the point of coinfection (5dpi), including significant 
increases in some cytokines such VEGF and MCSF were observed (see Appendix 
4 for table). However, the fold changes observed were relatively small. Consistent 
with the trend for reduced neutrophils observed, proinflammatory cytokines such 
as MIP2 and TNF-α were reduced at 7dpi during high dose coinfection (see 
Appendix 4 for table). This confirms CCR2 deficiency removes inflammatory 
monocytes at the point of coinfection, without affecting other cell populations or 
causing major changes in the influenza-induced cytokine response. After bacterial 
superinfection, less bacterial outgrowth in CCR2 deficient mice leads to reduced 
neutrophil recruitment and proinflammatory cytokine production. 
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Figure 20. CCR2-/- mice do not recruit inflammatory monocytes to the lung during influenza 
or coinfection.
Flow cytometry quantification of (A) Neutrophils (Ly6G+CD11b+) (B) Inflammatory monocytes 
(Ly6C+CD11b+F4/80+) (C) Alveolar macrophages (CD11c+F4/80+) (D) CD3+ cells (CD3+) and (E) B 
cells (CD3-CD19+) (pooled from 2 independent experiments, n=2-3) in the lung during high dose 
coinfection. Data displayed as arithmetic means ± SEM. Significance assessed by Mann-Whitney 
test. n.s. = not significant. **p<0.01.
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CCR2-/- mice have reduced damage at the point of coinfection 
 
Having confirmed that inflammatory monocytes are absent in CCR2-/- mice, the 
effect of this on lung damage was then assessed. Free lactate dehydrogenase 
(LDH) in the airway, which indicates cell lysis, and total protein levels, which 
indicate alveolar leakage, have previously been used as readouts for lung damage 
during influenza (Lin et al., 2008). CCR2-/- mice had reduced levels of airway 
protein (Fig. 21A) and LDH activity (Fig. 21B) at the point of coinfection (5dpi). 
Lung histology also showed reduced pathology (Fig. 21C) (experimental 
assistance provided by Histology Section, NIMR). Therefore CCR2-/- mice have 
reduced lung damage at the point of coinfection, consistent with their reduced 
susceptibility to bacterial colonization. As major changes in other immune cell 
populations and cytokine levels at the point of coinfection were not observed, it is 
likely that reduced damage in CCR2-/- mice is responsible for their reduced 
susceptibility to coinfection.  
 
It is however notable that airway protein (Fig. 21D) and LDH activity (Fig. 21E) 
are not reduced in CCR2-/- mice during influenza or coinfection at 7dpi. This 
suggests that there is redundancy between inflammatory monocytes and other 
sources of damage later in influenza - this will be discussed later.  
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Figure 21. CCR2 deficiency reduces lung damage prior to coinfection.
(A) Airway protein and (B) LDH activity during high dose influenza infection at 5dpi in wild 
type (C57BL/6) or CCR2-/- (B6) mice assessed (n=2-3, data shown is pooled from 3 inde-
pendent experiments, LDH activity shown relative to mean of 5dpi wild type IAV infected 
group, defined as 100%). (C) H+E staining of lung tissue sections at 5dpi (n=2-3). (D) Airway 
protein and (E) LDH activity during high dose coinfection at 7dpi in wild type (C57BL/6) or 
CCR2-/- (B6) mice assessed (n=2-3, data shown is pooled from 2 independent experiments, 
LDH activity shown relative to mean of 7dpi wild type IAV infected group, defined as 100%). 
Data shown as arithmetic means (SEM. *p<0.05.
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TRAIL expressing inflammatory monocytes are present at the point of coinfection 
 
Therefore CCR2-/- mice have reduced susceptibility to coinfection, and that this 
likely due to reduced damage and subsequent bacterial colonization at the point of 
coinfection. Inflammatory monocyte damage may be mediated through TRAIL. A 
substantial population of TRAIL expressing cells is recruited at the point of 
coinfection (5dpi) (Fig. 22A). These are largely inflammatory monocytes, and 
therefore are absent - greatly reducing the levels of total TRAIL expressing cells - 
in CCR2-/- mice. DR5, the receptor for TRAIL, is upregulated during influenza, 
and as expected this is not affected by CCR2 deficiency (Fig. 22B). Therefore 
reduced damage in CCR2-/- mice at 5dpi is likely due to less TRAIL ligand, as 
TRAIL-expressing inflammatory monocytes are absent. Note - FACS strategy for 
identification of TRAIL+ cells is shown in Appendix 5A. Strategy for assessing 
DR5 expression on epithelial cells is shown in Appendix 5B. 
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Figure 22. The majority of TRAIL expressing cells at the point of coinfection are 
CCR2-dependent inflammatory monocytes.
Flow cytometry quantification of (A) TRAIL+ cells and (B) DR5+ epithelial cells 
(E-cadherin+Ep-Cam+) at 5dpi during high dose influenza infection (n=5, data shown repre-
sentative of 2 independent experiments). Data displayed as arithmetic means ± SEM. 
Significance assessed by Mann-Whitney test. n.s. = not significant. **p<0.01.
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Anti-TRAIL treatment during influenza phase is protective during low dose 
coinfection 
 
To confirm that inflammatory-monocyte mediated damage is harmful, the effect 
of TRAIL blockade was tested during low dose coinfection. Initially, to prevent 
all TRAIL-mediated damage, continuous treatment with anti-TRAIL was given 
during both influenza and bacterial phases of coinfection (from 1 to 9dpi). This 
ameliorated weight loss (Fig. 23A) and mortality (Fig. 23B), and had no effect in 
IAV or Strep single infections. This confirms TRAIL expressing-inflammatory 
monocyte mediated damage is harmful during coinfection, but did not confirm at 
when this harmful effect is mediated. 
 
I hypothesised that the presence of influenza-induced damage at the point of 
bacterial inoculation is crucial for determining whether colonization will occur. 
This implied that only anti-TRAIL treatment starting during the influenza phase 
of infection would be effective. Therefore treatment with anti-TRAIL was given 
in the influenza phase (“early”, 1 and 3dpi) or bacterial phase (“late”, 6 and 8dpi) 
of low dose coinfection. Only early anti-TRAIL treatment ameliorated weight loss 
(Fig. 23C) and mortality (Fig. 23D). This confirms that the protective effect of 
blocking inflammatory-monocyte TRAIL is mediated during the influenza phase. 
Once bacteria have colonized due to inflammatory monocyte induced damage, 
anti-TRAIL treatment is ineffective. Confirming the role of TRAIL in promoting 
bacterial colonization, early anti-TRAIL treatment also significantly reduced lung 
bacterial load following high dose coinfection at 5dpi + 16hrs; a trend for 
reduction was also observed following low dose coinfection (Fig. 23E).  
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Figure 23. Anti-TRAIL treatment during prior influenza ameliorates low dose coinfection.
(A) Weights and (B) mortality during low dose coinfection with either anti-TRAIL treatment or vehi-
cle control (PBS) every 48 hours from 1-9dpi (”continuous”) (n=6-9, pooled from 2 independent 
experiments, arrows indicate timing of antibody treatment, on weight loss plot mice reaching end-
point retained thereafter at final weight, in some groups to aid visualisation final data point 
extended). (C) Weights and (D) mortality during low dose coinfection with either anti-TRAIL treat-
ment at 1 and 3 dpi (”early”), 6 and 8dpi (”late”) or vehicle control (1,3,6 and 8dpi) (n=8-9, pooled 
from 2 independent experiments, solid arrows indicate early treatment, dashed arrows indicate 
late treatment, on weight loss plot mice reaching endpoint retained thereafter at final weight, in 
some groups to aid visualisation final data point extended). (E) Lung streptococcal load during 
high or low dose coinfection at 5dpi+16hrs following treatment with anti-TRAIL or vehicle control 
at 1 and 3 dpi (n=7-9). Data shown as geometric mean (bacterial loads) or arithmetic means 
(SEM (weights) or percent survival (mortality). Significance assessed by Mann-Whitney test 
(bacterial loads), 2-way-ANOVA (weights) or Log-Rank (Mantel-Cox) test (mortality). n.s.=not 
significant. *p<0.05. ****p<0.0001
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7.4. Conclusions and Discussion 
 
From these results a mechanism for coinfection emerges where influenza-induced 
inflammatory monocytes, via TRAIL signalling to DR5 on epithelial cells, cause 
lung damage, which enables bacterial colonization and subsequent outgrowth. 
Prior data in this thesis suggests that this bacterial outgrowth induces a strong and 
unimpaired neutrophil and pro-inflammatory cytokine response, which is 
protective but frequently insufficient to prevent mortality.  
 
A model of pre-colonization with Strep followed by influenza somewhat contrasts 
with the resistance of CCR2-/- mice to coinfection shown here. In this context 
these pathogens synergised to produce type I IFN, which reduced MCP-1 (a 
CCR2 ligand) production, reducing macrophage function and bacterial clearance 
(Nakamura et al., 2011). The protective role of MCP-1 in this study implies CCR2 
deficiency would be harmful in coinfection. It is likely this discrepancy is due to 
different order of pathogen exposure between models; pre-existing pneumococcal 
carriage exacerbated by influenza differs greatly from the model investigated here 
of secondary bacterial infection during the acute phase of influenza. 
 
The lack of effect of CCR2 deficiency or anti-TRAIL treatment during moderate 
influenza is not necessarily in contradiction with the varied literature regarding 
severe influenza. Consistent with severe influenza models (Lin et al., 2008), 
CCR2-dependent cells and TRAIL cause damage during the mild to moderate 
influenza used here; however, in this context this effect is likely too small for 
CCR2 deficiency or TRAIL blockade to substantially alter disease. Furthermore, 
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in severe influenza CCR2 and TRAIL appear to play both harmful and beneficial 
roles (Brincks et al., 2008; Herold et al., 2008; Aldridge et al., 2009), which may 
in a moderate setting “cancel out” in terms of overall disease severity. Although 
TRAIL-/- mice have been reported to be more susceptible to a virulent Strep strain 
(Steinwede et al., 2012), the lack of effect observed on Strep infection of anti-
TRAIL treatment in the present model is likely due to the low virulence of the 
strain used.  
 
Several other factors previously observed in other studies may indirectly 
corroborate the theory that influenza-induced inflammatory-monocyte mediated 
damage is responsible for bacterial colonization during coinfection. For example, 
the reported increased resistance of IFNαβR1-/- mice to coinfection (Shahangian et 
al., 2009) may be due to reduced TRAIL-expressing inflammatory monocytes, as 
IFNαβR-/- mice have been shown to have reduced monocyte numbers in severe 
influenza infection (Seo et al., 2011), and upregulation of TRAIL appears to be 
somewhat dependent on type I IFNs (Hogner et al., 2013; Davidson et al., 2014).  
 
Furthermore, studies showing influenza strains encoding PB1-F2 - a pro-apoptotic 
viral peptide - lead to more severe coinfections (McAuley et al., 2007; Alymova 
et al., 2013) support lung damage as a mechanism of coinfection. These studies 
focus on direct viral rather than immune-mediated damage, which may be 
sufficient in a severe context to cause coinfection susceptibility. It could also be 
argued that more severe viral infections often induce a greater immune response, 
and therefore the source of damage in these systems is difficult to determine. 
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It is notable that, although inflammatory monocyte deficiency leads to reduced 
damage at the point of coinfection (5dpi), it does not affect damage later in 
influenza infection (7dpi). Other sources of damage, such as viral cytolysis or the 
cytotoxic CD8 T-cell response, rather than inflammatory monocytes, may be the 
major cause of damage at this point. If the model of damage allowing bacterial 
colonization is correct, CCR2-/- mice given secondary infection at 7dpi may be 
susceptible to coinfection; this may be a useful future experiment. In addition, 
blockade of other sources of damage, for example by depleting CD8 T cells, may 
merit investigation. Different sources of damage at different time points highlight 
that coinfection is a multifactorial process, and even if underlying lung damage is 
the primary mechanism, it may have multiple sources. As coinfection at 7dpi has 
been reported to be more severe than at other time points (McCullers et al., 2002), 
it is possible that this reflects multiple sources of damage at this point. Therefore 
although in this model - where coinfection is performed at 5dpi - early influenza-
induced TRAIL-expressing inflammatory monocytes appears to be the primary 
cause of damage that allows subsequent bacterial colonization, other sources of 
damage must also be considered. 
 
It is possible that CCR2 deficiency affects other cells types in influenza and 
coinfection in addition to inflammatory monocytes; one study reports moderately 
reduced levels of CD11c+MHCII+ dendritic cells in CCR2-/- mice during influenza 
(Lin et al., 2008). Here changes are not observed in lymphocyte, neutrophil or 
alveolar macrophage numbers in CCR2-/- mice; however the dendritic cell 
numbers are not assessed. As inflammatory monocytes are almost completely 
abolished by CCR2 deficiency, in comparison to the modest reduction in dendritic 
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cells described in the study cited, absence of inflammatory monocytes can be 
considered the major effect of CCR2 deficiency. However, the possible reduction 
in dendritic cell numbers must be considered as another factor. Relating to this, 
another study also reports a drop in “tipDCs” in CCR2-/- mice during influenza 
(Aldridge et al., 2009). However, tipDCs are classified as Ly6C+CD11b+, and 
therefore can be considered more equivalent to inflammatory monocytes than 
CD11c+ conventional dendritic cells  (Serbina et al., 2006).  
 
Overall, several other studies indirectly corroborate a model where influenza-
induced inflammatory-monocyte mediated damage causes susceptibility to 
coinfection. This model will be discussed further in chapter 10; however, chapters 
8 and 9 will focus on other investigations into coinfection, including bacterial 
spread to the brain and other aspects of the immune response. 	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Chapter 8. Bacterial spread to the brain in coinfection 
 
8.1. Background 
 
A striking feature of coinfection is bacterial spread to the brain (Fig. 2C). 
Furthermore during low dose coinfection bacterial dissemination to the brain is 
common even among recovering mice (Fig. 11E), that otherwise show no spread 
to the spleen (Fig. 11D), and exhibit low bacterial loads in the lung (Fig. 11C). 
Bacterial spread to the brain therefore merited further investigation. 
 
Meningitis is well-characterised complication of Strep infection (Koedel et al., 
2002), and has been modelled in mice through direct intracisternal application of 
streptococci (Mook-Kanamori et al., 2012). This led to high bacterial loads, brain 
inflammation and pathology. It has been speculated that there is an association 
between viral infection and bacterial meningitis (Krasinski et al., 1987), although 
this finding has been disputed (Foy et al., 1988). A recent mouse model reported 
bacterial spread to many peripheral organs during IAV-Strep coinfection, 
including the brain, although they did not pursue these investigations further 
(Damjanovic et al., 2013). 
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8.2. Hypotheses and Aims 
 
As only one study had previously tested whether Strep spreads to the brain during 
coinfection, I aimed to verify this and confirm that it was not an artefact. I also 
wanted to investigate whether spread caused inflammatory changes in the brain, 
as an indicator whether this area might merit further research.  
 
I hypothesised that: 
• Bacterial spread to the brain in coinfection was not an artefact of 
extraction technique, contamination from the blood, or intranasal 
infection. 
• Bacterial spread to the brain induces inflammatory changes. 
 
8.3. Results 
 
Detection of bacteria in the brain is not due to contamination 
 
To verify that bacterial spread to the brain was not an artefact of surgical 
contamination, mouse brains were extracted during a high dose coinfection. To 
exclude external contamination, brain tissue was washed serially in PBS prior to 
processing. To rule out contamination from the nasal cavity, the front of the brain 
- which may have come into contact with the nasal cavity during extraction - was 
excised. These mice were then compared to control mice, where whole brains 
were extracted conventionally without these measures. These alterations in 
 162	  
extraction protocol did not affect bacterial loads (Fig. 24A), confirming bacterial 
presence was not due to surgical contamination. 
 
It was possible that bacteria spread directly from the nasal cavity to the brain 
following intranasal infection, rather than through dissemination from the lung. 
To test this, bacterial loads in the brain of high dose coinfected mice infected by 
the intranasal or intratracheal route were compared. Intratracheal inoculation 
bypasses the nasal cavity and directly infects the lungs. Intratracheal infection did 
not reduce, and indeed marginally increased streptococcal loads in the brain, 
confirming bacterial dissemination to the brain occurs via the lung (Fig. 24B). 
 
As brains harvested for bacterial quantification were not perfused, it was 
necessary to confirm that the presence of streptococci in the brain was not due to 
bacteria from the blood. Brains and corresponding bloods were therefore 
harvested from high and low dose coinfected mice. In many cases, particularly 
during low dose coinfection, the bacterial load in the brain was higher than in a 
substantial (100µl) volume of blood (Fig. 24C). This strongly suggests bacterial 
presence in the brain is not due to blood contamination. 
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Figure 24. Verification of streptococcal presence in the brain.
(A) Streptococcal load in the brain during high dose coinfection at 7dpi; either extracted con-
ventionally, with washing of the exterior in PBS, or with the front of the brain excised (n=3-4). 
(B) Streptococcal load in the brain during high dose coinfection at 7dpi with bacterial infec-
tion by the intranasal or intratracheal route (n=2-3). (C) Streptococcal load in whole brain 
and corresponding blood (100+l blood supernatant plated, brain and blood samples from 
same mice connected by line) during low or high dose coinfection at 8dpi (n=4-5). Data 
shown as geometric means. Significance assessed by Mann-Whitney test. n.s.=not signifi-
cant.
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Bacterial spread to the brain leads to slight inflammation 
 
As bacterial spread to the brain did not appear to be an artefact, whether this 
spread caused inflammation was then investigated. As an initial experiment, 
uninfected mice were compared with high dose coinfected mice, where the 
greatest bacterial spread to the brain is observed. Brains were extracted from 
naïve or high dose coinfected mice and cell numbers compared by flow 
cytometry. Coinfection led to a slight increase in neutrophils (Fig. 25A) and 
inflammatory monocytes (Fig. 25B), and caused a decrease in the number of 
(non-inflammatory monocyte) F4/80+ cells (Fig. 25C), which may represent the 
resident microglia (Kettenmann et al., 2011). Very low levels of CD4 T cells were 
detected, which were unaffected by coinfection (Fig. 25D), while CD8 T cells 
were almost entirely absent from the brain in all settings (Fig. 25E). Therefore 
bacterial spread to the brain induces a modest neutrophil and inflammatory 
monocyte response, with a corresponding reduction in resident F4/80+ cells. 
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Figure 25. Coinfection increases inflammatory cells and reduces F4/80+ cells in the 
brain. 
Flow cytometry quantification of (A) Neutrophils (Ly6G+CD11b+), (B) Inflammatory mono-
cytes (Ly6C+CD11b+F4/80+), (C) Non-inflammatory monocyte F4/80+ cells (CD11blowLy6C-
F4/80+), (D) CD4 T cells (CD3+CD4+) and (E) CD8 T cells (CD3+CD8+) in the brain during 
coinfection (n=3). Data displayed as arithmetic means ± SEM. 
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8.4. Conclusions and Discussion 
 
I have therefore demonstrated through several methods that bacterial spread to the 
brain during coinfection is not an artefact. Preliminary experiments suggest 
bacterial spread induces an inflammatory response.  
 
It is notable that there is a modest, although not significant, decrease in bacterial 
loads detected in the brain when the exterior of the tissue is washed during 
harvesting (Fig. 24A). This implies some of the streptococci detected in the brain 
may be due to contamination from other tissues or the blood. As this result is not 
significant, this may simply be experimental variation, and therefore repeating 
this experiment, possibly with more mice, may be necessary. If this modest 
decrease represents a real result, some contamination from the blood may be an 
explanation, as some mice do show bacterial loads in the blood during high dose 
coinfection (Fig. 24C). Nevertheless, it is likely that a substantial proportion of 
the bacteria detected in the brain represents genuine infection of this tissue. 
 
In this preliminary investigation single infection controls have not been performed 
for brain inflammatory cell quantification, and therefore another aspect of Strep or 
IAV single infections not related to coinfection may responsible for brain 
inflammation. Strep alone affecting brain inflammation is somewhat unlikely as 
no bacterial dissemination to the brain is observed during single infection (Fig. 
2C).  Nevertheless, a follow-up experiment should include all single infection 
controls.  
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Furthermore, as brain tissues are not perfused, it is possible the inflammatory 
response observed in the brain is a result of systemic changes in inflammatory cell 
proportions in the vasculature rather than infiltrate into the brain. Flow cytometry 
on perfused brain tissues, or comparison of changes in cell number during 
coinfection in the brain and blood may be useful future experiments to test this. 
Alternatively, histology of brain tissue to directly observe immune cells and 
bacteria may be useful. 
 
As inflammation during bacterial meningitis has been correlated with severe 
disease (Kettenmann et al., 2002), bacterial spread to the brain may be one of the 
contributing factors to mortality during coinfection. However, it is notable that 
bacterial dissemination to the brain is also detected in recovering mice (Fig. 11E), 
although total loads are lower than in mice reaching endpoint. Therefore the 
absolute presence or absence of bacteria in the brain correlates poorly with 
disease, although the actual bacterial load correlates well. It is not clear whether 
bacteria persist in the brain in recovering mice, and this could be tested by 
harvesting at later time points. In summary, the presence of bacteria in the brain 
during coinfection appears to be a genuine phenomenon that moderately 
correlates with disease severity, and therefore merits further investigation. 
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Chapter 9. Other aspects of the immune response in 
coinfection 
 
9.1. Background 
 
In addition to studying the role of influenza-induced inflammatory monocyte 
mediated damage as an upstream cause of coinfection, and the downstream 
neutrophil and TNF-α response, I also investigated other aspects of the immune 
response in coinfection, although in a less comprehensive manner. Here studies 
relevant to the aspects investigated will be introduced.  
 
IL-22 is an IL-10 family cytokine involved in antimicrobial immunity at the 
epithelial barrier. Expression of IL-22 is restricted to hematopoietic immune cells, 
while expression of its receptor is limited to non-hematopoetic organ surfaces 
(Sonnenberg et al., 2011). A recent study showed that IL-22 mice are moderately 
more susceptible to IAV-Strep coinfection (Ivanov et al., 2012). As IL-22 was 
marginally reduced during coinfection (Fig 6B), this may merit further 
investigation. 
 
TLR2 is a pattern-recognition receptor involved in activating the immune system 
in response to recognition of bacterial lipopeptides in the cell walls of gram-
positive bacteria (Yoshimura et al., 1999; Manukyan et al., 2005). It has been 
speculated that TLR2 may have a role in mediating the immune response to 
coinfection, although a previous study demonstrated no effect of TLR2 deficiency 
in a severe IAV-Strep coinfection (Dessing et al., 2007). In a recent IAV-L. 
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pneumophila coinfection model where tissue damage rather than bacterial 
outgrowth appears to be the primary driver of mortality, abolition of TLR2 and 
TLR4 signalling in conjunction with amphiregulin (an epidermal growth factor) 
treatment ameliorates coinfection (Jamieson et al., 2013). However the relevance 
of an L. pneumophila coinfection model to IAV-Strep coinfection, where bacterial 
outgrowth occurs, may be limited. Furthermore TLR2 deficiency only has an 
effect in the context of both TLR4 deficiency and amphiregulin treatment, and 
therefore its contribution to tissue damage is hard to assess. In summary, the role 
of TLR2 in a moderate IAV-Strep coinfection context has not yet been assessed. 
 
As previously outlined, the role of type I IFNs in coinfection has been shown to 
be detrimental. IFNαβR-/- mice have improved survival in coinfection, due to 
greater neutrophil recruitment (Shahangian et al., 2009); however, this study does 
not assess whether neutrophil function is also increased. Type I IFN also induces 
IL-27, which leads to inhibition of IL-17 production by γδ T cells during 
coinfection (Cao et al., 2014). To recapitulate the negative effect of type I IFN, a 
recent study used Poly I:C, a TLR3 agonist that promotes a type I IFN response, 
to recapitulate the effects of prior influenza infection. This study reported that 
Poly I:C treatment increased bacterial loads during moderate to severe Strep 
infection (Tian et al., 2012). A similar study was performed using resiquimod 
(R848), a TLR7 agonist that can induce type I IFN and transient leukopenia; 
however, this did not cause susceptibility to subsequent Strep infection 
(Stegemann et al., 2009). In addition, Poly I:C treatment exacerbated M. 
tuberculosis infection through recruitment of a myeloid population that may be 
inflammatory monocytes (Antonelli et al., 2010). Therefore whether type I IFNs 
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affect neutrophil function, and whether susceptibility to secondary Strep infection 
can be caused by inducing a type 1 IFN response alone may be of interest.  
 
The adaptive immune response to influenza may be a contributing factor to 
coinfection susceptibility. Production of IFN-γ by T cells during influenza can 
impair alveolar macrophage function during coinfection (Sun et al., 2008). As 
previously postulated, the CD8 T cell response to influenza may be responsible 
for the inflammatory-monocyte independent damage observed at 7dpi (Fig. 21D 
and E).  
 
However, adaptive responses may also contribute to protection from Strep 
infection. Mice reach endpoint rapidly during coinfection, and it is unlikely an 
adaptive response to bacterial outgrowth is mounted during this timescale. 
However, it is possible that preformed natural antibodies may play a protective 
role, as has been described during Strep infection (Mold et al., 2002). A lethal 
IAV-H. influenza coinfection model directly modelled the role of the adaptive 
response in recombination-activating-gene (Rag) deficient mice, which lack T or 
B cells (Mombaerts et al., 1992); however, absence of the adaptive response did 
not ameliorate coinfection (Lee et al., 2010). Therefore the role of the adaptive 
response to IAV-Strep coinfection is a possible target for investigation. 
 
9.2. Hypotheses and Aims 
 
In this chapter I outline several experiments undertaken to investigate other 
aspects of the immune response, which were largely not comprehensively 
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followed up. Generally this was due to negative results or corroboration of 
existing published data, which therefore did did not merit further investigation.  
 
Several hypotheses were investigated in the course of these experiments: 
• IL-22 is protective during coinfection. 
• TLR2 plays a role in Strep recognition during coinfection.   
• Neutrophil function during coinfection is not affected by type I interferon 
signalling. 
• Poly I:C increases susceptibility to streptococcal infection. 
• Adaptive immunity contributes to coinfection susceptibility. 
 
9.3. Results 
 
IL-22 is marginally protective during coinfection 
 
As shown earlier in this thesis, the levels of IL-22 are marginally reduced from 
low levels by influenza infection and coinfection, both at 5dpi + 4hrs and 7dpi (in 
tables in Fig. 6B and 8B, shown graphically in Fig. 26A). To investigate whether 
the residual levels of IL-22 play a protective role, IL-22-/- mice were infected with 
a low dose coinfection. Total absence of IL-22 marginally but not significantly 
increased weight loss (Fig. 26B) and mortality (Fig. 26C). Therefore IL-22 is 
modestly reduced during coinfection, and total abolition of the remaining 
signalling is harmful, although this effect appears to be quite small.  
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Figure 26
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Figure 26. IL-22 is reduced during coinfection; IL-22 deficiency slightly exacerbates 
low dose coinfection.
(A) ELISA quantification of IL-22 levels during high dose coinfection (n=3-8, data pooled 
from 3 independent experiments). (B) Weights and (C) mortality of wild-type (C57BL/6) and 
IL-22-/- (B6) mice during low dose coinfection (n=6-7, on weight loss plot mice reaching end-
point retained thereafter at final weight). Data is shown as arithmetic means (SEM (weights) 
or percent survival (mortality). Significance assessed by Mann-Whitney test (IL-22 quantifi-
cation), 2-way ANOVA (weights) or Log-Rank (Mantel-Cox) test (mortality). n.s.=not signifi-
cant. *p<0.05, **p<0.01.
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TLR2 does not play a role in coinfection 
 
To assess the role of TLR2 in coinfection, the susceptibility of TLR2-/- mice to 
low dose coinfection was tested. TLR2-/- mice showed similar weight loss (Fig. 
27A) and mortality (Fig. 27B) to wild-type mice during coinfection, although 
TLR2-/- mice did show slightly reduced weights following Strep infection. 
Therefore TLR2 plays no role in coinfection in this model. 
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Figure 27 
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Figure 27. TLR2 deficiency does not affect low dose coinfection.
(A) Weights and (B) mortality of wild-type (C57BL/6) and TLR2-/- (B6) during low dose coin-
fection (n=6-9, on weight loss plot mice reaching endpoint retained thereafter at final weight, 
in some groups to aid visualisation final data point extended). Data shown as arithmetic 
means (SEM (weights) or percent survival (mortality). Significance assessed by 2-way-
ANOVA (weights) or Log-Rank (Mantel-Cox) test (mortality). n.s. = not significant. 
****p<0.0001. 
 175	  
Poly I:C treatment does not recapitulate the effect of influenza on secondary 
bacterial infection 
 
Poly I:C has been shown to increase bacterial loads in a subsequent Strep 
infection (Tian et al., 2012). To attempt to reproduce this results the effects of 
prior influenza or intranasal Poly I:C treatment on secondary Strep infection were 
compared. Poly I:C treatment marginally exacerbated weight loss (Fig. 28A) and 
did not significantly affect mortality (Fig. 28B) during subsequent Strep infection, 
as opposed to the strong synergy observed between IAV and Strep infection. 
Therefore in a mild Strep infection, induction of a prior type I IFN response with 
Poly I:C is not sufficient to recapitulate the synergy seen during IAV-Strep 
coinfection. 
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Figure 28 
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Figure 28. Poly(I:C) treatment does not recapitulate coinfection. 
(A) Weights and (B) mortality during Strep infection preceeded by either treatment with 50+
g Poly(I:C) at 3 and 4 dpi or 1AV infection at 0 dpi (i.e. normal low dose coinfection) (n=6-9, 
on weight loss plot mice reaching endpoint retained thereafter at final weight). Data shown 
as arithmetic means ±SEM or percent survival. Signficance assessed by 2-way-ANOVA 
(weights)  or Mantel-Cox (Log-Rank) test. n.s.=not significant. *p<0.05, **p<0.01, 
****p<0.0001.
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Type I interferon signalling does not affect neutrophil function during coinfection 
 
IFNαβR-/- mice are better protected from coinfection and recruit more neutrophils 
(Shahangian et al., 2009). As type I interferon has been reported to have 
detrimental effects on neutrophils (Navarini et al., 2006), it is possible greater 
resistance is also due to increased neutrophil function. It has previously been 
verified in this thesis that type I IFNs are present during influenza and coinfection 
in wild-type mice (Fig. 6B and 8B).  
 
To test whether this prior exposure to type I IFN in vivo affects neutrophil 
function, neutrophils extracted from coinfected IFNαβR-/- and wild-type lungs 
were functionally profiled. Wild-type and IFNαβR-/- neutrophils had similar ROS 
production (A) and cytokine production (Fig. 29B) upon restimulation. IFNαβR-/- 
neutrophils produced moderately less TNF-α following PDBu stimulation, and 
slightly more KC following Pam3CSK4, LPS and PDBu stimulation; however, 
these trends are quite marginal. This data suggests that prior type I interferon 
exposure does not substantially alter neutrophil function, although it may 
somewhat suppress KC production upon restimulation.  
 
An alternative approach to testing whether type I IFN affects neutrophil function 
is to expose neutrophils that have not experienced interferon signalling to IFNα in 
vitro. Naïve neutrophils were used, as these cells would not have previously 
experience type I IFN in vivo (note – as few lung neutrophils are purified from 
naïve mice, only 5x104 neutrophils were used per replicate in this assay, as 
compared to 1x105 normally used to test cytokine secretion). Pretreatment of 
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naïve wild-type neutrophils in culture with increasing concentrations of IFNα did 
not affect cytokine (TNF-α) production upon stimulation with Pam3CSK4 (Fig. 
29C). Therefore in an in vitro setting stimulation of type I IFN signalling does not 
appear to affect neutrophil function as assessed by cytokine production.   
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Figure 29. Type I IFN does not affect neutrophil function.
(A) ROS production by luminol assay of PDBu (50nM) stimulated MACS purified lung neu-
trophils from high dose coinfected wild-type (C57BL/6) or IFN_`R-/- (B6) mice at 6dpi 
(neutrophils from 3 mice pooled into wild-type or IFN_`-/-group, with technical triplicates 
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Rag1-/- mice display moderate synergy during coinfection and are susceptible to 
Strep infection 
 
To investigate whether the adaptive immune response contributes to coinfection 
susceptibility, Rag1-/- mice, which lack peripheral T and B cells (Mombaerts et 
al., 1992), were used. As the adaptive immune response is required for clearance 
of influenza (Brown et al., 2004), Rag1-/- mice eventually succumb to influenza 
infection. Therefore in this context total mortality could not be used to test 
whether IAV-Strep coinfection was more severe than IAV infection alone. 
However, as IAV-Strep coinfection leads to rapid mortality in wild-type mice at a 
high dose, whether coinfected mice reach endpoint more rapidly than IAV 
infected mice could be assessed. To attempt to induce the strongest synergy and 
the most rapid mortality in coinfected mice, high dose coinfection was used.  
 
High dose IAV-Strep coinfection caused moderately more rapid weight loss (Fig. 
30A) and mortality (Fig. 30B) than IAV infection alone. Therefore synergy 
between IAV and Strep still occurs in the absence of adaptive immunity. However 
the modest nature of the synergy observed highlights the technical challenge in 
assessing the rapidity of mortality in a setting where all mice eventually reach 
endpoint due to influenza infection. Notably, a substantial proportion of Rag1-/- 
mice also eventually succumb to Strep infection, which is somewhat surprising 
given that Strep appears to be rapidly cleared in the first four hours following 
inoculation (Fig.  3A). These results are discussed further below. 
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Figure 30
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Figure 30. Coinfection synergy is not dependent on adaptive immunity.
(A) Weights and (B) mortality of wild type (C57BL/6) or Rag1-/- - MOM (C57BL/6/J/CD45.1) 
mice during high dose coinfection (n=8-9, on weight loss plot mice reaching endpoint 
retained thereafter at final weight). Data displayed as arithmetic means ±SEM (weights) or 
percent survival (mortality). Significance assessed by 2-way ANOVA (weight time course) or 
Log-rank (Mantel-Cox) test (mortality). n.s. = not significant. *p<0.05. ***p<0.001. 
****p<0.0001.   
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9.3. Conclusions and Discussion 
 
Investigation of other aspects of the immune response has given much useful 
information regarding coinfection. The small protective role of IL-22 described in 
a previous study (Ivanov et al., 2012) has been corroborated. Furthermore it has 
been shown that IL-22 levels are slightly suppressed during moderate influenza 
infection. This is in contrast to the study cited above, which shows an induction in 
IL-22 early at several different timepoints during coinfection from 3 to 7dpi, 
during both moderate and severe influenza infections. The reasons for this 
discrepancy are not clear, but may reflect the different influenza strains used.  
 
The suppression of IL-22 during coinfection may explain why further reduction in 
signalling to zero using IL-22 deficient mice only causes a modest increase in 
mortality. Whether the modest suppression of IL-22 plays a role in susceptibility 
is not clear. As taking a loss-of-function approach using IL-22 deficient mice may 
be limited here due to existing suppression, taking a gain-of-function approach by 
adding exogenous IL-22 during coinfection may be more informative. Exogenous 
IL-22 marginally reduced bacterial loads in IL-22-/- mice during coinfection 
(Ivanov et al., 2012), but addition of IL-22 to wild-type mice has not been 
previously been performed. 
 
It has been shown that TLR2 does not have a role in severe coinfection (Dessing 
et al., 2007); however, this setting does not allow a negative effect of TLR2 
deficiency to be detected. As TLR2 is involved in bacterial recognition, it was 
hypothesised that its absence might exacerbate coinfection, which would be 
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detectable in a low dose context. However, in a moderate, low dose coinfection 
context, TLR2 deficiency had no effect. This is consistent with the study cited 
above, and confirms that the lack of effect in this study this was not due to the 
severe coinfection used.  
 
Another study also observes no effect of TLR2 deficiency in a severe coinfection 
(Karlstrom et al., 2011). This study however does propose that bactericidal 
ampicillin treatment, although protective, is less so than bacteriostatic antibiotics 
as it leads to bacterial lysis. This study speculates that lysed bacteria activate 
TLR2 and cause subsequent immunopathology. Therefore in the context of 
antibiotic treatment, where immunopathology may replace bacterial outgrowth as 
the primary driver of mortality during coinfection, TLR2 may play a detrimental 
role, and this may be worthy of further investigation. Combination of this with 
addition of factors promoting tissue repair such as amphiregulin could also be 
considered, as this may ameliorate immunopathology further in this setting.  
 
Prior type I interferon signalling did not appear to affect neutrophil function upon 
restimulation. In addition, Poly I:C did not recapitulate the effect of influenza 
upon secondary bacterial infection, in contrast to a recent study (Tian et al., 
2012). The lack of effect of Poly I:C prestimulation may be due to the different 
severities of Strep infections used. This result suggests that, although influenza-
induced type I IFNs have been reported to play a detrimental role during 
coinfection, induction of a type I IFN response alone without other aspects of 
influenza such as lung damage is not sufficient to promote susceptibility to Strep 
infection. Alternatively - although equivalent to the amount used in the previous 
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study described - the amount of Poly I:C stimulation used here may be inadequate 
to recapitulate an equivalent type 1 IFN response to IAV. Furthermore although 
Poly I:C can induce a type I IFN response via TLR3, it does not mimic the 
multiple signalling pathways (such as the RIG-I pathway) stimulated by influenza 
(Iwasaki et al., 2014), therefore crucial aspects that promote susceptibility to 
Strep may be absent. Possible further experiments could include quantification of 
type I IFN levels following Poly I:C stimulation, and to test the levels of damage-
causing inflammatory monocytes, TRAIL-expression, and DR5 expression on 
epithelia induced by this.  
 
More rapid mortality during coinfection than either IAV or Strep single infections 
was evident in Rag1-/- mice, which lack adaptive immunity (Mombaerts et al., 
1992). This suggests that the adaptive response to influenza is not required to 
cause coinfection susceptibility. The synergy observed however was modest, 
showing the difficulty in assessing rapidity of mortality in a context where all 
mice eventually succumb to influenza. A possible experiment that may address 
this is to perform secondary bacterial infection earlier in Rag1-/- mice, giving a 
longer period to observe coinfection synergy before mice succumb to viral 
infection. However, it has been reported that coinfection at earlier time points 
than 5dpi is less severe (McCullers et al, 2002) - possibly reflecting reduced lung 
damage - and therefore changing timepoint may make synergy even more difficult 
to detect.  
 
Alternatively, other parameters than eventual mortality could be used to assess 
synergy in Rag1-/- mice - for example, cytokine levels in coinfection versus 
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influenza infection, or bacterial loads in Strep versus coinfection, assessed at the 
latest possible timepoint (such as 6dpi).  However, as Rag1-/- mice, unlike wild-
type mice, control both virus and bacterial single infections poorly, this is likely to 
elevate all readouts of disease such as bacterial load and cytokine induction. This 
suggests it may be difficult to detect synergy by any readout in the complete 
absence of adaptive immunity and viral control, and other approaches may be 
more suitable. 
 
One approach that could be taken is specific depletion of some aspects of the 
adaptive response, such as depletion of CD8 T cells, in wild-type mice. As there is 
some redundancy in the adaptive response (Brown et al., 2004) this may leave 
some viral control intact and give more scope to observe synergy. This may allow 
a more clear assessment than in Rag deficient mice of whether adaptive immune 
aspects are involved in promoting coinfection susceptibility. 
 
It is possible that lung damage later in influenza infection is due to the adaptive 
response. I have previously shown in wild-type mice that lung damage in 
influenza infection at 5dpi, but not 7dpi, appears to be inflammatory monocyte-
dependent (Fig. 21A-B; Fig. 21D-E). This suggests at later timepoints other 
factors, which may include the antiviral CD8 cytotoxic T cell response, cause 
damage. Therefore performing secondary infection at 5dpi may not be suitable for 
assessing the contribution of adaptive immunity to coinfection susceptibility. 
Although not possible with Rag1-/- mice, which begin to succumb to influenza 
infection from 7dpi onwards, it would be instructive to perform coinfection at 
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7dpi in wild-type mice and assess the role of adaptive immunity by other 
methods; for example, as suggested above, by depleting CD8 T cells.  
 
Strikingly, a substantial proportion of Strep infected Rag1-/- mice also succumb to 
coinfection. This suggests a role for adaptive immunity in protection against 
Strep. However, somewhat paradoxically, Strep is almost completely cleared from 
the airways 4 hours following infection in wild-type mice (Fig. 3A), which 
strongly suggests an adaptive response - which typically takes several days to 
develop - is not required. A possibility is that the absence of preformed natural 
antibodies in Rag1-/- mice may cause susceptibility, as natural antibodies have 
been described to be protective against Strep infection (Mold et al., 2002). 
Opsonophagocytosis mediated by neutrophils or other phagocytes may also be 
impaired in the absence of natural antibodies, although I have previously shown 
that neutrophils are not required to clear low virulence single Strep infection. In 
summary, the role of adaptive immunity in coinfection remains unclear, and Rag1-
/- mice may be a relatively unsuitable model to investigate this, due to their 
susceptibility to both Strep and IAV single infections. Other approaches - for 
example, antibody mediated depletion of adaptive immune cells during 
coinfection – could be considered. 
  
 187	  
Chapter 10. Summary and General Discussion 
 
10.1. Summary 
 
In this thesis I have established and analysed mouse model of Influenza A-Strep 
coinfection. This has led to several conclusions (summarised diagrammatically in 
Fig. 31): 
 
• Moderate severity influenza infection predisposes mice to secondary 
coinfection with a mild Strep strain, which in the absence of influenza 
colonizes poorly and rarely induces disease. 
• Coinfection is characterised by bacterial, but not viral, outgrowth and 
spread. 
• Bacterial outgrowth appears to be the primary driver of mortality during 
coinfection. 
• Bacterial outgrowth during coinfection induces a strong proinflammatory 
response, including greatly elevated levels of neutrophils and TNF-α. 
• The neutrophil and TNF-α response to coinfection is on balance 
protective. 
• Neutrophils and TNF-α are not required for clearance of Strep alone, 
supporting the concept that in the absence of influenza low virulence 
Strep does not colonize. 
• Influenza infection leads to recruitment of inflammatory monocytes, 
which induce lung damage by a TRAIL-dependent mechanism at the 
point of coinfection. 
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• Lung damage allows colonization by Strep, leading to bacterial 
outgrowth. 
 
Highly specific and technical aspects of these conclusions relating to pertinent 
studies have already been discussed in prior chapters. Here I will discuss the 
merits and disadvantages of the scientific approach taken, and these conclusions 
in more general, conceptual terms.  
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10.2. General Discussion 
 
10.2.1. Advantages and disadvantages of the Influenza A-S. pneumoniae 
mouse model 
 
Mouse models 
 
There are both advantages and disadvantages to using mouse models to 
investigate coinfection. Inbred mice are the most common models for both IAV 
and Strep infections (Chiavolini et al., 2008; Bouvier et al., 2010), and this, along 
with the low genetic variability of inbred mice, allows substantial consistency and 
comparison with other studies. However, IAV is not a natural mouse pathogen, 
and it has been argued that ferret models more accurately recapitulate human 
disease (Bouvier et al., 2010). However, mouse models have practical advantages 
over the use of ferrets, as much larger numbers of animals can be used for 
experimentation, and many more species-specific reagents and genetically 
modified strains are available.  
 
Although rare in a laboratory setting, natural infections of mice with Strep have 
been reported (Baker et al., 1998), with transmission primarily from infected 
humans. Mouse models of Strep have similar advantages of mouse models to 
those investigating influenza. Therefore, the requirement for large numbers of 
animals, the range of reagents and genetically modified strains, and the abundance 
of existing information make mice a highly suitable model for studying 
coinfection. 
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Pathogen virulence and dosing 
 
In this thesis mild to moderate virulence single Strep and IAV infections have 
been used to model coinfection. There are multiple advantages to this. Neutrophils 
and TNF-α have been reported to have roles during more severe single infections 
(Tate et al., 2009; Hussell et al., 2001). Use of moderate virulence strains reduces 
the likelihood of interventions such as neutrophil depletion perturbing single 
infections, and therefore allows focus on the role of neutrophils and TNF-α in 
coinfection.  
 
Inflammatory monocytes have also been reported to have a detrimental effect 
during severe influenza infection (Herold et al., 2008). Use of moderate virulence 
influenza means alterations that affect the inflammatory-monocyte response and 
reduce lung damage, such as CCR2 deficiency or anti-TRAIL treatment, do not 
substantially alter the outcome of viral disease. This allows investigation of the 
role of inflammatory monocytes in promoting coinfection, where the positive 
effect of inflammatory monocyte deficiency can be detected. 
 
In addition to using mild to moderate virulence strains of Strep and IAV, both 
“high” and “low” dose settings of these pathogens were used to investigate 
coinfection, giving different strength synergy. High dose induced almost 100% 
mortality during coinfection, while low dose caused approximately 50%. Many 
studies only use a setting that gives 100% mortality (for example, Damjanovic et 
al., 2013). Both settings have different advantages and drawbacks. High dose 
coinfection gives consistently severe disease and therefore is useful to profile 
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coinfection as results are highly homogenous. However, in a setting where all 
mice reach clinical endpoint, only strongly positive interventions can be detected.  
Therefore low dose coinfection - with variable disease and moderate mortality - 
was used to assess the effect of interventions, where both positive and negative 
effects of interventions could be detected. Low dose coinfection is less suitable 
for profiling disease due to the greater heterogeneity of coinfected mice, as 
demonstrated by the large spread in bacterial loads (for example, in Fig. 11C). 
 
It could be argued that a low dose setting should be used for all experiments, as is 
likely more similar to physiological pathogen doses. Furthermore, it cannot be 
assumed that conclusions drawn profiling in a high dose setting always apply at a 
lower dose. However, performing profiling experiments at a low dose would, due 
to huge diversity in bacterial outgrowth and disease outcome, greatly increase the 
number of mice required to draw a clear conclusion, and therefore is deeply 
impractical. Furthermore, bacterial outgrowth appears to be the cause of mortality 
at both low and high dose, suggesting mechanisms that promote coinfection are 
similar between doses, and only differ in intensity. 
 
Difficulty of correlating readouts with mouse fate 
 
Where possible in this thesis the effects of coinfection were profiled in vivo in the 
lung or other organs. This is useful as the lung is the primary disease site and 
gives direct readouts on changes occurring during coinfection. However, to 
harvest the lung or other organs mice must be sacrificed at a defined timepoint. 
This does not allow monitoring of changes in a single mouse over time. It also 
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prevents directly relating readouts with mouse fate, as once mice are sacrificed, 
subsequent disease development cannot be monitored.  
 
In some instances lung and other organs were harvested at endpoint, rather than a 
defined timepoint (for example, showing bacterial outgrowth correlated with 
mortality in Figure 11). This allowed direct correlation between disease severity 
and subsequent readouts.  However, this is not practical for all experiments, as 
mice harvested at variable timepoints cannot always be directly compared. It may 
be useful to develop readouts that do not require sacrifice, such as cytokine levels 
or bacterial loads in the blood that can be assessed serially in the same mouse. 
Serial in vivo imaging of fluorescent bacteria in mice may also be useful, as has 
been performed in a previous coinfection study (Diavatopoulous et al., 2010). 
These readouts could be predictive and correlated with eventual mouse fate. 
 
Defining the sequence of events in coinfection 
 
An issue in IAV-Strep coinfection models is that it is difficult to separate out 
upstream causes and downstream consequences of bacterial outgrowth. Here these 
factors were separated out in two ways. Firstly, the immune response was profiled 
after coinfection at both early (5dpi + 4hrs) and late (5dpi + 48 hrs) timepoints. 
Therefore the early response to bacterial colonization and the downstream 
response to bacterial outgrowth can be temporally separated.  
 
Secondly, a temporal component was given to interventions during IAV-Strep 
coinfection. Neutrophils and TNF-α were depleted during coinfection but not 
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during prior influenza infection, allowing assessment of their downstream role in 
bacterial phase. CCR2 mice were used to investigate upstream causes of 
coinfection. By definition CCR2-/- mice lack inflammatory monocytes in both 
viral and bacterial phases of infection. Therefore from these mice alone it was not 
possible to tell when the harmful effects of inflammatory monocytes were 
mediated, although reduced lung damage at 5dpi in CCR2-/- mice was highly 
suggestive. Use of anti-TRAIL to block inflammatory monocyte mediated 
damage allowed more clear temporal assessment. Anti-TRAIL treatment was 
protective if given during viral phase of infection. This intervention alone does 
not confirm when the harmful effect of TRAIL is mediated, as anti-TRAIL 
antibodies may persist into the bacterial phase of infection. However, anti-TRAIL 
treatment is ineffective if given in bacterial phase only, indicating the beneficial 
effect of TRAIL blockade is prior to this. Therefore, the harmful effect of TRAIL-
expressing inflammatory monocytes is mediated in viral phase. Overall these 
interventions enabled separation of the upstream role of inflammatory monocytes 
in promoting bacterial colonization from the downstream protective role of 
neutrophils and TNF-α. 
 
10.2.2. Bacterial outgrowth during coinfection  
 
The conclusion that bacterial outgrowth occurs in coinfection is consistent with 
many other mouse models (LeVine et al., 2001, van der Sluijs et al., 2004; Sun et 
al., 2008). Furthermore increased bacterial loads relative to single infection are 
also observed in IAV-S. aureus models, although these do not consistently show 
clear outgrowth over time (Kudva et al, 2010, Small et al., 2011). Increased 
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bacterial loads are also observed during a systemic L. monocytogenes infection 
(Jamieson et al., 2010), and an IAV-B. pertussis model observes delayed bacterial 
clearance (Zavitz et al., 2010). In addition, in all cases and interventions 
investigated here, bacterial outgrowth and mortality strongly correlate. The 
diversity of bacterial species for which prior influenza promotes outgrowth 
suggests two possibilities: that influenza causes a universal single problem that 
leads to susceptibility to multiple species, or it promotes a variety of problems, 
with specific disease mechanisms in each setting. As this thesis focuses on IAV-
Strep coinfection, it is not possible to give a definitive answer to this proposition; 
the range of mechanisms suggested in different coinfection models suggests the 
latter, but influenza-mediated damage is likely to relatively non-specifically 
promote colonization.  
 
In contrast to the results shown here and other IAV-Strep coinfection models, a 
study modelling IAV-L. pneumophila coinfection does not observe changes in 
bacterial load, and instead attributes mortality to immune-mediated tissue damage 
(Jamieson et al., 2013). In this study the authors state bacterial outgrowth can 
complicate analysis of the causes of morbidity and mortality, and they therefore 
sought a model where this did not occur. This study is therefore useful in 
highlighting how tissue damage can contribute to mortality during coinfection; 
however, the lack of bacterial outgrowth may not reflect the events in 
physiological coinfections.   
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10.2.3. Immune impairment during coinfection  
 
A striking feature of the model of IAV-Strep coinfection described here is that no 
clear immune impairment is observed. No cytokine (with the exception of a 
marginal reduction in IL-22) or cell type profiled is significantly reduced in 
coinfection; in contrast, a strong immune response is observed. Furthermore, 
depletion of neutrophils and TNF-α does not affect low virulence single Strep 
infection, suggesting that these responses are not required at all in the absence of 
prior influenza. Therefore in this context impairment in neutrophils and TNF-α 
cannot be the cause of coinfection susceptibility. In contrast, several previous 
studies have suggested the immune response is impaired during coinfection. There 
are several possible reasons for this discrepancy. 
 
Firstly, the immune profiling performed here, while broad, is by no means 
absolutely comprehensive, and there are aspects of the immune response reported 
to be impaired by other studies, such as γδ T cell (Li et al., 2012) and alveolar 
macrophage function (Goulding et al., 2011), that are outside the scope of this 
study. It is possible that these are contributing factors to susceptibility in this 
model. However, it must be noted that alveolar macrophage numbers show a trend 
towards reduction in both coinfection susceptible (wild-type) and resistant  
(CCR2-/-) mice, suggesting their role is not crucial here. 
 
Furthermore several studies reporting immune impairment do not include 
comparisons of the response between coinfection and single infections. This 
makes it difficult to assess the extent of immune impairment. For example, a gain-
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of-function study shows IFNαβR-/- mice recruit more neutrophils than wild type 
and are less susceptible to coinfection. This implies that neutrophil recruitment is 
deficient during coinfection in wild-type mice (Shahangian et al., 2009). 
However, neutrophils recruited during Strep alone are not quantified. Therefore in 
this context it is not possible to assess whether neutrophil recruitment during 
coinfection can be considered impaired relative to Strep infection alone. 
 
Some studies reporting immune impairment have not been reproduced. For 
example, while one study showed anti-IL-10 ameliorates coinfection (van der 
Sluijs et al., 2004), this effect was not reproduced in IL-10-/- mice (Sun et al., 
2008). This may reflect differences in mouse and streptococcal strains, as well as 
timing differences between models, which further underlines the difficulties 
involved in comparing mouse models of IAV-Strep coinfection.  
 
A criticism of some coinfection studies is that they focus on a single aspect of the 
immune response which is reduced during coinfection, while overlooking a 
simultaneous very strong proinflammatory response. For example, one study 
attributes susceptibility to reduced IL-17 production, while simultaneously 
observing increased IL-1β, IL-6, TNF-α, KC, MIP-2 and G-CSF (Li et al, 2012). 
Therefore whether the overall immune response can be considered impaired in 
this context is not clear.  
 
Finally, I use low virulence Strep and IAV infections, which themselves only 
induce modest immune responses. As low virulence Strep largely does not 
colonize, it is likely that the immune response (with the possible exception of pre-
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existing natural antibodies) is not required for bacterial clearance. However 
previous studies have shown aspects of the immune response are required in more 
virulent Strep single infections. Therefore a more virulent Strep infection may 
induce a stronger immune response than observed here, giving more scope for 
immune impairment in coinfection. In conclusion there are many reasons why 
some studies observe immune impairment and others, including this thesis, do 
not, and its relative importance during IAV-Strep coinfection remains to be 
determined. It is possible that in coinfection models with a more virulent Strep, 
influenza mediated immune impairment is a major factor; however, in low 
virulence Strep models such as in this thesis, immune impairment does not appear 
to contribute to coinfection. 
 
10.2.4. Lung damage and integrity during coinfection  
 
In this thesis I propose a mechanism for bacterial colonization where influenza-
induced inflammatory monocytes cause lung damage. Most previous studies 
focusing on lung damage have used severe influenza strains and focused on direct 
viral damage. Here a moderate influenza strain is used, and the proposed 
mechanism focuses on damage mediated by the immune response to the virus, 
rather than direct viral damage. Nevertheless, these other studies corroborate the 
concept that the extent of lung damage is strongly correlated to the severity of 
secondary streptococcal infection. However, their focus on a different source of 
damage - directly viral mediated - highlights how multiple factors contribute to 
coinfection susceptibility. 
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Studies showing direct viral damage can increase the severity of coinfection focus 
on expression of PB1-F2, a pro-apoptotic peptide. Influenza strains expressing 
this lead to worse damage and more severe secondary bacterial coinfections 
(McAuley et al., 2007). This has been shown to be dependent on specific PB1-F2 
sequences (Alymova et al., 2013), and different PB1-F2 expressing variants have 
different severity coinfections (Weeks-Gorosope et al., 2012). Furthermore 
addition of C-terminal peptide from PB1-F2 alone is sufficient to predispose to 
secondary Strep infection (McAuley et al., 2007). This suggests that in severe 
influenza infection, viral damage alone can promote coinfection susceptibility. 
The relative contributions of viral and immune-mediated damage in promoting 
coinfection susceptibility remain to be determined, and may differ greatly 
depending on the severity of the viral strain used. 
 
Other studies also suggest that influenza reduces lung integrity through other 
mechanisms than damage. This suggests that there may be other factors 
promoting coinfection in addition to viral or inflammatory-monocyte mediated 
damage. Reduced mechanical clearance by the cilia of the bacteria is observed in 
an ex vivo trachea model (Pittet et al., 2010). In vivo models have also suggested 
that influenza increases adhesion of streptococci to epithelial cells (Plotkowski et 
al., 1986), and that this is partly viral neuraminidase dependent (McCullers et al., 
2004). In summary, the results in this thesis showing that inflammatory monocyte 
mediated damage can lead to bacterial colonization during coinfection are 
consistent with other studies on lung integrity prior to coinfection, but suggest a 
new immune-mediated mechanism for this in addition to direct viral damage. 
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10.2.5. The multifactorial nature of coinfection  
 
Several key points have been outlined in this discussion. Firstly, influenza causes 
susceptibility to coinfection by a range of bacterial species, typically leading to 
bacterial outgrowth. Multiple mechanisms have been proposed for this, which 
largely fall into the categories of immune impairment or lung damage – whether 
directly viral mediated, or, as is shown here, immune-mediated. Although 
immune impairment is not observed in this thesis, there are a range of conceptual 
and technical reasons which may account for this discrepancy. Studies that show 
increasing lung damage leads to more severe coinfection indirectly corroborate 
the findings shown here.  
 
Influenza appears to promote a variety of mechanisms that allow secondary 
bacterial coinfection by a range of species. These may be detectable in different 
experimental contexts, suggesting coinfection is a highly multifactorial issue. 
Therefore it is likely that the mechanism proposed here - while evidently a crucial 
component of susceptibility - is not the sole cause of coinfection, and that many 
other factors also play a role.  
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10.3. Possible further investigations 
 
Testing immune impairment in other aspects of the downstream response to 
coinfection  
 
There are several possible follow-up experiments that could further elucidate 
mechanisms of coinfection. More in depth investigation into the downstream 
immune response to bacterial outgrowth during coinfection could be carried out. 
Immune cell function or numbers that have not profiled in this thesis could be 
investigated. Flow cytometry could be used to enumerate γδ T cells, and 
intracellular staining could be used to assess γδ T cell cytokine production. 
Furthermore, alveolar macrophage function could be profiled through different 
approaches. Purification of alveolar macrophages and in vitro restimulation may 
be suitable, or use of in vivo readouts such as uptake of fluorescently labelled 
bacteria by alveolar macrophages in the lung.  
 
The strong immune response in coinfection appears to correlate with bacterial 
outgrowth. Therefore it could be argued that this represents a greater stimulus to 
the immune system, and thus it is not possible in the context of bacterial 
outgrowth to determine whether influenza “impairs” the immune response – i.e. 
influenza may reduce the immune response per bacterium, but this cannot be 
detected due to greater bacterial outgrowth. It would be technically difficult to 
assess this experimentally. One approach would be to observe the immune 
response to secondary infection with a non-replicating bacterial stimulus such as 
Pam3CSK4, where the secondary stimulus is of a consistent strength. However, as 
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non-replicating stimuli do not replicate coinfection synergy (Fig. 4B) this may not 
be a suitable model system.  
 
Assessing neutrophil phagocytosis during coinfection 
 
Neutrophil phagocytosis has previously been reported to be impaired during 
coinfection (Damjanovic et al., 2013). In this thesis phagocytosis of streptococci 
by neutrophils was not assessed. Although neutrophils in coinfection appeared 
functional by all readouts tested, it is possible that phagocytosis is impaired. 
Different approaches could be taken: purified neutrophils could be incubated with 
streptococci (as well as appropriate opsonisation factors) in vitro and uptake 
assessed by gentamicin protection assay. Alternatively, use of fluorescent bacteria 
would allow in vitro and in vivo uptake to be assessed by flow cytometry.  
 
Further investigations into the role of TNF-α in coinfection 
 
Although it is clearly demonstrated in this thesis that TNF-α is protective during 
coinfection, how this is mediated remains unclear. Several aspects of the role of 
TNF-α during coinfection could therefore be further investigated. The source of 
TNF-α could be determined by intracellular staining of different lung cell 
populations. Furthermore, as both neutrophils and inflammatory monocytes have 
been reported as TNF-α producers (Zhang et al., 2009), the levels of TNF-α in 
neutrophil depleted or CCR2-/- mice could be profiled. Also, the downstream 
targets of TNF-α signalling that promote its protective effects could be 
investigated; as TNF-α promotes neutrophil recruitment to peripheral tissues 
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(Nathan, 2006; Bradley, 2008) it may be that its primary protective effect is 
enhancing neutrophil recruitment. Flow cytometry to quantify neutrophils and 
other cells in coinfected lungs following anti-TNF-α treatment could test this. 
 
Improving readouts for and further investigation into inflammatory-monocyte 
mediated lung damage 
 
More investigation into inflammatory-monocyte mediated lung damage and its 
role in coinfection could be carried out. LDH activity and protein in the airways 
are somewhat blunt readouts, and more specific aspects of epithelial damage 
could be investigated, such as assessing the levels of cellular apoptosis. 
Furthermore, in addition to the previous loss-of-function approach taken to 
inflammatory-monocyte mediated damage using CCR2-/- mice and anti-TRAIL, a 
gain of function approach could be taken, supplementing CCR2-/- mice with 
inflammatory monocytes early during influenza. 
 
It is possible inflammatory monocytes mediate damage through other mechanisms 
than TRAIL. Anti-TRAIL treatment reduces coinfection susceptibility to a similar 
extent as CCR2 deficiency, suggesting this is the main effector of inflammatory 
monocytes in this context. However, an alternative explanation is that anti-TRAIL 
treatment, by coating inflammatory monocytes with antibody, promotes 
phagocytic clearance of these cells. This may leads to partial depletion of 
monocytes, which would also reduce other monocyte effector mechanisms. 
Therefore whether anti-TRAIL treatment reduces inflammatory monocyte 
numbers at the point of coinfection should be tested by flow cytometry. 
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Furthermore, other inflammatory monocyte killing mechanisms could be 
investigated. Monocytes have been reported to mediate cell death through surface 
expression of Fas ligand (Imanishi et al., 2002), which could be investigated by 
flow cytometry. 
 
The specific mechanisms of how lung damage allows colonization at the level of 
an individual bacterium is not clear, and it would be useful to investigate this 
further. It is possible the death of epithelial cells exposes possible bacterial 
binding sites – for example, PAFR (van der Sluijs et al., 2006). This could be 
possibly be investigated using immunohistochemistry staining for PAFR. Another 
possibility is that epithelial death reduces production of antibacterial compounds 
and mucus; these could be quantified in the lung. Furthermore, increased 
epithelial permeability may allow more bacterial dissemination. However, the 
greater bacterial loads in the lung observed than in other organs throughout 
coinfection suggest colonization in the lung itself is the crucial determinant of 
susceptibility. 
 
Replicating influenza-mediated damage with a non-infectious stimulus 
 
Although somewhat technically challenging, the importance of lung damage 
could be demonstrated directly by following a non-infectious but damaging 
stimulus with Strep infection. Different agents have previously been used in other 
settings to induce lung damage, such as bleomycin, which induces damage and 
fibrosis (Wilson et al., 2010) or napthalene, which kills lung clara cells found in 
the bronchioles (Van Winkle et al., 1995). Although these reagents have 
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drawbacks (for example, bleomycin is an antibiotic, and the damage caused may 
not be similar to that caused by viral infection), they could be used to model 
influenza-induced damage, and to determine if lung damage alone is sufficient to 
cause susceptibility to bacterial colonization. A previous study showing the C-
terminal peptide of viral PB1-F2 alone can promote susceptibility to secondary 
Strep infection strongly suggests this is the case (McAuley et al., 2007). 
 
Investigating the link between type I IFNs and monocytes in coinfection 
 
The link between type I IFNs and inflammatory monocytes may be highly 
relevant to coinfection. Other studies focusing on influenza-induced 
inflammatory-monocyte mediated lung damage have suggested it is partially type 
I IFN dependent (Hogner et al., 2013; Davidson et al., 2014), and an absence of 
type I IFNs reduces inflammatory monocyte recruitment during influenza (Seo et 
al., 2011). This may be an additional factor contributing to the reported resistance 
of IFNαβR-/- mice to coinfection (Shahangian et al., 2009).  
 
It may be difficult to separate out the two proposed protective effects of IFNαβR 
deficiency – namely reduced inflammatory monocyte recruitment and TRAIL 
expression, and increased neutrophil recruitment. A method of investigating this 
could be to take a gain-of-function approach, supplementing IFNαβR-/- mice with 
inflammatory monocytes early during influenza, which may increase 
susceptibility to coinfection. Neutrophils could also be depleted in IFNαβR-/- mice 
to confirm directly their protective effects. 
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Investigating neutrophils as a source of early damage during influenza infection 
 
It would also be useful to investigate whether other aspects of the immune 
response to influenza - in addition to inflammatory monocytes - contribute 
upstream to damage and bacterial colonization. Neutrophils have been described 
to cause lung damage during influenza (Narasaraju et al., 2011). Therefore 
neutrophils, while protective once bacterial colonization occurs, may contribute to 
damage early in influenza. It is possible that neutrophil depletion during the viral 
phase only would ameliorate coinfection. However this experiment would be 
technically challenging for two reasons: firstly, depleting antibody may persist 
into bacterial phase, which has been demonstrated here to exacerbate coinfection. 
Secondly, early neutrophil depletion may affect single IAV infection, as 1A8 
treatment has been shown to exacerbate IAV (Tate et al., 2009). Despite this, 
comparing the effect of neutrophil depleting antibody given during viral and 
bacterial phases of coinfection may be of some interest. 
 
Confirming how the protective effect of anti-TRAIL is mediated 
 
One limitation of the results shown here is that it has not been explicitly 
confirmed that the protective effect of anti-TRAIL is mediated through blocking 
cell-surface TRAIL on inflammatory monocytes in the lung and preventing lung 
damage. The presence of TRAIL-expressing inflammatory monocytes and their 
absence in resistant CCR2-/- mice strongly suggest that the therapeutic effect of 
anti-TRAIL is through blocking damage mediated by these cells; however, this 
has not been confirmed. Various experiments to further investigate this could be 
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performed. Whether anti-TRAIL treatment reduces lung damage in influenza 
could be assessed by observing airway LDH and protein. Furthermore, if the main 
effect of anti-TRAIL is on inflammatory monocytes, it could be confirmed that 
anti-TRAIL treatment has no effect on lung damage in CCR2-/- mice.  
 
Furthermore, TRAIL can be a soluble or cell-surface ligand (Benedict et al., 
2012), and soluble TRAIL has been shown to play a role in Strep infection 
(Steinwede et al., 2012). Although in this thesis the majority of cell-surface 
TRAIL was detected on inflammatory monocytes, the levels of soluble TRAIL 
have not been assessed. Soluble TRAIL could be quantified by ELISA. If soluble 
TRAIL is detected the cellular source could be investigated; although it would be 
somewhat difficult to distinguish from cell-surface TRAIL by flow cytometry or 
qPCR. 
 
Further study on bacterial spread to the brain in coinfection 
 
Bacterial spread to the brain was investigated in a preliminary manner in this 
thesis. Bacterial spread induced inflammation in the brain; a more comprehensive 
flow cytometry analysis of this could be performed. Furthermore, bacterial 
invasion and inflammation in the brain may affect permeability. Brain 
permeability could be assessed by testing protein levels by BCA assay in perfused 
brain tissue, or by application of dyes in the blood and observation of colour 
changes in the brain. As bacteria spreads more consistently to the brain than other 
organs, this may merit more detailed investigation into streptococcal adhesion to 
the brain endothelium, and more research on the systemic effects of influenza.  
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Bacterial meningitis is frequently modelled in mice by somewhat unphysiological 
intracisternal application of bacteria (Chiavolini, 2008). As during IAV-Strep 
coinfection bacteria spread to the brain following intranasal infection, another use 
of the IAV-Strep coinfection model may a more physiological system to assess 
bacterial meningitis. 
 
Investigating treatment options for coinfection 
 
Different treatment options could be investigated in the IAV-Strep coinfection 
mouse model used here. Two approaches could be taken to ameliorating disease: 
controlling downstream bacterial outgrowth, or preventing bacterial colonization 
by reducing influenza-induced lung damage. Patients exhibiting severe symptoms 
are likely to have bacterial outgrowth, and therefore controlling this may represent 
a more suitable therapeutic strategy. However, in the instance of an influenza 
pandemic, ameliorating viral-induced lung damage may be a suitable prophylactic 
strategy.  
 
The role of bacterial outgrowth as the primary driver of mortality suggests 
therapeutic antibiotic treatment would be highly effective during coinfection. 
Other studies have assessed the merits of different antibiotics in coinfection 
(Karlstrom et al., 2009; Damjanovic et al., 2013; Fukada et al., 2014). One study 
suggests bacteriostatic antibiotics are superior to bactericidal, as they do not cause 
rapid bacterial lysis and excessive inflammation (Karlstrom et al., 2009). Another 
method of controlling bacterial outgrowth may be to stimulate the neutrophil and 
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TNF-α response. Direct treatment with recombinant TNF-α or neutrophil 
recruiting chemokines such as MIP2 and KC may be protective. In a previous 
IAV-Strep mouse model, treatment with MIP2 and KC reduced bacterial loads 
(Shahangian et al., 2009).  
 
To reduce viral-mediated damage two approaches could be taken. Direct antiviral 
treatment is likely to lead to reduced viral loads and possibly reduced damage. 
Consistent with this, neuraminidase inhibitors have been shown to be protective in 
coinfection (McCullers et al., 2003). Alternatively, an implication of the results 
here is that inhibition of the inflammatory monocyte response to influenza may be 
protective. Inhibition of monocyte-recruiting chemokines such as MCP-1 may be 
a treatment option; anti-MCP1 treatment has been shown to reduce inflammatory 
infiltrate during influenza (Narasaraju et al., 2010, Damjanovic et al., 2011). 
 
Another strategy to counter lung damage may be to promote epithelial repair. In a 
coinfection study where bacterial outgrowth does not occur, and tissue damage is 
the driver of mortality, treatment with the epithelial growth factor family member 
amphiregulin treatment is beneficial (Jamieson et al., 2013). It is possible 
treatment with amphiregulin may be protective if given during the viral phase of 
coinfection to promote epithelial repair, countering inflammatory-monocyte 
mediated lung damage. However, its usefulness as a therapeutic option in the in 
the bacterial phase, where outgrowth is the driver of mortality, may be more 
limited. In conclusion the results in this thesis suggest several possible treatment 
strategies during coinfection. 
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10.4. Concluding remarks 
 
In this thesis, I have attempted to investigate the role of the immune response in 
IAV-Strep coinfection. Susceptibility to coinfection is a multifactorial issue, and a 
new aspect of this has been uncovered. Influenza-induced inflammatory-
monocyte mediated lung damage promotes susceptibility to secondary Strep 
colonization via a TRAIL-dependent mechanism. This leads to bacterial 
outgrowth, which is countered by a protective and unimpaired, but frequently 
insufficient, neutrophil and TNF-α response. This is a significant contribution to 
the understanding of IAV-Strep coinfection and will hopefully promote further 
research into this pressing public health problem. 
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Appendices 
 
1A – Typical flow cytometry gating strategy for myeloid cells 
1B – Typical flow cytometry gating strategy for lymphoid cells 
2A – Cytokines in the airway 12hrs following coinfection 
2B – Cytokines in the airway 16hrs following coinfection 
3 – Flow cytometry gating strategy for identifying neutrophils without anti-Ly6G 
(1A8) staining 
4 – Cytokines in the airway in CCR2-/- and wild-type mice at the point of and 
during coinfection 
5A – Identification of TRAIL+ cells 
5B – Determination of DR5 expression on epithelial cells  
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Appendix 1 A: Typical flow cytometry gating strategy for myeloid cells. 
Typical flow cytometry gating strategy used for myeloid cells (neutrophils, inflammatory 
monocytes, alveolar macrophages) Representative 7dpi high dose IAV infected lung shown. 
Black arrows indicate progressionto the next gate. Dashed arrows indicate populations 
derived, for which their respective forward and side scatter is shown.  
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Appendix 1 B
Appendix 1 B: Typical flow cytometry gating strategy for lymphoid cells. 
Typical flow cytometry gating strategy used for lymphoid cells (CD4 and CD8 T cells, B cells, NK 
cells). Representative 7dpi high dose IAV infected lung shown. Black arrows indicate progression 
to the next gate. Dashed arrows indicate populations derived, for which their respective forward 
and side scatter is shown. 
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Appendix 2 A
 Cytokine at 5dpi + 12hrs (pg/ml)   
 Naïve Strep IAV IAV + Strep 
Fold change 
vs. single 
infections 
MCP1 1 1 821 867 25 
IFNa 4 17 2932 5048 23 * 
IL10 1 1 102 101 9 *
Eotaxin 2 2 72 108 8 
MIG 4 613 6526 10546 5.3 * 
MIP1` 64 334 1142 3074 5 *
RANTES 4 7 28 55 4.0 * 
IP10 2 792 2430 5529 4.0 
IL5 13 39 376 408 3.4 
TNF  6 122 95 350 3.2 
MIP1_ 45 657 774 2267 3.2 
GCSF 1 1801 1381 4820 3.1 
MIP2 38 161 150 395 2.5 
LIF 1 27 112 131 2.4 
IL6 5 1809 4654 5955 2.1 
IL4 1 2 45 18 1.9 
IL1_ 33 38 21 50 1.8 
IL17 0 25 10 23 1.5 
KC 12 235 277 375 1.5 
M CSF 1 30 12 26 1.4 
IL1` 28 99 34 78 1.4 
GMCSF 44 71 44 76 1.4 
VEGF 10 95 13 48 1.4 † 
IL15 29 25 38 34 1.1 
IL9 71 43 77 58 1.0 
LIX 76 379 121 146 0.7 
IFN_ 4 3 35 18 1.8 
IL22 24 35 15 23 1.0 
IL2, IL3, IL7, IL12p40, IL12 (p70), IL13, IFN` excluded as means all < than 20pg/ml 
Appendix 2 A. Cytokines in the airway 12hrs following coinfection.
Multiplex and ELISA quantification of airway cytokines at 5dpi + 12hrs during high dose 
coinfection (n=3-6). Multiplex is top section of table, lower section is ELISAs. Data shown as 
arithmetic means only.Cytokines in table ranked by fold change relative to single infections, 
shown in the right hand column. This is calculated by the taking the geometric mean of fold 
change IAV+Strep vs. IAV and fold change of IAV+Strep vs. Strep. Significance assessed by 
Mann-Whitney test. *p<0.05 IAV+Strep vs. Strep; †p<0.05 IAV + Strep vs IAV.
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Appendix 2 B
 Cytokine at 5dpi + 16hrs (pg/ml)   
 Naïve Strep IAV IAV + Strep 
IFNa 4 18 7422 8203 22 * 
MIP1  ` 64 242 2356 16960 22 *,† 
TNF_ 6 52 150 1553 18  *
MIP1_ 45 457 1445 10028 12 *,† 
MIP2 38 80 222 1439 11 *,† 
LIX 76 18 96 443 10.7 *,† 
IL10 1 3 357 298 10 * 
RANTES 4 8 49 175 9 *,† 
IL6 5 735 9553 21874 8 * 
GCSF 1 1044 3689 15505 7.9 * 
LIF 1 7 282 315 7.3 * 
MIG 4 1159 16629 30895 7.0 * 
MCP1 1 60 1463 2074 7.0 * 
IP10 2 649 4712 10462 6.0 * 
IL1  ` 28 66 44 311 5.8 † 
Eotaxin 2 2 246 114 4.7 * 
IL1_ 33 36 17 96 3.9  *,†
IL9 71 63 114 322 3.8 * 
KC 12 113 510 841 3.5 * 
IL5 13 34 1104 666 3.4 * 
IL12 (p70) 12 8 16 40 3.4 *,† 
MCSF 1 18 15 50 3.1 † 
IL15 29 33 41 99 2.7 *,† 
GMCSF 44 103 70 217 2.6 
IL4 1 2 60 27 2.2 * 
IL17 0 16 18 24 1.4 
VEGF 10 78 13 33 1.0 
IFN` 4 2 10 71 16.0  *
IFN_ 4 2 49 34 3.6 * 
IL22 24 52 19 28 0.9 
Fold change 
vs. single 
infections 
IL2, IL3, IL7, IL12 (p40) and IL13 excluded as means all < than 20pg/ml 
Appendix 2 B. Cytokines in the airway 16hrs following coinfection.
Multiplex and ELISA quantification of airway cytokines at 5dpi + 16hrs during high dose 
coinfection (n=3-6). Multiplex is top section of table, lower section is ELISAs. Data shown as 
arithmetic means. Cytokines in table ranked by fold change relative to single infections, 
shown in the right hand column. This is calculated by the taking the geometric mean of fold 
change IAV+Strep vs. IAV and fold change of IAV+Strep vs. Strep. Significance assessed by 
Mann-Whitney test. *p<0.05 IAV+Strep vs. Strep; †p<0.05 IAV + Strep vs IAV.
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Appendix 3
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Appendix 3: Flow cytometry gating strategy for identifying neutrophils without anti-Ly6G 
(1A8) stain:
Gating strategy used to identify neutrophils in 1A8 treated mice. Top section shows vehicle 
treated (i.e. no 1A8 treatment) representative 6dpi low dose coinfected mouse. Neutrophils identi-
fied as CD11b+ SSC>low Ly6Clow F4/80- MHCII- CD11c- (1st three panels) and this strategy verified 
by comparing population derived to Ly6G staining (fourth panel). Bottom section shows 1A8 
treated representative 6dpi low dose coinfected mouse. Neutrophils identified as above, and sup-
pression of anti-Ly6G staining 1A8 treatment in residual population derived shown in fourth panel.
Death 
Stain-
Live 
cells
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Appendix 4
5dpi IAV 7dpi IAV 7dpi IAV + Strep  
Wild-type CCR2-/- Wild-type CCR2-/- Wild-type CCR2-/-
Fold change 
CCR2-/- vs. wt 
5dpi 
VEGF 29 158 86 403 426 226 5.4 * 
MCSF 61 257 48 512 349 892 4.2 *,†,‡ 
IL10 21 78 137 817 1858 741 3.6 *,†  
MCP1 2076 7425 1828 7611 21613 10867 3.6 *,† 
MIP1  1107 2676 1338 3894 87599 10518 2.4 *,†,‡ 
MIP2 158 334 190 324 8962 614 2.1 *,†,‡ 
MIP1  1514 2800 1139 4025 30002 9534 1.8 *,‡ 
IL1  67 110 36 61 366 273 1.7 * 
RANTES 32 53 16 59 1517 117 1.6 † 
GCSF 4674 6799 4864 19130 183797 20696 1.5 †,‡ 
Eotaxin 58 60 565 381 830 186 1.0 ‡ 
IL1  100 104 90 89 441 269 1.0 
GMCSF 53 54 37 37 75 111 1.0 
KC 484 462 281 335 4778 382 1.0 ‡ 
IP10 13204 12001 10511 11414 253229 22443 0.9 ‡ 
MIG 4636 4044 10622 15494 75288 41236 0.9 
LIX 404 288 174 109 717 905 0.9  
TNF  110 75 45 85 5682 191 0.7 ‡ 
IFN  1613 985 3591 3315 14232 1556 0.7 ‡ 
IL15 19 11 7 8 48 18 0.6 ‡ 
IL6  15206 7701 9325 9414 69182 8430 0.6 ‡ 
IL4  55 27 11 13 9 7 0.5 
LIF 217 98 311 249 431 257 0.5 *,‡ 
IL12 (p40) 61 26 22 25 57 83 0.5 * 
IL5  674 212 429 296 225 203 0.4 * 
IL17 13 4 16 9 34 8 0.3 ‡ 
Cytokine (pg/ml) at: 
IL2, IL3, IL7, IL12 (p70) and IL13 excluded as means all < than 20pg/ml 
Appendix 4. Cytokines in the airway in CCR2-/- and wild-type mice at the point of and during 
coinfection.
Multiplex quantification of airway cytokines in wild-type (C57BL/6) or CCR2-/- (B6) at during high 
dose influenza infection or coinfection at 5 and 7dpi (n=5-6). Data shown as arithmetic means. 
Cytokines in table ranked in descending order of fold change of CCR2-/- IAV infected mice at 5dpi 
relative to wild-type. Significance assessed by Mann-Whitney test. *p<0.05 wild-type IAV 5dpi vs. 
CCR2-/- IAV 5dpi; †p<0.05 wild type IAV 7dpi vs CCR2-/- IAV 7dpi; ‡p<0.05 wild type IAV + Strep 
7dpi vs CCR2-/- IAV + Strep 7dpi.
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TRAIL+ 
Appendix 5 A: Identification of TRAIL+ cells.
Gating strategy used to determine TRAIL+ cells and identify them as neutrophils 
(Ly6G+CD11b+) or inflammatory monocytes (Ly6G-CD11b+Ly6C+). TRAIL staining histogram 
shows representative samples - colours as indicated. Alveolar macrophages (here classed 
as CD11b-SSChigh cells) excluded due to autofluorescence confounding stain. Control is 
fluorescence-1 - a mix of all samples stained for all markers except TRAIL and used to deter-
mine background. Dot plots show representative 5dpi high dose IAV infected lung. Black 
arrows indicate progression to the next gate. Dashed arrows indicate populations identified. 
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Appendix 5 B
DR5+
Appendix 5 B: Determination of DR5 expression on epithelial cells.
Gating strategy used to determine DR5+ on epithelial cells. CD45- cells identified as epithe-
lial by expression of Ep-Cam and E-cadherin. DR5 staining histogram shows representative 
samples - colours as indicated. Control is fluorescence-1 - a mix of all samples stained for 
all markers except DR5 and used to determine background. Dot plot shows representative 
5dpi high dose IAV infected lung. Black arrows indicate progression to the next gate.
 222	  
 
Bibliography 
Aldridge, J.R., Jr., C.E. Moseley, D.A. Boltz, N.J. Negovetich, C. Reynolds, J. 
Franks, S.A. Brown, P.C. Doherty, R.G. Webster, and P.G. Thomas. 2009. 
TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza 
virus infection. Proc Natl Acad Sci U S A 106:5306-5311. 
Allen, I.C., M.A. Scull, C.B. Moore, E.K. Holl, E. McElvania-TeKippe, D.J. 
Taxman, E.H. Guthrie, R.J. Pickles, and J.P. Ting. 2009. The NLRP3 
inflammasome mediates in vivo innate immunity to influenza A virus through 
recognition of viral RNA. Immunity 30:556-565. 
Alonso, J.M., A. Guiyoule, M.L. Zarantonelli, F. Ramisse, R. Pires, A. Antignac, 
A.E. Deghmane, M. Huerre, S. van der Werf, and M.K. Taha. 2003. A model of 
meningococcal bacteremia after respiratory superinfection in influenza A virus-
infected mice. FEMS Microbiol Lett 222:99-106. 
Alymova, I.V., A. Samarasinghe, P. Vogel, A.M. Green, R. Weinlich, and J.A. 
McCullers. 2014. A novel cytotoxic sequence contributes to influenza A viral 
protein PB1-F2 pathogenicity and predisposition to secondary bacterial infection. 
J Virol 88:503-515. 
Antonelli, L.R., A. Gigliotti Rothfuchs, R. Goncalves, E. Roffe, A.W. Cheever, A. 
Bafica, A.M. Salazar, C.G. Feng, and A. Sher. 2010. Intranasal Poly-IC treatment 
exacerbates tuberculosis in mice through the pulmonary recruitment of a 
pathogen-permissive monocyte/macrophage population. J Clin Invest 120:1674-
1682. 
Auerbuch, V., D.G. Brockstedt, N. Meyer-Morse, M. O'Riordan, and D.A. 
Portnoy. 2004. Mice lacking the type I interferon receptor are resistant to Listeria 
monocytogenes. J Exp Med 200:527-533. 
Avadhanula, V., C.A. Rodriguez, J.P. Devincenzo, Y. Wang, R.J. Webby, G.C. 
Ulett, and E.E. Adderson. 2006. Respiratory viruses augment the adhesion of 
bacterial pathogens to respiratory epithelium in a viral species- and cell type-
dependent manner. J Virol 80:1629-1636. 
Avery, O.T., C.M. Macleod, and M. McCarty. 1944. Studies on the Chemical 
Nature of the Substance Inducing Transformation of Pneumococcal Types : 
Induction of Transformation by a Desoxyribonucleic Acid Fraction Isolated from 
Pneumococcus Type Iii. J Exp Med 79:137-158. 
 223	  
Baker, D.G. 1998. Natural pathogens of laboratory mice, rats, and rabbits and 
their effects on research. Clin Microbiol Rev 11:231-266. 
Beiter, K., F. Wartha, B. Albiger, S. Normark, A. Zychlinsky, and B. Henriques-
Normark. 2006. An endonuclease allows Streptococcus pneumoniae to escape 
from neutrophil extracellular traps. Curr Biol 16:401-407. 
Belisle, S.E., J.R. Tisoncik, M.J. Korth, V.S. Carter, S.C. Proll, D.E. Swayne, M. 
Pantin-Jackwood, T.M. Tumpey, and M.G. Katze. 2010. Genomic profiling of 
tumor necrosis factor alpha (TNF-alpha) receptor and interleukin-1 receptor 
knockout mice reveals a link between TNF-alpha signaling and increased severity 
of 1918 pandemic influenza virus infection. J Virol 84:12576-12588. 
Benedict, C.A., and C.F. Ware. 2012. TRAIL: not just for tumors anymore? J Exp 
Med 209:1903-1906. 
Blok, D.C., K.F. van der Sluijs, S. Florquin, O.J. de Boer, C. van 't Veer, A.F. de 
Vos, and T. van der Poll. 2013. Limited anti-inflammatory role for interleukin-1 
receptor like 1 (ST2) in the host response to murine postinfluenza pneumococcal 
pneumonia. PLoS One 8:e58191. 
Blyth, C.C., S.A. Webb, J. Kok, D.E. Dwyer, S.J. van Hal, H. Foo, A.N. Ginn, 
A.M. Kesson, I. Seppelt, J.R. Iredell, A.I. Investigators, and C.M. Investigators. 
2013. The impact of bacterial and viral co-infection in severe influenza. Influenza 
Other Respir Viruses 7:168-176. 
Bogaert, D., R. De Groot, and P.W. Hermans. 2004. Streptococcus pneumoniae 
colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:144-154. 
Bordon, J., S. Aliberti, R. Fernandez-Botran, S.M. Uriarte, M.J. Rane, P. Duvvuri, 
P. Peyrani, L.C. Morlacchi, F. Blasi, and J.A. Ramirez. 2013. Understanding the 
roles of cytokines and neutrophil activity and neutrophil apoptosis in the 
protective versus deleterious inflammatory response in pneumonia. Int J Infect 
Dis 17:e76-83. 
Borregaard, N. 2010. Neutrophils, from marrow to microbes. Immunity 33:657-
670. 
Borregaard, N., and J.B. Cowland. 1997. Granules of the human neutrophilic 
polymorphonuclear leukocyte. Blood 89:3503-3521. 
Bouvier, N.M., and A.C. Lowen. 2010. Animal Models for Influenza Virus 
Pathogenesis and Transmission. Viruses 2:1530-1563. 
 224	  
Bouvier, N.M., and P. Palese. 2008. The biology of influenza viruses. Vaccine 26 
Suppl 4:D49-53. 
Bradley, J.R. 2008. TNF-mediated inflammatory disease. J Pathol 214:149-160. 
Breslow-Deckman, J.M., C.M. Mattingly, S.E. Birket, S.N. Hoskins, T.N. Ho, 
B.A. Garvy, and D.J. Feola. 2013. Linezolid decreases susceptibility to secondary 
bacterial pneumonia postinfluenza infection in mice through its effects on IFN-
gamma. J Immunol 191:1792-1799. 
Brincks, E.L., P. Gurung, R.A. Langlois, E.A. Hemann, K.L. Legge, and T.S. 
Griffith. 2011. The magnitude of the T cell response to a clinically significant 
dose of influenza virus is regulated by TRAIL. J Immunol 187:4581-4588. 
Brincks, E.L., A. Katewa, T.A. Kucaba, T.S. Griffith, and K.L. Legge. 2008a. 
CD8 T cells utilize TRAIL to control influenza virus infection. J Immunol 
181:4918-4925. 
Brincks, E.L., T.A. Kucaba, K.L. Legge, and T.S. Griffith. 2008b. Influenza-
induced expression of functional tumor necrosis factor-related apoptosis-inducing 
ligand on human peripheral blood mononuclear cells. Hum Immunol 69:634-646. 
Brown, D.M., E. Roman, and S.L. Swain. 2004. CD4 T cell responses to influenza 
infection. Semin Immunol 16:171-177. 
Cao, J., D. Wang, F. Xu, Y. Gong, H. Wang, Z. Song, D. Li, H. Zhang, D. Li, L. 
Zhang, Y. Xia, H. Xu, X. Lai, S. Lin, X. Zhang, G. Ren, Y. Dai, and Y. Yin. 
2014. Activation of IL-27 signalling promotes development of postinfluenza 
pneumococcal pneumonia. EMBO Mol Med 6:120-140. 
Carrero, J.A., B. Calderon, and E.R. Unanue. 2004. Type I interferon sensitizes 
lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med 
200:535-540. 
Casal, J., and D. Tarrago. 2003. Immunity to Streptococcus pneumoniae: Factors 
affecting production and efficacy. Curr Opin Infect Dis 16:219-224. 
Centers for Disease, C., and Prevention. 2009. Bacterial coinfections in lung 
tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United 
States, May-August 2009. MMWR Morb Mortal Wkly Rep 58:1071-1074. 
 225	  
Chen, W.H., F.R. Toapanta, K.A. Shirey, L. Zhang, A. Giannelou, C. Page, M.B. 
Frieman, S.N. Vogel, and A.S. Cross. 2012. Potential role for alternatively 
activated macrophages in the secondary bacterial infection during recovery from 
influenza. Immunol Lett 141:227-234. 
Chiavolini, D., G. Pozzi, and S. Ricci. 2008. Animal models of Streptococcus 
pneumoniae disease. Clin Microbiol Rev 21:666-685. 
Cilloniz, C., S. Ewig, R. Menendez, M. Ferrer, E. Polverino, S. Reyes, A. 
Gabarrus, M.A. Marcos, J. Cordoba, J. Mensa, and A. Torres. 2012. Bacterial co-
infection with H1N1 infection in patients admitted with community acquired 
pneumonia. J Infect 65:223-230. 
Colamussi, M.L., M.R. White, E. Crouch, and K.L. Hartshorn. 1999. Influenza A 
virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects 
of bacteria. Blood 93:2395-2403. 
Coulombe, F., S. Fiola, S. Akira, Y. Cormier, and J. Gosselin. 2012. Muramyl 
dipeptide induces NOD2-dependent Ly6C(high) monocyte recruitment to the 
lungs and protects against influenza virus infection. PLoS One 7:e36734. 
Crowe, C.R., K. Chen, D.A. Pociask, J.F. Alcorn, C. Krivich, R.I. Enelow, T.M. 
Ross, J.L. Witztum, and J.K. Kolls. 2009. Critical role of IL-17RA in 
immunopathology of influenza infection. J Immunol 183:5301-5310. 
Cruveilhier, L. 1919. Action du sérum antipneumococcique au cours de la 
pneumonie et dans les complications de la grippe. Annales de l’Institut Pasteur 
33:448-461. 
Daley, J.M., A.A. Thomay, M.D. Connolly, J.S. Reichner, and J.E. Albina. 2008. 
Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J 
Leukoc Biol 83:64-70. 
Damjanovic, D., M. Divangahi, K. Kugathasan, C.L. Small, A. Zganiacz, E.G. 
Brown, C.M. Hogaboam, J. Gauldie, and Z. Xing. 2011. Negative regulation of 
lung inflammation and immunopathology by TNF-alpha during acute influenza 
infection. Am J Pathol 179:2963-2976. 
Damjanovic, D., A. Khera, M.F. Medina, J. Ennis, J.D. Turner, J. Gauldie, and Z. 
Xing. 2014. Type 1 interferon gene transfer enhances host defense against 
pulmonary Streptococcus pneumoniae infection via activating innate leukocytes. 
Molecular Therapy — Methods & Clinical Development 1:14005. 
 226	  
Damjanovic, D., R. Lai, M. Jeyanathan, C.M. Hogaboam, and Z. Xing. 2013. 
Marked improvement of severe lung immunopathology by influenza-associated 
pneumococcal superinfection requires the control of both bacterial replication and 
host immune responses. Am J Pathol 183:868-880. 
Davidson, S., S. Crotta, T.M. McCabe, and A. Wack. 2014. Pathogenic potential 
of interferon alphabeta in acute influenza infection. Nat Commun 5:3864. 
Davis, K.M., S. Nakamura, and J.N. Weiser. 2011. Nod2 sensing of lysozyme-
digested peptidoglycan promotes macrophage recruitment and clearance of S. 
pneumoniae colonization in mice. J Clin Invest 121:3666-3676. 
Dawood, F.S., S.S. Chaves, A. Perez, A. Reingold, J. Meek, M.M. Farley, P. 
Ryan, R. Lynfield, C. Morin, J. Baumbach, N.M. Bennett, S. Zansky, A. Thomas, 
M.L. Lindegren, W. Schaffner, L. Finelli, and N. Emerging Infections Program. 
2014. Complications and associated bacterial coinfections among children 
hospitalized with seasonal or pandemic influenza, United States, 2003-2010. J 
Infect Dis 209:686-694. 
Dawson, T.C., M.A. Beck, W.A. Kuziel, F. Henderson, and N. Maeda. 2000. 
Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary 
inflammatory response to influenza A virus. Am J Pathol 156:1951-1959. 
De Santo, C., M. Salio, S.H. Masri, L.Y. Lee, T. Dong, A.O. Speak, S. Porubsky, 
S. Booth, N. Veerapen, G.S. Besra, H.J. Grone, F.M. Platt, M. Zambon, and V. 
Cerundolo. 2008. Invariant NKT cells reduce the immunosuppressive activity of 
influenza A virus-induced myeloid-derived suppressor cells in mice and humans. 
J Clin Invest 118:4036-4048. 
Deberge, M.P., K.H. Ely, and R.I. Enelow. 2014. Soluble, but Not 
Transmembrane, TNF-alpha Is Required during Influenza Infection To Limit the 
Magnitude of Immune Responses and the Extent of Immunopathology. J Immunol  
Denison, A.M., M. Deleon-Carnes, D.M. Blau, E.C. Shattuck, L.K. McDougal, 
J.K. Rasheed, B.M. Limbago, S.R. Zaki, and C.D. Paddock. 2013. Molecular 
characterization of Staphylococcus aureus and influenza virus coinfections in 
patients with fatal Pneumonia. J Clin Microbiol 51:4223-4225. 
Dessing, M.C., K.F. van der Sluijs, S. Florquin, S. Akira, and T. van der Poll. 
2007a. Toll-like receptor 2 does not contribute to host response during 
postinfluenza pneumococcal pneumonia. Am J Respir Cell Mol Biol 36:609-614. 
 227	  
Dessing, M.C., K.F. van der Sluijs, S. Florquin, and T. van der Poll. 2007b. 
Monocyte chemoattractant protein 1 contributes to an adequate immune response 
in influenza pneumonia. Clin Immunol 125:328-336. 
Diavatopoulos, D.A., K.R. Short, J.T. Price, J.J. Wilksch, L.E. Brown, D.E. 
Briles, R.A. Strugnell, and O.L. Wijburg. 2010. Influenza A virus facilitates 
Streptococcus pneumoniae transmission and disease. FASEB J 24:1789-1798. 
Didierlaurent, A., J. Goulding, S. Patel, R. Snelgrove, L. Low, M. Bebien, T. 
Lawrence, L.S. van Rijt, B.N. Lambrecht, J.C. Sirard, and T. Hussell. 2008. 
Sustained desensitization to bacterial Toll-like receptor ligands after resolution of 
respiratory influenza infection. J Exp Med 205:323-329. 
Diebold, S.S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa. 2004. Innate 
antiviral responses by means of TLR7-mediated recognition of single-stranded 
RNA. Science 303:1529-1531. 
Dienz, O., J.G. Rud, S.M. Eaton, P.A. Lanthier, E. Burg, A. Drew, J. Bunn, B.T. 
Suratt, L. Haynes, and M. Rincon. 2012. Essential role of IL-6 in protection 
against H1N1 influenza virus by promoting neutrophil survival in the lung. 
Mucosal Immunol 5:258-266. 
Doherty, P.C., S.J. Turner, R.G. Webby, and P.G. Thomas. 2006. Influenza and 
the challenge for immunology. Nat Immunol 7:449-455. 
Duplantier, A.J., and M.L. van Hoek. 2013. The Human Cathelicidin 
Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected 
Wounds. Front Immunol 4:143. 
Engelich, G., M. White, and K.L. Hartshorn. 2001. Neutrophil survival is 
markedly reduced by incubation with influenza virus and Streptococcus 
pneumoniae: role of respiratory burst. J Leukoc Biol 69:50-56. 
Engelich, G., M. White, and K.L. Hartshorn. 2002. Role of the respiratory burst in 
co-operative reduction in neutrophil survival by influenza A virus and Escherichia 
coli. J Med Microbiol 51:484-490. 
Estenssoro, E., F.G. Rios, C. Apezteguia, R. Reina, J. Neira, D.H. Ceraso, C. 
Orlandi, R. Valentini, N. Tiribelli, M. Brizuela, C. Balasini, S. Mare, G. 
Domeniconi, S. Ilutovich, A. Gomez, J. Giuliani, C. Barrios, P. Valdez, and S. 
Registry of the Argentinian Society of Intensive Care. 2010. Pandemic 2009 
influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J 
Respir Crit Care Med 182:41-48. 
 228	  
Ezoe, H., Y. Akeda, Z. Piao, T. Aoshi, S. Koyama, T. Tanimoto, K.J. Ishii, and K. 
Oishi. 2011. Intranasal vaccination with pneumococcal surface protein A plus 
poly(I:C) protects against secondary pneumococcal pneumonia in mice. Vaccine 
29:1754-1761. 
Faurschou, M., and N. Borregaard. 2003. Neutrophil granules and secretory 
vesicles in inflammation. Microbes Infect 5:1317-1327. 
Fleming-Dutra, K.E., T. Taylor, R. Link-Gelles, S. Garg, M.A. Jhung, L. Finelli, 
S. Jain, D. Shay, S.S. Chaves, J. Baumbach, E.B. Hancock, B. Beall, N. Bennett, 
S. Zansky, S. Petit, K. Yousey-Hindes, M.M. Farley, K. Gershman, L.H. 
Harrison, P. Ryan, C. Lexau, R. Lynfield, A. Reingold, W. Schaffner, A. Thomas, 
and M.R. Moore. 2013. Effect of the 2009 influenza A(H1N1) pandemic on 
invasive pneumococcal pneumonia. J Infect Dis 207:1135-1143. 
Foy, H.M., and G.E. Kenny. 1988. Re: "Possible association of mycoplasma and 
viral respiratory infections with bacterial meningitis". Am J Epidemiol 127:879-
881. 
Fujisawa, H. 2008. Neutrophils play an essential role in cooperation with antibody 
in both protection against and recovery from pulmonary infection with influenza 
virus in mice. J Virol 82:2772-2783. 
Fukuda, Y., Y. Furuya, Y. Nozaki, M. Takahata, N. Nomura, and J. Mitsuyama. 
2014. Therapeutic effects of garenoxacin in murine experimental secondary 
pneumonia by Streptococcus pneumoniae after influenza virus infection. Diagn 
Microbiol Infect Dis 78:168-171. 
Ghoneim, H.E., and J.A. McCullers. 2013. Adjunctive Corticosteroid Therapy 
Improves Lung Immunopathology and Survival During Severe Secondary 
Pneumococcal Pneumonia in Mice. J Infect Dis  
Ghoneim, H.E., P.G. Thomas, and J.A. McCullers. 2013. Depletion of alveolar 
macrophages during influenza infection facilitates bacterial superinfections. J 
Immunol 191:1250-1259. 
Gill, J.R., Z.M. Sheng, S.F. Ely, D.G. Guinee, M.B. Beasley, J. Suh, C. 
Deshpande, D.J. Mollura, D.M. Morens, M. Bray, W.D. Travis, and J.K. 
Taubenberger. 2010. Pulmonary pathologic findings of fatal 2009 pandemic 
influenza A/H1N1 viral infections. Arch Pathol Lab Med 134:235-243. 
Gingles, N.A., J.E. Alexander, A. Kadioglu, P.W. Andrew, A. Kerr, T.J. Mitchell, 
E. Hopes, P. Denny, S. Brown, H.B. Jones, S. Little, G.C. Booth, and W.L. 
McPheat. 2001. Role of genetic resistance in invasive pneumococcal infection: 
 229	  
identification and study of susceptibility and resistance in inbred mouse strains. 
Infect Immun 69:426-434. 
Gordon, S., and P.R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat 
Rev Immunol 5:953-964. 
Goulding, J., A. Godlee, S. Vekaria, M. Hilty, R. Snelgrove, and T. Hussell. 2011. 
Lowering the threshold of lung innate immune cell activation alters susceptibility 
to secondary bacterial superinfection. J Infect Dis 204:1086-1094. 
Grabowska, K., L. Hogberg, P. Penttinen, A. Svensson, and K. Ekdahl. 2006. 
Occurrence of invasive pneumococcal disease and number of excess cases due to 
influenza. BMC Infect Dis 6:58. 
Guarda, G., M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Forster, M. Farlik, 
T. Decker, R.A. Du Pasquier, P. Romero, and J. Tschopp. 2011. Type I interferon 
inhibits interleukin-1 production and inflammasome activation. Immunity 34:213-
223. 
Halaas, O., N.B. Liabakk, R. Vik, C. Beninati, P. Henneke, A. Sundan, and T. 
Espevik. 2004. Monocytes stimulated with group B streptococci or interferons 
release tumour necrosis factor-related apoptosis-inducing ligand. Scand J 
Immunol 60:74-81. 
Harata, G., F. He, N. Hiruta, M. Kawase, A. Kubota, M. Hiramatsu, and H. Yausi. 
2010. Intranasal administration of Lactobacillus rhamnosus GG protects mice 
from H1N1 influenza virus infection by regulating respiratory immune responses. 
Lett Appl Microbiol 50:597-602. 
Hatta, M., N. Yamamoto, A. Miyazato, N. Ishii, K. Nakamura, K. Inden, T. 
Aoyagi, H. Kunishima, Y. Hirakata, K. Suzuki, M. Kaku, and K. Kawakami. 
2010. Early production of tumor necrosis factor-alpha by Gr-1 cells and its role in 
the host defense to pneumococcal infection in lungs. FEMS Immunol Med 
Microbiol 58:182-192. 
Hayashi, K., S.E. Kadowaki, M. Takei, and H. Fukuda. 2006. Efficacy of 
quinolones against secondary pneumococcal pneumonia after influenza virus 
infection in mice. Antimicrob Agents Chemother 50:748-751. 
Hennet, T., H.J. Ziltener, K. Frei, and E. Peterhans. 1992. A kinetic study of 
immune mediators in the lungs of mice infected with influenza A virus. J 
Immunol 149:932-939. 
 230	  
Henriques-Normark, B., and E.I. Tuomanen. 2013. The pneumococcus: 
epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med 
3: 
Hernandez-Cuellar, E., K. Tsuchiya, H. Hara, R. Fang, S. Sakai, I. Kawamura, S. 
Akira, and M. Mitsuyama. 2012. Cutting edge: nitric oxide inhibits the NLRP3 
inflammasome. J Immunol 189:5113-5117. 
Herold, S., M. Steinmueller, W. von Wulffen, L. Cakarova, R. Pinto, S. Pleschka, 
M. Mack, W.A. Kuziel, N. Corazza, T. Brunner, W. Seeger, and J. Lohmeyer. 
2008. Lung epithelial apoptosis in influenza virus pneumonia: the role of 
macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med 
205:3065-3077. 
Herold, S., W. von Wulffen, M. Steinmueller, S. Pleschka, W.A. Kuziel, M. 
Mack, M. Srivastava, W. Seeger, U.A. Maus, and J. Lohmeyer. 2006. Alveolar 
epithelial cells direct monocyte transepithelial migration upon influenza virus 
infection: impact of chemokines and adhesion molecules. J Immunol 177:1817-
1824. 
Heumann, D., C. Barras, A. Severin, M.P. Glauser, and A. Tomasz. 1994. Gram-
positive cell walls stimulate synthesis of tumor necrosis factor alpha and 
interleukin-6 by human monocytes. Infect Immun 62:2715-2721. 
Hogner, K., T. Wolff, S. Pleschka, S. Plog, A.D. Gruber, U. Kalinke, H.D. 
Walmrath, J. Bodner, S. Gattenlohner, P. Lewe-Schlosser, M. Matrosovich, W. 
Seeger, J. Lohmeyer, and S. Herold. 2013. Macrophage-expressed IFN-beta 
contributes to apoptotic alveolar epithelial cell injury in severe influenza virus 
pneumonia. PLoS Pathog 9:e1003188. 
Huang, F.F., P.F. Barnes, Y. Feng, R. Donis, Z.C. Chroneos, S. Idell, T. Allen, 
D.R. Perez, J.A. Whitsett, K. Dunussi-Joannopoulos, and H. Shams. 2011. GM-
CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care 
Med 184:259-268. 
Hufford, M.M., G. Richardson, H. Zhou, B. Manicassamy, A. Garcia-Sastre, R.I. 
Enelow, and T.J. Braciale. 2012. Influenza-infected neutrophils within the 
infected lungs act as antigen presenting cells for anti-viral CD8(+) T cells. PLoS 
One 7:e46581. 
Hussell, T., A. Pennycook, and P.J. Openshaw. 2001. Inhibition of tumor necrosis 
factor reduces the severity of virus-specific lung immunopathology. Eur J 
Immunol 31:2566-2573. 
 231	  
Hyams, C., E. Camberlein, J.M. Cohen, K. Bax, and J.S. Brown. 2010. The 
Streptococcus pneumoniae capsule inhibits complement activity and neutrophil 
phagocytosis by multiple mechanisms. Infect Immun 78:704-715. 
Imai, Y., K. Kuba, G.G. Neely, R. Yaghubian-Malhami, T. Perkmann, G. van 
Loo, M. Ermolaeva, R. Veldhuizen, Y.H. Leung, H. Wang, H. Liu, Y. Sun, M. 
Pasparakis, M. Kopf, C. Mech, S. Bavari, J.S. Peiris, A.S. Slutsky, S. Akira, M. 
Hultqvist, R. Holmdahl, J. Nicholls, C. Jiang, C.J. Binder, and J.M. Penninger. 
2008. Identification of oxidative stress and Toll-like receptor 4 signaling as a key 
pathway of acute lung injury. Cell 133:235-249. 
Imanishi, T., D.K. Han, L. Hofstra, T. Hano, I. Nishio, W.C. Liles, A.M. Gown, 
and S.M. Schwartz. 2002. Apoptosis of vascular smooth muscle cells is induced 
by Fas ligand derived from monocytes/macrophage. Atherosclerosis 161:143-151. 
Ishikawa, E., M. Nakazawa, M. Yoshinari, and M. Minami. 2005. Role of tumor 
necrosis factor-related apoptosis-inducing ligand in immune response to influenza 
virus infection in mice. J Virol 79:7658-7663. 
Ivanov, S., J. Renneson, J. Fontaine, A. Barthelemy, C. Paget, E.M. Fernandez, F. 
Blanc, C. De Trez, L. Van Maele, L. Dumoutier, M.R. Huerre, G. Eberl, M. Si-
Tahar, P. Gosset, J.C. Renauld, J.C. Sirard, C. Faveeuw, and F. Trottein. 2013. 
Interleukin-22 reduces lung inflammation during influenza A virus infection and 
protects against secondary bacterial infection. J Virol 87:6911-6924. 
Iverson, A.R., K.L. Boyd, J.L. McAuley, L.R. Plano, M.E. Hart, and J.A. 
McCullers. 2011. Influenza virus primes mice for pneumonia from 
Staphylococcus aureus. J Infect Dis 203:880-888. 
Iwasaki, A., and P.S. Pillai. 2014. Innate immunity to influenza virus infection. 
Nat Rev Immunol 14:315-328. 
Jamieson, A.M., L. Pasman, S. Yu, P. Gamradt, R.J. Homer, T. Decker, and R. 
Medzhitov. 2013. Role of tissue protection in lethal respiratory viral-bacterial 
coinfection. Science 340:1230-1234. 
Jamieson, A.M., S. Yu, C.H. Annicelli, and R. Medzhitov. 2010. Influenza virus-
induced glucocorticoids compromise innate host defense against a secondary 
bacterial infection. Cell Host Microbe 7:103-114. 
Janoff, E.N., C. Fasching, J.M. Orenstein, J.B. Rubins, N.L. Opstad, and A.P. 
Dalmasso. 1999. Killing of Streptococcus pneumoniae by capsular 
polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin 
Invest 104:1139-1147. 
 232	  
Jones, M.R., B.T. Simms, M.M. Lupa, M.S. Kogan, and J.P. Mizgerd. 2005. Lung 
NF-kappaB activation and neutrophil recruitment require IL-1 and TNF receptor 
signaling during pneumococcal pneumonia. J Immunol 175:7530-7535. 
Julkunen, I., K. Melen, M. Nyqvist, J. Pirhonen, T. Sareneva, and S. Matikainen. 
2000. Inflammatory responses in influenza A virus infection. Vaccine 19 Suppl 
1:S32-37. 
Kadioglu, A., and P.W. Andrew. 2004. The innate immune response to 
pneumococcal lung infection: the untold story. Trends Immunol 25:143-149. 
Kadioglu, A., J.N. Weiser, J.C. Paton, and P.W. Andrew. 2008. The role of 
Streptococcus pneumoniae virulence factors in host respiratory colonization and 
disease. Nat Rev Microbiol 6:288-301. 
Karlstrom, A., K.L. Boyd, B.K. English, and J.A. McCullers. 2009. Treatment 
with protein synthesis inhibitors improves outcomes of secondary bacterial 
pneumonia after influenza. J Infect Dis 199:311-319. 
Karlstrom, A., S.M. Heston, K.L. Boyd, E.I. Tuomanen, and J.A. McCullers. 
2011. Toll-like receptor 2 mediates fatal immunopathology in mice during 
treatment of secondary pneumococcal pneumonia following influenza. J Infect 
Dis 204:1358-1366. 
Kash, J.C., K.A. Walters, A.S. Davis, A. Sandouk, L.M. Schwartzman, B.W. 
Jagger, D.S. Chertow, Q. Li, R.E. Kuestner, A. Ozinsky, and J.K. Taubenberger. 
2011. Lethal synergism of 2009 pandemic H1N1 influenza virus and 
Streptococcus pneumoniae coinfection is associated with loss of murine lung 
repair responses. MBio 2: 
Kawai, T., and S. Akira. 2006. TLR signaling. Cell Death Differ 13:816-825. 
Kerr, A.R., J.J. Irvine, J.J. Search, N.A. Gingles, A. Kadioglu, P.W. Andrew, 
W.L. McPheat, C.G. Booth, and T.J. Mitchell. 2002. Role of inflammatory 
mediators in resistance and susceptibility to pneumococcal infection. Infect 
Immun 70:1547-1557. 
Kettenmann, H., U.K. Hanisch, M. Noda, and A. Verkhratsky. 2011. Physiology 
of microglia. Physiol Rev 91:461-553. 
King, Q.O., B. Lei, and A.G. Harmsen. 2009. Pneumococcal surface protein A 
contributes to secondary Streptococcus pneumoniae infection after influenza virus 
infection. J Infect Dis 200:537-545. 
 233	  
Kirby, A.C., J.G. Raynes, and P.M. Kaye. 2005. The role played by tumor 
necrosis factor during localized and systemic infection with Streptococcus 
pneumoniae. J Infect Dis 191:1538-1547. 
Kobasa, D., A. Takada, K. Shinya, M. Hatta, P. Halfmann, S. Theriault, H. 
Suzuki, H. Nishimura, K. Mitamura, N. Sugaya, T. Usui, T. Murata, Y. Maeda, S. 
Watanabe, M. Suresh, T. Suzuki, Y. Suzuki, H. Feldmann, and Y. Kawaoka. 
2004. Enhanced virulence of influenza A viruses with the haemagglutinin of the 
1918 pandemic virus. Nature 431:703-707. 
Koedel, U., W.M. Scheld, and H.W. Pfister. 2002. Pathogenesis and 
pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2:721-736. 
Koon, K., C.M. Sanders, J. Green, L. Malone, H. White, D. Zayas, R. Miller, S. 
Lu, and J. Han. 2010. Co-detection of pandemic (H1N1) 2009 virus and other 
respiratory pathogens. Emerg Infect Dis 16:1976-1978. 
Koppe, U., N. Suttorp, and B. Opitz. 2012. Recognition of Streptococcus 
pneumoniae by the innate immune system. Cell Microbiol 14:460-466. 
Kosai, K., M. Seki, K. Yanagihara, S. Nakamura, S. Kurihara, Y. Imamura, K. 
Izumikawa, H. Kakeya, Y. Yamamoto, T. Tashiro, and S. Kohno. 2008. Two-
dimensional gel electrophoresis analysis in simultaneous influenza pneumonia 
and bacterial infection in mice. Clin Exp Immunol 152:364-371. 
Krasinski, K., J.D. Nelson, S. Butler, J.P. Luby, and H. Kusmiesz. 1987. Possible 
association of mycoplasma and viral respiratory infections with bacterial 
meningitis. Am J Epidemiol 125:499-508. 
Kudva, A., E.V. Scheller, K.M. Robinson, C.R. Crowe, S.M. Choi, S.R. Slight, 
S.A. Khader, P.J. Dubin, R.I. Enelow, J.K. Kolls, and J.F. Alcorn. 2011. Influenza 
A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J 
Immunol 186:1666-1674. 
Kukavica-Ibrulj, I., M.E. Hamelin, G.A. Prince, C. Gagnon, Y. Bergeron, M.G. 
Bergeron, and G. Boivin. 2009. Infection with human metapneumovirus 
predisposes mice to severe pneumococcal pneumonia. J Virol 83:1341-1349. 
Kuri, T., A.S. Sorensen, S. Thomas, G.B. Karlsson Hedestam, S. Normark, B. 
Henriques-Normark, G.M. McInerney, and L. Plant. 2013. Influenza A virus-
mediated priming enhances cytokine secretion by human dendritic cells infected 
with Streptococcus pneumoniae. Cell Microbiol 15:1385-1400. 
 234	  
Lakadamyali, M., M.J. Rust, and X. Zhuang. 2004. Endocytosis of influenza 
viruses. Microbes Infect 6:929-936. 
Lanie, J.A., W.L. Ng, K.M. Kazmierczak, T.M. Andrzejewski, T.M. Davidsen, 
K.J. Wayne, H. Tettelin, J.I. Glass, and M.E. Winkler. 2007. Genome sequence of 
Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and 
comparison with that of unencapsulated laboratory strain R6. J Bacteriol 189:38-
51. 
Le Goffic, R., J. Pothlichet, D. Vitour, T. Fujita, E. Meurs, M. Chignard, and M. 
Si-Tahar. 2007. Cutting Edge: Influenza A virus activates TLR3-dependent 
inflammatory and RIG-I-dependent antiviral responses in human lung epithelial 
cells. J Immunol 178:3368-3372. 
Le Hir, M., H. Bluethmann, M.H. Kosco-Vilbois, M. Muller, F. di Padova, M. 
Moore, B. Ryffel, and H.P. Eugster. 1995. Tumor necrosis factor receptor-1 
signaling is required for differentiation of follicular dendritic cells, germinal 
center formation, and full antibody responses. J Inflamm 47:76-80. 
Lee, L.N., P. Dias, D. Han, S. Yoon, A. Shea, V. Zakharov, D. Parham, and S.R. 
Sarawar. 2010. A mouse model of lethal synergism between influenza virus and 
Haemophilus influenzae. Am J Pathol 176:800-811. 
Lee, W.L., R.E. Harrison, and S. Grinstein. 2003. Phagocytosis by neutrophils. 
Microbes Infect 5:1299-1306. 
LeMessurier, K.S., H. Hacker, L. Chi, E. Tuomanen, and V. Redecke. 2013. Type 
I interferon protects against pneumococcal invasive disease by inhibiting bacterial 
transmigration across the lung. PLoS Pathog 9:e1003727. 
LeVine, A.M., V. Koeningsknecht, and J.M. Stark. 2001. Decreased pulmonary 
clearance of S. pneumoniae following influenza A infection in mice. J Virol 
Methods 94:173-186. 
Li, W., B. Moltedo, and T.M. Moran. 2012. Type I interferon induction during 
influenza virus infection increases susceptibility to secondary Streptococcus 
pneumoniae infection by negative regulation of gammadelta T cells. J Virol 
86:12304-12312. 
Liderot, K., M. Ahl, and V. Ozenci. 2013. Secondary bacterial infections in 
patients with seasonal influenza A and pandemic H1N1. Biomed Res Int 
2013:376219. 
 235	  
Lin, K.L., Y. Suzuki, H. Nakano, E. Ramsburg, and M.D. Gunn. 2008. CCR2+ 
monocyte-derived dendritic cells and exudate macrophages produce influenza-
induced pulmonary immune pathology and mortality. J Immunol 180:2562-2572. 
Lin, K.L., S. Sweeney, B.D. Kang, E. Ramsburg, and M.D. Gunn. 2011. CCR2-
antagonist prophylaxis reduces pulmonary immune pathology and markedly 
improves survival during influenza infection. J Immunol 186:508-515. 
Louie, J.K., M. Acosta, K. Winter, C. Jean, S. Gavali, R. Schechter, D. Vugia, K. 
Harriman, B. Matyas, C.A. Glaser, M.C. Samuel, J. Rosenberg, J. Talarico, D. 
Hatch, and G. California Pandemic Working. 2009. Factors associated with death 
or hospitalization due to pandemic 2009 influenza A(H1N1) infection in 
California. JAMA 302:1896-1902. 
Lundemose, J.B., H. Smith, and C. Sweet. 1993. Cytokine release from human 
peripheral blood leucocytes incubated with endotoxin with and without prior 
infection with influenza virus: relevance to the sudden infant death syndrome. Int 
J Exp Pathol 74:291-297. 
Manicassamy, B., S. Manicassamy, A. Belicha-Villanueva, G. Pisanelli, B. 
Pulendran, and A. Garcia-Sastre. 2010. Analysis of in vivo dynamics of influenza 
virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A 
107:11531-11536. 
Manukyan, M., K. Triantafilou, M. Triantafilou, A. Mackie, N. Nilsen, T. 
Espevik, K.H. Wiesmuller, A.J. Ulmer, and H. Heine. 2005. Binding of 
lipopeptide to CD14 induces physical proximity of CD14, TLR2 and TLR1. Eur J 
Immunol 35:911-921. 
Marks, L.R., B.A. Davidson, P.R. Knight, and A.P. Hakansson. 2013. 
Interkingdom signaling induces Streptococcus pneumoniae biofilm dispersion and 
transition from asymptomatic colonization to disease. MBio 4: 
Marks, M., T. Burns, M. Abadi, B. Seyoum, J. Thornton, E. Tuomanen, and L.A. 
Pirofski. 2007. Influence of neutropenia on the course of serotype 8 
pneumococcal pneumonia in mice. Infect Immun 75:1586-1597. 
Matikainen, S., J. Siren, J. Tissari, V. Veckman, J. Pirhonen, M. Severa, Q. Sun, 
R. Lin, S. Meri, G. Uze, J. Hiscott, and I. Julkunen. 2006. Tumor necrosis factor 
alpha enhances influenza A virus-induced expression of antiviral cytokines by 
activating RIG-I gene expression. J Virol 80:3515-3522. 
Mayer-Barber, K.D., B.B. Andrade, D.L. Barber, S. Hieny, C.G. Feng, P. Caspar, 
S. Oland, S. Gordon, and A. Sher. 2011. Innate and adaptive interferons suppress 
 236	  
IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during 
Mycobacterium tuberculosis infection. Immunity 35:1023-1034. 
McAuley, J.L., F. Hornung, K.L. Boyd, A.M. Smith, R. McKeon, J. Bennink, 
J.W. Yewdell, and J.A. McCullers. 2007. Expression of the 1918 influenza A 
virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial 
pneumonia. Cell Host Microbe 2:240-249. 
McCullers, J.A. 2004. Effect of antiviral treatment on the outcome of secondary 
bacterial pneumonia after influenza. J Infect Dis 190:519-526. 
McCullers, J.A., and K.C. Bartmess. 2003. Role of neuraminidase in lethal 
synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 
187:1000-1009. 
McCullers, J.A., J.L. McAuley, S. Browall, A.R. Iverson, K.L. Boyd, and B. 
Henriques Normark. 2010. Influenza enhances susceptibility to natural acquisition 
of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis 202:1287-
1295. 
McCullers, J.A., and J.E. Rehg. 2002. Lethal synergism between influenza virus 
and Streptococcus pneumoniae: characterization of a mouse model and the role of 
platelet-activating factor receptor. J Infect Dis 186:341-350. 
McNamee, L.A., and A.G. Harmsen. 2006. Both influenza-induced neutrophil 
dysfunction and neutrophil-independent mechanisms contribute to increased 
susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun 
74:6707-6721. 
Mildner, A., M. Djukic, D. Garbe, A. Wellmer, W.A. Kuziel, M. Mack, R. Nau, 
and M. Prinz. 2008. Ly-6G+CCR2- myeloid cells rather than Ly-6ChighCCR2+ 
monocytes are required for the control of bacterial infection in the central nervous 
system. J Immunol 181:2713-2722. 
Mina, M.J., K.P. Klugman, and J.A. McCullers. 2013. Live attenuated influenza 
vaccine, but not pneumococcal conjugate vaccine, protects against increased 
density and duration of pneumococcal carriage after influenza infection in 
pneumococcal colonized mice. J Infect Dis 208:1281-1285. 
Mina, M.J., J.A. McCullers, and K.P. Klugman. 2014. Live Attenuated Influenza 
Vaccine Enhances Colonization of Streptococcus pneumoniae and 
Staphylococcus aureus in Mice. MBio 5: 
 237	  
Mizgerd, J.P., B.B. Meek, G.J. Kutkoski, D.C. Bullard, A.L. Beaudet, and C.M. 
Doerschuk. 1996. Selectins and neutrophil traffic: margination and Streptococcus 
pneumoniae-induced emigration in murine lungs. J Exp Med 184:639-645. 
Mold, C., B. Rodic-Polic, and T.W. Du Clos. 2002. Protection from Streptococcus 
pneumoniae infection by C-reactive protein and natural antibody requires 
complement but not Fc gamma receptors. J Immunol 168:6375-6381. 
Mombaerts, P., J. Iacomini, R.S. Johnson, K. Herrup, S. Tonegawa, and V.E. 
Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. 
Cell 68:869-877. 
Mook-Kanamori, B., M. Geldhoff, D. Troost, T. van der Poll, and D. van de Beek. 
2012. Characterization of a pneumococcal meningitis mouse model. BMC Infect 
Dis 12:71. 
Morens, D.M., J.K. Taubenberger, and A.S. Fauci. 2008. Predominant role of 
bacterial pneumonia as a cause of death in pandemic influenza: implications for 
pandemic influenza preparedness. J Infect Dis 198:962-970. 
Nakamura, S., K.M. Davis, and J.N. Weiser. 2011. Synergistic stimulation of type 
I interferons during influenza virus coinfection promotes Streptococcus 
pneumoniae colonization in mice. J Clin Invest 121:3657-3665. 
Narasaraju, T., H.H. Ng, M.C. Phoon, and V.T. Chow. 2010. MCP-1 antibody 
treatment enhances damage and impedes repair of the alveolar epithelium in 
influenza pneumonitis. Am J Respir Cell Mol Biol 42:732-743. 
Narasaraju, T., E. Yang, R.P. Samy, H.H. Ng, W.P. Poh, A.A. Liew, M.C. Phoon, 
N. van Rooijen, and V.T. Chow. 2011. Excessive neutrophils and neutrophil 
extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J 
Pathol 179:199-210. 
Narayana Moorthy, A., T. Narasaraju, P. Rai, R. Perumalsamy, K.B. Tan, S. 
Wang, B. Engelward, and V.T. Chow. 2013. In vivo and in vitro studies on the 
roles of neutrophil extracellular traps during secondary pneumococcal pneumonia 
after primary pulmonary influenza infection. Front Immunol 4:56. 
Nathan, C. 2006. Neutrophils and immunity: challenges and opportunities. Nat 
Rev Immunol 6:173-182. 
Nauseef, W.M., B.D. Volpp, S. McCormick, K.G. Leidal, and R.A. Clark. 1991. 
Assembly of the neutrophil respiratory burst oxidase. Protein kinase C promotes 
 238	  
cytoskeletal and membrane association of cytosolic oxidase components. J Biol 
Chem 266:5911-5917. 
Negishi, H., H. Yanai, A. Nakajima, R. Koshiba, K. Atarashi, A. Matsuda, K. 
Matsuki, S. Miki, T. Doi, A. Aderem, J. Nishio, S.T. Smale, K. Honda, and T. 
Taniguchi. 2012. Cross-interference of RLR and TLR signaling pathways 
modulates antibacterial T cell responses. Nat Immunol 13:659-666. 
Nicholls, J.M. 2013. The battle between influenza and the innate immune 
response in the human respiratory tract. Infect Chemother 45:11-21. 
Niemann, S., C. Ehrhardt, E. Medina, K. Warnking, L. Tuchscherr, V. Heitmann, 
S. Ludwig, G. Peters, and B. Loffler. 2012. Combined action of influenza virus 
and Staphylococcus aureus panton-valentine leukocidin provokes severe lung 
epithelium damage. J Infect Dis 206:1138-1148. 
Nishikawa, T., K. Shimizu, T. Tanaka, K. Kuroda, T. Takayama, T. Yamamoto, 
N. Hanada, and Y. Hamada. 2012. Bacterial neuraminidase rescues influenza 
virus replication from inhibition by a neuraminidase inhibitor. PLoS One 
7:e45371. 
O'Connell, R.M., S.K. Saha, S.A. Vaidya, K.W. Bruhn, G.A. Miranda, B. 
Zarnegar, A.K. Perry, B.O. Nguyen, T.F. Lane, T. Taniguchi, J.F. Miller, and G. 
Cheng. 2004. Type I interferon production enhances susceptibility to Listeria 
monocytogenes infection. J Exp Med 200:437-445. 
Opatowski, L., E. Varon, C. Dupont, L. Temime, S. van der Werf, L. Gutmann, 
P.Y. Boelle, L. Watier, and D. Guillemot. 2013. Assessing pneumococcal 
meningitis association with viral respiratory infections and antibiotics: insights 
from statistical and mathematical models. Proc Biol Sci 280:20130519. 
Palese, P. 2004. Influenza: old and new threats. Nat Med 10:S82-87. 
Passariello, C., L. Nencioni, R. Sgarbanti, D. Ranieri, M.R. Torrisi, S. Ripa, E. 
Garaci, and A.T. Palamara. 2011. Viral hemagglutinin is involved in promoting 
the internalisation of Staphylococcus aureus into human pneumocytes during 
influenza A H1N1 virus infection. Int J Med Microbiol 301:97-104. 
Pedro-Botet, M.L., J. Burgos, M. Lujan, M. Gimenez, J. Rello, A. Planes, D. 
Fontanals, I. Casas, L. Mateu, P. Zuluaga, C. Ardanuy, and M. Sabria. 2014. 
Impact of the 2009 influenza A H1N1 pandemic on invasive pneumococcal 
disease in adults. Scand J Infect Dis 46:185-192. 
 239	  
Peper, R.L., and H. Van Campen. 1995. Tumor necrosis factor as a mediator of 
inflammation in influenza A viral pneumonia. Microb Pathog 19:175-183. 
Perrone, L.A., K.J. Szretter, J.M. Katz, J.P. Mizgerd, and T.M. Tumpey. 2010. 
Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and 
delay in onset of death following infection with a highly virulent H5N1 virus. J 
Infect Dis 202:1161-1170. 
Pittet, L.A., L. Hall-Stoodley, M.R. Rutkowski, and A.G. Harmsen. 2010. 
Influenza virus infection decreases tracheal mucociliary velocity and clearance of 
Streptococcus pneumoniae. Am J Respir Cell Mol Biol 42:450-460. 
Plotkowski, M.C., E. Puchelle, G. Beck, J. Jacquot, and C. Hannoun. 1986. 
Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice 
infected with influenza A/PR8 virus. Am Rev Respir Dis 134:1040-1044. 
Rayamajhi, M., J. Humann, K. Penheiter, K. Andreasen, and L.L. Lenz. 2010. 
Induction of IFN-alphabeta enables Listeria monocytogenes to suppress 
macrophage activation by IFN-gamma. J Exp Med 207:327-337. 
Redford, P.S., K.D. Mayer-Barber, F.W. McNab, E. Stavropoulos, A. Wack, A. 
Sher, and A. O'Garra. 2014. Influenza A virus impairs control of Mycobacterium 
tuberculosis coinfection through a type I interferon receptor-dependent pathway. J 
Infect Dis 209:270-274. 
Rijneveld, A.W., S. Florquin, J. Branger, P. Speelman, S.J. Van Deventer, and T. 
van der Poll. 2001. TNF-alpha compensates for the impaired host defense of IL-1 
type I receptor-deficient mice during pneumococcal pneumonia. J Immunol 
167:5240-5246. 
Robinson, K.M., S.M. Choi, K.J. McHugh, S. Mandalapu, R.I. Enelow, J.K. 
Kolls, and J.F. Alcorn. 2013. Influenza A exacerbates Staphylococcus aureus 
pneumonia by attenuating IL-1beta production in mice. J Immunol 191:5153-
5159. 
Robinson, K.M., K.J. McHugh, S. Mandalapu, M.E. Clay, B. Lee, E.V. Scheller, 
R.I. Enelow, Y.R. Chan, J.K. Kolls, and J.F. Alcorn. 2014. Influenza A Virus 
Exacerbates Staphylococcus aureus Pneumonia in Mice by Attenuating 
Antimicrobial Peptide Production. J Infect Dis 209:865-875. 
Rosenzweig, S.D., and S.M. Holland. 2004. Phagocyte immunodeficiencies and 
their infections. J Allergy Clin Immunol 113:620-626. 
 240	  
Salomon, R., E. Hoffmann, and R.G. Webster. 2007. Inhibition of the cytokine 
response does not protect against lethal H5N1 influenza infection. Proc Natl Acad 
Sci U S A 104:12479-12481. 
Sanders, R.D., A. Godlee, J.C. Goulding, D. Ma, M. Maze, and T. Hussell. 2013. 
Parenteral fluids do not affect pulmonary immune responses to influenza or 
susceptibility to secondary bacterial pneumonia in mice. Influenza Other Respir 
Viruses 7:895-899. 
Schmolke, M., and A. Garcia-Sastre. 2010. Evasion of innate and adaptive 
immune responses by influenza A virus. Cell Microbiol 12:873-880. 
Segal, A.W. 2005. How neutrophils kill microbes. Annu Rev Immunol 23:197-
223. 
Seki, M., K. Kosai, A. Hara, Y. Imamura, S. Nakamura, S. Kurihara, K. 
Izumikawa, H. Kakeya, Y. Yamamoto, K. Yanagihara, Y. Miyazaki, H. Mukae, 
T. Tashiro, and S. Kohno. 2009. Expression and DNA microarray analysis of a 
platelet activating factor-related molecule in severe pneumonia in mice due to 
influenza virus and bacterial co-infection. Jpn J Infect Dis 62:6-10. 
Seki, M., K. Yanagihara, Y. Higashiyama, Y. Fukuda, Y. Kaneko, H. Ohno, Y. 
Miyazaki, Y. Hirakata, K. Tomono, J. Kadota, T. Tashiro, and S. Kohno. 2004. 
Immunokinetics in severe pneumonia due to influenza virus and bacteria 
coinfection in mice. Eur Respir J 24:143-149. 
Seo, S.H., and R.G. Webster. 2002. Tumor necrosis factor alpha exerts powerful 
anti-influenza virus effects in lung epithelial cells. J Virol 76:1071-1076. 
Seo, S.U., J.J. Kim, H. Yang, H.J. Kwon, J.Y. Yang, R. Curtiss Iii, and M.N. 
Kweon. 2012. Effective protection against secondary pneumococcal pneumonia 
by oral vaccination with attenuated Salmonella delivering PspA antigen in mice. 
Vaccine 30:6816-6823. 
Seo, S.U., H.J. Kwon, H.J. Ko, Y.H. Byun, B.L. Seong, S. Uematsu, S. Akira, and 
M.N. Kweon. 2011. Type I interferon signaling regulates Ly6C(hi) monocytes 
and neutrophils during acute viral pneumonia in mice. PLoS Pathog 7:e1001304. 
Serbina, N.V., T. Jia, T.M. Hohl, and E.G. Pamer. 2008. Monocyte-mediated 
defense against microbial pathogens. Annu Rev Immunol 26:421-452. 
 241	  
Serbina, N.V., and E.G. Pamer. 2006. Monocyte emigration from bone marrow 
during bacterial infection requires signals mediated by chemokine receptor CCR2. 
Nat Immunol 7:311-317. 
Shahangian, A., E.K. Chow, X. Tian, J.R. Kang, A. Ghaffari, S.Y. Liu, J.A. 
Belperio, G. Cheng, and J.C. Deng. 2009. Type I IFNs mediate development of 
postinfluenza bacterial pneumonia in mice. J Clin Invest 119:1910-1920. 
Shanks, G.D., and J.F. Brundage. 2012. Pathogenic responses among young 
adults during the 1918 influenza pandemic. Emerg Infect Dis 18:201-207. 
Shieh, W.J., D.M. Blau, A.M. Denison, M. Deleon-Carnes, P. Adem, J. 
Bhatnagar, J. Sumner, L. Liu, M. Patel, B. Batten, P. Greer, T. Jones, C. Smith, J. 
Bartlett, J. Montague, E. White, D. Rollin, R. Gao, C. Seales, H. Jost, M. 
Metcalfe, C.S. Goldsmith, C. Humphrey, A. Schmitz, C. Drew, C. Paddock, T.M. 
Uyeki, and S.R. Zaki. 2010. 2009 pandemic influenza A (H1N1): pathology and 
pathogenesis of 100 fatal cases in the United States. Am J Pathol 177:166-175. 
Short, K.R., P.C. Reading, N. Wang, D.A. Diavatopoulos, and O.L. Wijburg. 
2012. Increased nasopharyngeal bacterial titers and local inflammation facilitate 
transmission of Streptococcus pneumoniae. MBio 3: 
Shrestha, S., B. Foxman, D.M. Weinberger, C. Steiner, C. Viboud, and P. Rohani. 
2013. Identifying the interaction between influenza and pneumococcal pneumonia 
using incidence data. Sci Transl Med 5:191ra184. 
Small, C.L., C.R. Shaler, S. McCormick, M. Jeyanathan, D. Damjanovic, E.G. 
Brown, P. Arck, M. Jordana, C. Kaushic, A.A. Ashkar, and Z. Xing. 2010. 
Influenza infection leads to increased susceptibility to subsequent bacterial 
superinfection by impairing NK cell responses in the lung. J Immunol 184:2048-
2056. 
Smith, A.M., F.R. Adler, R.M. Ribeiro, R.N. Gutenkunst, J.L. McAuley, J.A. 
McCullers, and A.S. Perelson. 2013. Kinetics of coinfection with influenza A 
virus and Streptococcus pneumoniae. PLoS Pathog 9:e1003238. 
Smith, M.W., J.E. Schmidt, J.E. Rehg, C.J. Orihuela, and J.A. McCullers. 2007. 
Induction of pro- and anti-inflammatory molecules in a mouse model of 
pneumococcal pneumonia after influenza. Comp Med 57:82-89. 
Snelgrove, R.J., L. Edwards, A.J. Rae, and T. Hussell. 2006. An absence of 
reactive oxygen species improves the resolution of lung influenza infection. Eur J 
Immunol 36:1364-1373. 
 242	  
Sonnenberg, G.F., L.A. Fouser, and D. Artis. 2011. Border patrol: regulation of 
immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat 
Immunol 12:383-390. 
Stegemann, S., S. Dahlberg, A. Kroger, M. Gereke, D. Bruder, B. Henriques-
Normark, and M. Gunzer. 2009. Increased susceptibility for superinfection with 
Streptococcus pneumoniae during influenza virus infection is not caused by 
TLR7-mediated lymphopenia. PLoS One 4:e4840. 
Steinhauer, D.A. 1999. Role of hemagglutinin cleavage for the pathogenicity of 
influenza virus. Virology 258:1-20. 
Steinwede, K., S. Henken, J. Bohling, R. Maus, B. Ueberberg, C. Brumshagen, 
E.L. Brincks, T.S. Griffith, T. Welte, and U.A. Maus. 2012. TNF-related 
apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of 
pneumococcal pneumonia in mice. J Exp Med 209:1937-1952. 
Steinwede, K., O. Tempelhof, K. Bolte, R. Maus, J. Bohling, B. Ueberberg, F. 
Langer, J.W. Christman, J.C. Paton, K. Ask, S. Maharaj, M. Kolb, J. Gauldie, T. 
Welte, and U.A. Maus. 2011. Local delivery of GM-CSF protects mice from 
lethal pneumococcal pneumonia. J Immunol 187:5346-5356. 
Subramaniam, R., P.F. Barnes, K. Fletcher, V. Boggaram, Z. Hillberry, P. 
Neuenschwander, and H. Shams. 2014. Protecting Against Post-influenza 
Bacterial Pneumonia by Increasing Phagocyte Recruitment and ROS Production. 
J Infect Dis  
Sun, K., and D.W. Metzger. 2008. Inhibition of pulmonary antibacterial defense 
by interferon-gamma during recovery from influenza infection. Nat Med 14:558-
564. 
Sun, K., and D.W. Metzger. 2014. Influenza Infection Suppresses NADPH 
Oxidase-Dependent Phagocytic Bacterial Clearance and Enhances Susceptibility 
to Secondary Methicillin-Resistant Staphylococcus aureus Infection. J Immunol 
192:3301-3307. 
Sun, K., S.L. Salmon, S.A. Lotz, and D.W. Metzger. 2007. Interleukin-12 
promotes gamma interferon-dependent neutrophil recruitment in the lung and 
improves protection against respiratory Streptococcus pneumoniae infection. 
Infect Immun 75:1196-1202. 
Sun, K., J. Ye, D.R. Perez, and D.W. Metzger. 2011. Seasonal FluMist 
vaccination induces cross-reactive T cell immunity against H1N1 (2009) 
influenza and secondary bacterial infections. J Immunol 186:987-993. 
 243	  
Swain, S.L., K.K. McKinstry, and T.M. Strutt. 2012. Expanding roles for CD4(+) 
T cells in immunity to viruses. Nat Rev Immunol 12:136-148. 
Swiergiel, A.H., and A.J. Dunn. 1999. The roles of IL-1, IL-6, and TNFalpha in 
the feeding responses to endotoxin and influenza virus infection in mice. Brain 
Behav Immun 13:252-265. 
Szretter, K.J., S. Gangappa, X. Lu, C. Smith, W.J. Shieh, S.R. Zaki, S. Sambhara, 
T.M. Tumpey, and J.M. Katz. 2007. Role of host cytokine responses in the 
pathogenesis of avian H5N1 influenza viruses in mice. J Virol 81:2736-2744. 
Takashima, K., K. Tateda, T. Matsumoto, Y. Iizawa, M. Nakao, and K. 
Yamaguchi. 1997. Role of tumor necrosis factor alpha in pathogenesis of 
pneumococcal pneumonia in mice. Infect Immun 65:257-260. 
Takayama, Y., H. Yano, Y. Nojima, R. Nakano, R. Okamoto, Y. Hirakata, K. 
Sunakawa, T. Akahoshi, and M. Kaku. 2014. Influence of prior pandemic 
A(H1N1)2009 virus infection on invasion of MDCK cells by community-
associated methicillin-resistant Staphylococcus aureus. J Infect Chemother 20:71-
73. 
Tanaka, A., S. Nakamura, M. Seki, K. Fukudome, N. Iwanaga, Y. Imamura, T. 
Miyazaki, K. Izumikawa, H. Kakeya, K. Yanagihara, and S. Kohno. 2013. Toll-
like receptor 4 agonistic antibody promotes innate immunity against severe 
pneumonia induced by coinfection with influenza virus and Streptococcus 
pneumoniae. Clin Vaccine Immunol 20:977-985. 
Tate, M.D., A.G. Brooks, and P.C. Reading. 2008. The role of neutrophils in the 
upper and lower respiratory tract during influenza virus infection of mice. Respir 
Res 9:57. 
Tate, M.D., Y.M. Deng, J.E. Jones, G.P. Anderson, A.G. Brooks, and P.C. 
Reading. 2009. Neutrophils ameliorate lung injury and the development of severe 
disease during influenza infection. J Immunol 183:7441-7450. 
Tate, M.D., L.J. Ioannidis, B. Croker, L.E. Brown, A.G. Brooks, and P.C. 
Reading. 2011. The role of neutrophils during mild and severe influenza virus 
infections of mice. PLoS One 6:e17618. 
Tian, X., F. Xu, W.Y. Lung, C. Meyerson, A.A. Ghaffari, G. Cheng, and J.C. 
Deng. 2012. Poly I:C enhances susceptibility to secondary pulmonary infections 
by gram-positive bacteria. PLoS One 7:e41879. 
 244	  
Trinchieri, G. 2010. Type I interferon: friend or foe? J Exp Med 207:2053-2063. 
Tripathi, S., M.R. White, and K.L. Hartshorn. 2013. The amazing innate immune 
response to influenza A virus infection. Innate Immun  
Tumpey, T.M., A. Garcia-Sastre, J.K. Taubenberger, P. Palese, D.E. Swayne, 
M.J. Pantin-Jackwood, S. Schultz-Cherry, A. Solorzano, N. Van Rooijen, J.M. 
Katz, and C.F. Basler. 2005. Pathogenicity of influenza viruses with genes from 
the 1918 pandemic virus: functional roles of alveolar macrophages and 
neutrophils in limiting virus replication and mortality in mice. J Virol 79:14933-
14944. 
Turner, S.J., N.L. La Gruta, J. Stambas, G. Diaz, and P.C. Doherty. 2004. 
Differential tumor necrosis factor receptor 2-mediated editing of virus-specific 
CD8+ effector T cells. Proc Natl Acad Sci U S A 101:3545-3550. 
Tuvim, M.J., S.E. Evans, C.G. Clement, B.F. Dickey, and B.E. Gilbert. 2009. 
Augmented lung inflammation protects against influenza A pneumonia. PLoS 
One 4:e4176. 
Urban, C.F., S. Lourido, and A. Zychlinsky. 2006a. How do microbes evade 
neutrophil killing? Cell Microbiol 8:1687-1696. 
Urban, C.F., U. Reichard, V. Brinkmann, and A. Zychlinsky. 2006b. Neutrophil 
extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell 
Microbiol 8:668-676. 
Vacheron, F., A. Rudent, S. Perin, C. Labarre, A.M. Quero, and M. Guenounou. 
1990. Production of interleukin 1 and tumour necrosis factor activities in 
bronchoalveolar washings following infection of mice by influenza virus. J Gen 
Virol 71 ( Pt 2):477-479. 
van der Poll, T., C.V. Keogh, W.A. Buurman, and S.F. Lowry. 1997. Passive 
immunization against tumor necrosis factor-alpha impairs host defense during 
pneumococcal pneumonia in mice. Am J Respir Crit Care Med 155:603-608. 
van der Sluijs, K.F., M. Nijhuis, J.H. Levels, S. Florquin, A.L. Mellor, H.M. 
Jansen, T. van der Poll, and R. Lutter. 2006a. Influenza-induced expression of 
indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial 
outgrowth during secondary pneumococcal pneumonia. J Infect Dis 193:214-222. 
van der Sluijs, K.F., L.J. van Elden, M. Nijhuis, R. Schuurman, S. Florquin, T. 
Shimizu, S. Ishii, H.M. Jansen, R. Lutter, and T. van der Poll. 2006b. Involvement 
 245	  
of the platelet-activating factor receptor in host defense against Streptococcus 
pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol 
Physiol 290:L194-199. 
van der Sluijs, K.F., L.J. van Elden, M. Nijhuis, R. Schuurman, J.M. Pater, S. 
Florquin, M. Goldman, H.M. Jansen, R. Lutter, and T. van der Poll. 2004. IL-10 is 
an important mediator of the enhanced susceptibility to pneumococcal pneumonia 
after influenza infection. J Immunol 172:7603-7609. 
van Helden, M.J., D.M. Zaiss, and A.J. Sijts. 2012. CCR2 defines a distinct 
population of NK cells and mediates their migration during influenza virus 
infection in mice. PLoS One 7:e52027. 
Van Winkle, L.S., A.R. Buckpitt, S.J. Nishio, J.M. Isaac, and C.G. Plopper. 1995. 
Cellular response in naphthalene-induced Clara cell injury and bronchiolar 
epithelial repair in mice. Am J Physiol 269:L800-818. 
Wack, A., P. Openshaw, and A. O'Garra. 2011. Contribution of cytokines to 
pathology and protection in virus infection. Curr Opin Virol 1:184-195. 
Wang, J., F. Li, R. Sun, X. Gao, H. Wei, L.J. Li, and Z. Tian. 2013a. Bacterial 
colonization dampens influenza-mediated acute lung injury via induction of M2 
alveolar macrophages. Nat Commun 4:2106. 
Wang, X.Y., P.E. Kilgore, K.A. Lim, S.M. Wang, J. Lee, W. Deng, M.Q. Mo, B. 
Nyambat, J.C. Ma, M.O. Favorov, and J.D. Clemens. 2011. Influenza and 
bacterial pathogen coinfections in the 20th century. Interdiscip Perspect Infect Dis 
2011:146376. 
Wang, Y., C.A. Gagnon, C. Savard, N. Music, M. Srednik, M. Segura, C. 
Lachance, C. Bellehumeur, and M. Gottschalk. 2013b. Capsular sialic acid of 
Streptococcus suis serotype 2 binds to swine influenza virus and enhances 
bacterial interactions with virus-infected tracheal epithelial cells. Infect Immun 
81:4498-4508. 
Wareing, M.D., A. Lyon, C. Inglis, F. Giannoni, I. Charo, and S.R. Sarawar. 
2007. Chemokine regulation of the inflammatory response to a low-dose influenza 
infection in CCR2-/- mice. J Leukoc Biol 81:793-801. 
Weeks, J.N., K.L. Boyd, G. Rajam, E.W. Ades, and J.A. McCullers. 2011. 
Immunotherapy with a combination of intravenous immune globulin and p4 
peptide rescues mice from postinfluenza pneumococcal pneumonia. Antimicrob 
Agents Chemother 55:2276-2281. 
 246	  
Weeks-Gorospe, J.N., H.R. Hurtig, A.R. Iverson, M.J. Schuneman, R.J. Webby, 
J.A. McCullers, and V.C. Huber. 2012. Naturally occurring swine influenza A 
virus PB1-F2 phenotypes that contribute to superinfection with Gram-positive 
respiratory pathogens. J Virol 86:9035-9043. 
Weiser, J.N. 2010. The pneumococcus: why a commensal misbehaves. J Mol Med 
(Berl) 88:97-102. 
Wilson, M.S., S.K. Madala, T.R. Ramalingam, B.R. Gochuico, I.O. Rosas, A.W. 
Cheever, and T.A. Wynn. 2010. Bleomycin and IL-1beta-mediated pulmonary 
fibrosis is IL-17A dependent. J Exp Med 207:535-552. 
Winter, C., K. Taut, M. Srivastava, F. Langer, M. Mack, D.E. Briles, J.C. Paton, 
R. Maus, T. Welte, M.D. Gunn, and U.A. Maus. 2007. Lung-specific 
overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to 
Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. J 
Immunol 178:5828-5838. 
Wolter, N., C. Cohen, S. Tempia, S.A. Madhi, M. Venter, J. Moyes, S. Walaza, B. 
Malope Kgokong, M. Groome, M. du Plessis, M. Pretorius, H. Dawood, K. Kahn, 
E. Variava, K.P. Klugman, and A. von Gottberg. 2014. HIV and influenza virus 
infections are associated with increased blood pneumococcal load: a prospective, 
hospital-based observational study in South Africa, 2009-2011. J Infect Dis 
209:56-65. 
Wu, Y., H. Mao, M.T. Ling, K.H. Chow, P.L. Ho, W. Tu, and Y.L. Lau. 2011. 
Successive influenza virus infection and Streptococcus pneumoniae stimulation 
alter human dendritic cell function. BMC Infect Dis 11:201. 
Wurzer, W.J., C. Ehrhardt, S. Pleschka, F. Berberich-Siebelt, T. Wolff, H. 
Walczak, O. Planz, and S. Ludwig. 2004. NF-kappaB-dependent induction of 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is 
crucial for efficient influenza virus propagation. J Biol Chem 279:30931-30937. 
Yamada, M., J.C. Gomez, P.E. Chugh, C.A. Lowell, M.C. Dinauer, D.P. Dittmer, 
and C.M. Doerschuk. 2011. Interferon-gamma production by neutrophils during 
bacterial pneumonia in mice. Am J Respir Crit Care Med 183:1391-1401. 
Yoshimura, A., E. Lien, R.R. Ingalls, E. Tuomanen, R. Dziarski, and D. 
Golenbock. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall 
components by the innate immune system occurs via Toll-like receptor 2. J 
Immunol 163:1-5. 
 247	  
Youn, H.N., D.H. Lee, Y.N. Lee, J.K. Park, S.S. Yuk, S.Y. Yang, H.J. Lee, S.H. 
Woo, H.M. Kim, J.B. Lee, S.Y. Park, I.S. Choi, and C.S. Song. 2012. Intranasal 
administration of live Lactobacillus species facilitates protection against influenza 
virus infection in mice. Antiviral Res 93:138-143. 
Zavitz, C.C., C.M. Bauer, G.J. Gaschler, K.M. Fraser, R.M. Strieter, C.M. 
Hogaboam, and M.R. Stampfli. 2010. Dysregulated macrophage-inflammatory 
protein-2 expression drives illness in bacterial superinfection of influenza. J 
Immunol 184:2001-2013. 
Zhang, X., L. Majlessi, E. Deriaud, C. Leclerc, and R. Lo-Man. 2009a. 
Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria 
promotes regulatory properties of neutrophils. Immunity 31:761-771. 
Zhang, Z., T.B. Clarke, and J.N. Weiser. 2009b. Cellular effectors mediating 
Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 
119:1899-1909. 
Zhou, J., H.K. Law, C.Y. Cheung, I.H. Ng, J.S. Peiris, and Y.L. Lau. 2006. 
Functional tumor necrosis factor-related apoptosis-inducing ligand production by 
avian influenza virus-infected macrophages. J Infect Dis 193:945-953. 
Zysk, G., L. Bejo, B.K. Schneider-Wald, R. Nau, and H. Heinz. 2000. Induction 
of necrosis and apoptosis of neutrophil granulocytes by Streptococcus 
pneumoniae. Clin Exp Immunol 122:61-66. 
 
 
 
 
 
 	  
 
 
